

Title Page

Protocol Title:		A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite)	
Short Protocol Title:		A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite)	
Protocol Number:		20210142	
Investigational Product:		Rocatinlimab (AMG 451)	
Trade Name:		Not Applicable	
Sponsor	Name of Sponsor:	Amgen Inc.	
	Address:	One Amgen Center Drive Thousand Oaks, CA, 91320	
	Telephone Number:	+1 805-447-1000	
Protocol Approver	Name:	[REDACTED], MD, MBA	
	Function:	VP Global Development	
Key Sponsor Contact	Name:	[REDACTED], MD	
	Address:	One Amgen Center Drive Thousand Oaks, CA, 91320-1799	
	Telephone Number:	[REDACTED]	
	Email Address:	[REDACTED]	
EU CT Number:		2022-501540-15	
NCT Number:		NCT05398445	
Protocol Version Date:		<u>Document Version</u>	<u>Date</u>
		Original	08 February 2022
		Superseding Original	01 April 2022
		Amendment 1	27 April 2022

	Amendment 2	15 September 2022
	Amendment 3	28 February 2023
	Superseding Amendment 3	15 March 2023
	Superseding Amendment 3	23 March 2023
	Amendment 4	24 May 2023
	Amendment 5	16 January 2024
	Amendment 6	26 February 2024
Data Elements Standards Version:	8.0	

This protocol was developed, reviewed, and approved in accordance with Amgen's standard operating procedures. This format and content of this protocol is aligned with Good Clinical Practice: Consolidated Guidance (International Council for Harmonisation [ICH] E6).

Confidentiality Notice

This document contains confidential information of Amgen Inc.

This document must not be disclosed to anyone other than the site study staff and members of the institutional review board/independent ethics committee/institutional scientific review board or equivalent.

The information in this document cannot be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Amgen Inc.

If you have questions regarding how this document may be used or shared, call the Amgen Medical Information number: US sites, 1- 800-77-AMGEN; Canadian sites, 1-866-50-AMGEN; Amgen's general number in the US, 1-805-447-1000.

Investigator's Agreement:

I have read the attached protocol entitled A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite), dated **26 February 2024**, and agree to abide by all provisions set forth therein.

I agree to comply with the International Council for Harmonisation (ICH) Tripartite Guideline on Good Clinical Practice (GCP), Declaration of Helsinki, and applicable national or regional regulations/guidelines.

I agree to ensure that Financial Disclosure Statements will be completed by: me (including, if applicable, my spouse or legal partner and dependent children) and my subinvestigators (including, if applicable, their spouses or legal partners and dependent children) at the start of the study and for up to 1 year after the study is completed, if there are changes that affect my financial disclosure status.

I agree to ensure that the confidential information contained in this document will not be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Amgen Inc.

Signature

Name of Investigator

Date (DD Month YYYY)

Title and Role of Investigator

Institution Name


Address and Telephone Number of Institution

Table of Contents

Table of Contents	5
1. Protocol Summary	12
1.1 Synopsis	12
1.2 Study Schema.....	22
1.3 Schedule of Activities (SoA)	23
2. Introduction.....	30
2.1 Study Rationale.....	30
2.2 Background.....	31
2.2.1 Disease	31
2.2.2 Amgen Investigational Product Background: Rocatinlimab	32
2.3 Benefit Risk Assessment.....	32
2.3.1 COVID-19.....	34
3. Objectives and Endpoints/Estimands.....	34
4. Study Design	42
4.1 Overall Design	42
4.2 Patient Input into the Study Design	44
4.3 Justification for Dose.....	44
4.3.1 Justification for Investigational Product Dose.....	44
4.4 End of Study	45
5. Study Population	45
5.1 Inclusion Criteria	45
5.2 Exclusion Criteria	46
5.3 Lifestyle Considerations	49
5.3.1 Meals and Dietary Restrictions	49
5.3.2 Activity.....	50
5.4 Subject Enrollment.....	50
5.5 Screen Failures	51
6. Study Intervention.....	51
6.1 Study Interventions Administered	51
6.1.1 Investigational Products	51
[REDACTED]	
6.1.3 Medical Devices	52
6.1.4 Other Intervention Procedures.....	53
6.1.5 Product Complaints	53
6.1.6 Excluded Treatments, Medical Devices, and/or Procedures During Study Period	53
6.1.6.1 Atopic Dermatitis Rescue Therapy	53

	6.1.6.2	Other Excluded/Discouraged Therapies for Atopic Dermatitis or Related Conditions	53
	6.1.6.3	Guidance for Certain Therapeutics for Non-atopic Dermatitis Related Conditions, Including Prohibited Therapies	53
6.2		Dose Modification.....	55
	6.2.1	Dose-group/Cohort Study Escalation/De-escalation and Stopping Rules.....	55
	6.2.2	Dosage Adjustments, Delays, Rules for Withholding or Restarting, Permanent Discontinuation	55
	6.2.2.1	Amgen Investigational Product: Rocatinlimab/Placebo.....	55
	6.2.3	Hepatotoxicity Stopping and Rechallenge Rules	56
6.3		Preparation/Handling/Storage/Accountability	56
6.4		Measures to Minimize Bias: Randomization and Blinding.....	57
	6.4.1	Method of Treatment Assignment.....	57
	6.4.2	Blinding	57
	6.4.2.1	Site Personnel Access to Unblinding Information	57
	6.4.2.2	Access to Unblinding Information by Amgen or Designees.....	58
6.5		Treatment Compliance	58
6.6		Treatment of Overdose	58
6.7		Prior and Concomitant Treatment	58
	6.7.1	Prior Treatment	58
	6.7.2	Concomitant Treatment.....	59
	6.7.3	Rescue Therapies for Atopic Dermatitis or Related Conditions	60
7.		Discontinuation of Study Treatment and Subject Discontinuation/Withdrawal.....	62
	7.1	Discontinuation of Study Treatment.....	62
	7.2	Subject Discontinuation/Withdrawal From the Study	63
	7.2.1	Reasons for Removal From Study	63
	7.3	Lost to Follow-up.....	64
8.		Study Assessments and Procedures	64
	8.1	General Study Periods	64
	8.1.1	Screening, Enrollment, and/or Randomization.....	64
	8.1.2	Treatment Period.....	65
	8.1.3	End of Treatment.....	65
	8.1.4	Safety Follow-up.....	66
	8.1.5	End of Study.....	66
	8.2	General Assessments	66
	8.2.1	Informed Consent.....	66
	8.2.2	Demographics	67

8.2.3	Medical History	67
8.2.4	Physical Examination	67
8.2.5	Physical Measurements	67
8.2.6	Substance Use History	67
8.2.8	Mental Health Assessment	68
8.3	Efficacy Assessments	70
8.3.1	Assessments Completed by Investigator	70
8.3.1.1	Validated Investigator Global Assessment for Atopic Dermatitis	70
8.3.1.2	Atopic Dermatitis Morphology Assessment	71
8.3.1.3	Eczema Area and Severity Index	71
8.3.1.4	Severity Scoring of Atopic Dermatitis	71
8.3.2	Assessments Completed by Subject	72
8.3.2.1	Worst Pruritus NRS	72
8.3.2.2	Atopic Dermatitis Skin Pain NRS	73
8.3.2.3	Sleep Disturbance NRS	73
8.3.2.4	Dermatology Life Quality Index	73
8.3.2.5	Patient Oriented Eczema Measure	73
8.3.2.6	Hospital Anxiety and Depression Scale (HADS)	73
8.3.2.7	EuroQol-5 Dimension-5 Level (EQ-5D-5L)	74
8.3.2.8	Work Productivity and Activity Impairment (WPAI) for AD	74
8.3.2.9	Patient Global Impression of Severity (PGI-S)	74
8.3.2.10	Patient Global Impression of Change (PGI-C)	75
8.4	Safety Assessments	75
8.4.1	Vital Signs	75
8.4.2	Post-dose Monitoring and Vital Signs	75
8.4.3	Electrocardiograms (ECGs)	76
8.4.4	Clinical Laboratory Assessments	76
8.4.5	Adverse Events and Serious Adverse Events	77
8.4.5.1	Time Period and Frequency for Collecting and Reporting Safety Event Information	77
8.4.5.2	Method of Detecting Adverse Events and Serious Adverse Events	78

8.4.5.3	Follow-up of Adverse Events and Serious Adverse Events	79
8.4.5.4	Regulatory Reporting Requirements for Safety Information	79
8.4.5.5	Safety Monitoring Plan	80
8.4.5.6	Pregnancy and Lactation.....	80
		
8.10	Other Assessments.....	84
8.10.1	Tuberculosis Testing and Tuberculosis Risk Assessment Questionnaire.....	84
9.	Statistical Considerations.....	85
9.1	Statistical Hypotheses	85
9.2	Sample Size Determination.....	86
9.3	Populations for Analysis	86
9.3.1	Covariates	86
9.3.2	Subgroups.....	86
9.4	Statistical Analyses	87
9.4.1	Planned Analyses.....	87
9.4.1.1	Primary Analysis	87
9.4.1.2	Final Analysis	87
9.4.2	Methods of Analyses	87
9.4.2.1	General Considerations.....	87
9.4.2.2	Efficacy Analyses	88
9.4.2.3	Safety Analyses	89
9.4.2.4	Other Analyses.....	90
10.	References	91
11.	Appendices.....	94
11.1	Appendix 1. List of Abbreviations	95
11.2	Appendix 2. Clinical Laboratory Tests	98
11.3	Appendix 3. Study Governance Considerations	101

11.4	Appendix 4. Safety Events: Definitions and Procedures for Recording, Evaluating, Follow-up and Reporting.....	110
11.5	Appendix 5. Contraceptive Guidance and Collection of Pregnancy and Lactation Information	122
11.6	Appendix 6. Sample Storage and Destruction	128
11.7	Appendix 7. Hepatotoxicity Stopping Rules: Suggested Actions and Follow-up Assessments and Study Treatment Rechallenge Guidelines	130
11.8	Appendix 8. Topical Corticosteroids Potency Category	134
11.9	Appendix 9. Country Specific Requirements	136

List of Tables

Table 1-1. Schedule of Activities.....	23
Table 6-1. Investigational Products.....	51
Table 6-2. Guidance for Certain Therapeutics for Non-atopic Dermatitis Related Conditions, Including Prohibited Therapies.....	54
Table 6-3. Rescue Therapy for Atopic Dermatitis	60
Table 8-1. Hospital Anxiety and Depression Score Categorization	74
Table 11-1. Analyte Listing	99
Table 11-2. Potential DILI Analyte Listing	100
Table 11-3. Conditions for Withholding and/or Permanent Discontinuation of Amgen Investigational Product and [REDACTED] [REDACTED] Due to Potential Hepatotoxicity	131
Table 11-4. Topical Corticosteroids Potency Category	134
Table 11-5. European Economic Area Summary of Changes.....	136

List of Figures

Figure 1-1. Study Schema 21

Figure 11-1. Sample Electronic Serious Adverse Event Contingency Report
Form (paper-based form)..... 115

Figure 11-2. Pregnancy and Lactation Notification Forms..... 124



1. Protocol Summary

1.1 Synopsis

Protocol Title: A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite)

Short Protocol Title: A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite)

Study Phase: 3

Indication: Atopic Dermatitis

Study Rationale


Atopic dermatitis (AD) is a chronic relapsing and remitting, inflammatory skin disease dominated by reactive T helper type 2 (Th2) cells. The proximate pathophysiologic mechanism for eczematous lesions is now understood to be largely due to inflammation related to dysregulation of Th2 cells (Guttman-Yassky, 2018). OX40 (CD134) is expressed predominantly on T-cells, including effector cells, shortly after their activation (Croft, 2010). OX40 and its ligand, OX40L, are crucial for the generation of Th2 memory cells, and may thus play a central role in the pathogenesis and chronicity of AD (Sitrin et al, 2017). Blocking OX40 signaling has resulted in inhibition of T-cell responses and pathogenic symptoms in animal models of autoimmune diseases (Salek-Ardakani and Croft, 2006; Croft et al, 2009). Rocatinlimab (formerly known as AMG 451 and KHK4083) is a human, non-fucosylated, immunoglobulin G1 (IgG1) monoclonal antibody that binds and inhibits the OX40/OX40L interaction, and thereby, suppresses clonal T-cell expansion. In a Phase 2 study (Study 4083-006) evaluating the efficacy, safety, and tolerability of repeated doses of rocatinlimab in subjects with moderate-to-severe AD, and conducted by Amgen partner Kyowa Kirin Co., Ltd, statistically significant improvements in percent change from baseline to week 16 in Eczema Area and Severity Index (EASI) score was observed in all rocatinlimab-treated cohorts versus placebo. In this study, all doses tested were well tolerated with an acceptable adverse event profile.

The current phase 3 placebo-controlled study will be conducted in adult subjects presenting with moderate-to-severe AD whose disease cannot be adequately controlled with topical medications or for whom topical medications cannot be prescribed medically because of intolerance or safety risks. The study is designed to confirm the efficacy and safety of 2 doses of rocatinlimab monotherapy and to establish the beneficial impact on

the related patient reported outcomes including pruritus, skin pain, sleep loss, and impaired quality of life.

Benefit/Risk Assessment

Rocatinlimab has been generally well tolerated and no adverse events with fatal outcome attributed to rocatinlimab have been reported in the completed studies.



Only the SC route of administration is planned, which limits the risk of adverse effects associated with IV infusion. Overall, SC administration is associated with lower incidence of systemic reactions and/or lower severity of acute reactions that tend to be local (Mateos et al 2020, Davies et al 2017, Assouline et al 2016). Eligibility criteria have been implemented to exclude subjects vulnerable to acute allergic reactions and infections and all subjects will be observed after investigational product administration and will be monitored throughout the study with hematology and standard adverse event and serious adverse event reporting.

Objectives and Endpoints/Estimands

Objectives	Endpoints
Coprimary	
To evaluate the efficacy of rocatinlimab ■■■ mg and ■■■ mg compared with placebo at week 24, assessed using the Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™)	Achieving a vIGA-AD score of 0 (clear) or 1 (almost clear) with ≥ 2-point reduction from baseline (vIGA-AD 0/1) at week 24

To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 24, assessed using Eczema Area and Severity Index (EASI)	Achieving $\geq 75\%$ reduction from baseline in EASI score (EASI 75) at week 24
Key Secondary	
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 16, assessed using EASI	Achieving EASI 75 at week 16
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 16, assessed using vIGA-AD	Achieving vIGA-AD 0/1 at week 16
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 16 and week 24 on the patient-reported outcome (PRO) measure of pruritus	- Achieving [REDACTED] from baseline in weekly average of daily worst pruritus numeric rating scale (NRS) score at week 16 in subjects with baseline weekly average of daily worst pruritus NRS score [REDACTED] - Achieving [REDACTED] from baseline in weekly average of daily worst pruritus NRS score at week 24 in subjects with baseline weekly average of daily worst pruritus NRS score [REDACTED]
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 24, assessed using EASI	Achieving [REDACTED] from baseline in EASI score ([REDACTED]) at week 24
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 24 on the PRO measure of atopic dermatitis (AD) skin pain	Achieving [REDACTED] from baseline in weekly average of AD skin pain NRS score at week 24 in subjects with baseline weekly average of AD skin pain NRS score [REDACTED]
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 24, assessed using vIGA-AD with an additional assessment of morphology	Achieving vIGA-AD 1 response with presence of only barely perceptible erythema or vIGA-AD 0 response (revised Investigator's Global Assessment [rIGA™] 0/1) at week 24
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo on [REDACTED]	Achieving a [REDACTED]
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo on [REDACTED]	Achieving a [REDACTED]

Other Secondary	
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 16 and week 24 on the PRO measure of pruritus	- Change from baseline in weekly average of daily worst pruritus NRS score at week 16 - Change from baseline in weekly average of daily worst pruritus NRS score at week 24 - Change from baseline in Scoring Atopic Dermatitis (SCORAD) itch visual analogue scale (VAS) score at week 16 - Change from baseline in SCORAD itch VAS score at week 24
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 24 on the PRO measure using the Dermatology Life Quality Index (DLQI)	- Achieving [REDACTED] from baseline in DLQI score at week 24 in subjects with baseline DLQI score [REDACTED] Change from baseline in DLQI score at week 24
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 24 on the PRO measure using the Patient Oriented Eczema Measure (POEM)	- Achieving [REDACTED] from baseline in POEM score at week 24 in subjects with baseline POEM score [REDACTED] - Change from baseline in POEM score at week 24
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 16 and week 24 on the PRO measure of AD skin pain	Achieving [REDACTED] from baseline in weekly average of AD skin pain NRS score at week 16 in subjects with baseline weekly average of AD skin pain NRS score [REDACTED] - Change from baseline in weekly average of daily AD skin pain NRS score at week 24 Change from baseline in weekly average of daily AD skin pain NRS score at week 16 Achieving [REDACTED] from baseline in weekly average of AD skin pain NRS score at week 24 in subjects with baseline weekly average of AD skin pain NRS score [REDACTED] Achieving [REDACTED] from baseline in weekly average of AD skin pain NRS score at week 16 in subjects with baseline weekly average of AD skin pain NRS score [REDACTED]

To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 24 on the PRO measure of sleep disturbance	Change from baseline in weekly average of daily sleep disturbance NRS score at week 24
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 24 on the PRO measure of anxiety and depression using the Hospital Anxiety and Depression Scale (HADS)	- Achieving HADS-anxiety subscale score [REDACTED] at week 24 in subjects with baseline HADS-anxiety subscale score [REDACTED] - Achieving HADS-depression subscale score [REDACTED] at week 24 in subjects with baseline HADS-depression subscale score [REDACTED] - Change from baseline in HADS-anxiety subscale score at week 24 - Change from baseline in HADS-depression subscale score at week 24
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 24 using the SCORAD	Achieving [REDACTED] from baseline in SCORAD score at week 24 in subjects with baseline SCORAD score [REDACTED]
Safety and Immunogenicity	
To characterize the safety and tolerability of rocatinlimab in the proposed population	Treatment-emergent adverse events (including clinically significant changes in laboratory values and vital signs) and serious adverse events
[REDACTED]	

Primary Estimands

Two intercurrent events will be considered to estimate the treatment effects: initiation of rescue therapy for AD (Table 6-3) and permanent discontinuation of investigational product without rescue therapy for AD. Subjects are encouraged to complete all remaining study visits and procedures with the exception of investigational product administration and post-dose monitoring procedures through week 24 after permanent discontinuation of investigational product for evaluation of endpoints (see Section 1.3).

The primary estimand for a binary endpoint is to measure the effect of rocatinlimab as assessed by the difference in response rates between each of the 2 rocatinlimab treatment groups ([REDACTED] mg and [REDACTED] mg) and placebo among randomized subjects within moderate-to-severe AD population without rescue therapy for AD, regardless of permanent discontinuation of investigational product. Subjects initiating rescue therapy

for AD will be classified as nonresponders at all subsequent time points (composite strategy reflecting lack of response). For subjects who do not use rescue therapy for AD but permanently discontinue investigational product, data retrieved after permanent discontinuation of investigational product will be included as collected (treatment policy strategy).

The primary estimand for a continuous endpoint is to measure the effect of rocatinlimab as assessed by the difference in **means of change or percent** change from baseline value between each of the 2 rocatinlimab treatment groups (■ mg and ■ mg) and placebo among randomized subjects within moderate-to-severe AD population without rescue therapy for AD, regardless of permanent discontinuation of investigational product. Subjects initiating rescue therapy for AD will be included in the analysis, and each subject's worst observation, including baseline value, before initiation of rescue therapy for AD will be carried forward (Worst **O**bservation **C**arried **F**orward [WOCF]) to all subsequent time points (composite strategy reflecting lack of response). For subjects who do not use rescue therapy for AD but permanently discontinue investigational product, data retrieved after permanent discontinuation of investigational product will be included as collected (treatment policy strategy).

Overall Design

This is a phase 3, 24-week, randomized, placebo-controlled, double-blind study to assess the efficacy, safety, and tolerability of rocatinlimab monotherapy in adult subjects with moderate-to-severe AD with inadequate response to topical medications. Prior advanced therapy, including biologic or targeted-small molecules (eg, Janus kinase [JAK] inhibitors) use is allowed with an adequate washout period.

Subjects will undergo an initial screening visit to confirm eligibility requirements, and those who meet all eligibility criteria that can be confirmed at the initial screening visit will be assigned an electronic diary (eDiary) device where they will be expected to complete the daily questionnaires each day throughout the screening period. The screening period, which starts with the initial screening visit and ends with the day 1 prerandomization visit, will be a minimum of ■ days and a maximum of ■ days. At the day 1 prerandomization visit, subjects who meet all eligibility criteria will be randomized. Subjects who do not meet all eligibility requirements at the initial screening and day 1 prerandomization visits will be considered screen failures. Subjects may be allowed to rescreen once.

Treatment Period

Approximately [REDACTED] eligible subjects will be randomized in [REDACTED] ratio to 3 treatment groups for a duration of 24 weeks as follows:

- Rocatinlimab [REDACTED] mg [REDACTED] with a loading dose at week [REDACTED] (N = [REDACTED])
- Rocatinlimab [REDACTED] mg [REDACTED] with a loading dose at week [REDACTED] (N = [REDACTED])
- Placebo [REDACTED] with a loading dose at week [REDACTED] (N = [REDACTED])

Randomization will be stratified by baseline disease severity (moderate Validated Investigator's Global Assessment for Atopic Dermatitis [vIGA-AD™ score = 3] versus severe [vIGA-AD score = 4]) and geographic region (Japan versus non-Japan Asian countries versus Rest of World).

Subjects may be eligible to enroll into a long-term maintenance study (Study [REDACTED]).

Rescue Therapies for AD

Use of topical corticosteroids (TCS) of any potency, topical calcineurin inhibitors (TCI), topical phosphodiesterase 4 (PDE4) inhibitors, topical JAK inhibitors, phototherapy, or systemic therapies for AD during the 24-week treatment period will be considered use of rescue therapy in the analysis. Allowed rescue therapies are those approved for treatment of AD as well as local standard of care. Subjects may continue investigational product if there is concurrent use of topical rescue therapies (excluding topical JAK inhibitors), or phototherapy. Subjects may require temporary interruption of investigational product if systemic corticosteroids are used for ≤ 2 consecutive weeks to avoid concurrent administration with investigational product. Subjects must permanently discontinue investigational product if there is use of specific prohibited therapies: systemic corticosteroids for > 2 consecutive weeks, conventional non-biologic, non-targeted immunosuppressive systemic therapies, biologics, targeted systemic AD rescue therapies, or topical JAK inhibitors (see [Table 6-2](#) and Table 6-3 for additional details).

Discontinuation of Study Treatment and Subject Discontinuation

Subjects who permanently discontinue investigational product for any reason during the study are encouraged to complete all remaining study visits and procedures with the exception of investigational product administration and post-dose monitoring procedures through week 24 for the evaluation of the coprimary endpoints, which will correspond to their End of Treatment (EOT) visit.

Subjects who permanently discontinue investigational product and do not complete the remaining study visits through week 24 should complete the EOT visit at the next scheduled visit following the last dose of the investigational product.

Safety Follow-up

A safety follow-up (SFU) visit is required [REDACTED] weeks after the last dose of investigational product for all subjects who do not enroll into the long-term maintenance study (Study [REDACTED]).

The maximum study duration for a single subject will be approximately [REDACTED] weeks, including [REDACTED]

The overall study design is described by a study schema in Section 1.2. The endpoints are defined in Section 3.

Number of Subjects

Approximately [REDACTED]

Summary of Subject Eligibility Criteria

- Males or females aged ≥ 18 years or legal adult age within subject's country, whichever is older, with a diagnosis of AD (according to American Academy of Dermatology Consensus Criteria; Eichenfield et al, 2014), that has been present for at least 12 months before signing of informed consent.
- Prior to informed consent, history of inadequate response to TCS of medium to higher potency (refer to Table 11-4) (with or without TCI as appropriate) or for whom topical treatments are otherwise medically inadvisable (eg, because of important side effects or safety risks)

- Presence of moderate-to-severe AD at both initial screening and day 1 prerandomization visit, defined as EASI score ≥ 16 , vIGA-AD score ≥ 3 (on the 0 to 4 vIGA-AD scale, in which 3 is moderate and 4 is severe) and $\geq 10\%$ [REDACTED] of AD involvement. Additionally, patient-reported worst pruritus NRS ≥ 4 based on a single-question item with 7-day recall is required at initial screening.

For a full list of eligibility criteria, please refer to Section 5.1 to Section 5.2.

Treatments

The blinded treatment during the 24-week treatment period includes:

- Rocatinlimab [REDACTED] mg with a loading dose at week [REDACTED]
- Rocatinlimab [REDACTED] mg with a loading dose at week [REDACTED]
- Placebo with a loading dose at week [REDACTED]

For full understanding of the study treatment groups, see Study Schema below ([Figure 1-1](#)).

Statistical Considerations

Approximately [REDACTED] subjects will be randomized in [REDACTED] ratio to 3 treatment groups for a duration of 24 weeks as follows:

- Rocatinlimab [REDACTED] mg (N = [REDACTED])
- Rocatinlimab [REDACTED] mg (N = [REDACTED])
- Placebo (N = [REDACTED])


Statistical Hypotheses

The primary hypothesis is that either rocatinlimab [REDACTED] mg or [REDACTED] mg is superior to placebo as treatment in subjects with moderate-to-severe AD, as assessed by the coprimary endpoints, and both coprimary endpoints need to achieve statistical significance to declare success for each rocatinlimab dose.

Sponsor Name: Amgen

1.2 Study Schema

Figure 1-1. Study Schema



N = number of subjects; [redacted]

1.3 Schedule of Activities (SoA)

Table 1-1. Schedule of Activities

Procedure	Screening Period ^y (Up to █ Days)		Treatment Period (█) ^a									
	Initial screening	Day 1 Pre rand	Day 1								EOS/SFU (+ 3d)	Unscheduled Visit ^x
			Post rand ^b									
GENERAL AND SAFETY ASSESSMENTS												
Informed consent	X											
Inclusion and exclusion criteria	X	X ^b										
Demographics	X											
Physical examination ^{cc}	X						X			X	X	
Vital signs ^d	X		X	X	X	X	X	X	X	X	X	X
Height	X											
Body weight	X											
Medical history	X											
Cardiovascular medical history	X											
Dermatologic medical history	X											
Immunologic medical history	X											
Medication history	X											

Procedure	Screening Period ^y (Up to [REDACTED] Days)		Treatment Period ([REDACTED]) ^a									
	Initial screening	Day 1 Pre rand	Day 1 Post rand ^b								EOS/SFU (+ 3d)	Unscheduled Visit ^x
Substance use history ^f	X											
ECG	X						X			X		X
Cardiovascular risk factors			X									
Adverse events			X	X	X	X	X	X	X	X	X	X
Serious adverse events ^h	X	X	X	X	X	X	X	X	X	X	X	X
Concomitant therapies review	X	X		X	X	X	X	X	X	X	X	X
Screening TB risk assessment questionnaire		X										
On-study TB risk assessment questionnaire ^m							X			X	X	
LABORATORY ASSESSMENTSⁱ												
Coagulation	X											X
HIV, Hepatitis B and C screening ^j	X											X
Hepatitis B DNA (reactivation monitoring only) ^z										X		X

Procedure	Screening Period ^y (Up to █ Days)		Treatment Period (█) ^a									
	Initial screening	Day 1 Pre rand	Day 1 Post rand ^b								EOS/SFU (+ 3d)	Unscheduled Visit ^x
Serum pregnancy test (females of childbearing potential only) ^k	X											X
Urine pregnancy test (females of childbearing potential only) ^k		X			X	X	X	X	X	X	X	X
Hematology	X		X		X	X		X		X	X	X
Chemistry	X		X			X		X		X	X	X
Urinalysis ^l	X											X
QuantiFERON GOLD ^m	X										X	X

Procedure	Screening Period ^y (Up to [] Days)		Treatment Period ([]) ^a									
	Initial screening	Day 1 Pre rand	Day 1 Post rand ^b								EOS/SFU (+ 3d)	Unscheduled Visit ^x
EFFICACY/CLINICAL OUTCOME ASSESSMENTS - ASSESSED BY INVESTIGATOR ^{aa}												
vIGA-AD	X	X		X	X	X	X	X	X	X		X
AD morphology assessment ^o				X	X	X	X	X	X	X		X
EASI	X	X		X	X	X	X	X	X	X		X
SCORAD (investigator facing)			X	X	X	X	X	X	X	X		
EFFICACY/CLINICAL OUTCOME ASSESSMENTS - ASSESSED BY SUBJECT ^{aa}												
Site assigns e-diary	X											

Procedure	Screening Period ^y (Up to [REDACTED] Days)		Treatment Period ([REDACTED]) ^a									
	Initial screening	Day 1 Pre rand	Day 1 Post rand ^b	[REDACTED]							EOS/SFU (+ 3d)	Unscheduled Visit ^x
Worst pruritus NRS ^{p, u}	←===== Daily e-Diary =====→											
AD skin pain NRS ^u	←===== Daily e-Diary =====→											
Sleep disturbance NRS ^u	←===== Daily e-Diary =====→											
SCORAD (subject facing)			X	X	X	X	X	X	X	X		
DLQI			X	X		X		X		X		
POEM			X		X	X		X		X		
HADS	X	X		X	X	X	X	X	X	X	X	X
EQ-5D-5L			X					X		X		
WPAI-AD			X					X		X		
PGI-S–AD skin pain and sleep disturbance			X	X				X		X		
PGI-C–AD skin pain and sleep disturbance								X		X		
[REDACTED]												
STUDY TREATMENT												
Randomization			X									

Procedure	Screening Period ^y (Up to [REDACTED] Days)		Treatment Period ([REDACTED]) ^a									
	Initial screening	Day 1 Pre rand	Day 1 Post rand ^b								EOS/SFU (+ 3d)	Unscheduled Visit ^x
Mental health recommendation review ^{ee}		X		X	X	X	X	X	X	X		

[REDACTED]; AD = atopic dermatitis; [REDACTED] COA = clinical outcome assessments; DLQI = Dermatology Life Quality Index; DNA = deoxyribonucleic acid; EASI = Eczema Area and Severity Index; ECG = electrocardiogram; EOS = end of study; EOT = end of treatment; EQ-5D-5L = 5-level EuroQoL 5 Dimensions; HADS = Hospital Anxiety and Depression Scale; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; HIV = human immunodeficiency virus; NRS = numeric rating scale; PGI-C = Patient Global Impression of Change; PGI-S = Patient Global Impression of Severity; [REDACTED]; POEM = Patient Oriented Eczema Measure; SCORAD = SCORing Atopic Dermatitis; SFU = safety follow-up; TB = tuberculosis; vIGA-ADTM = Validated Investigator's Global Assessment for Atopic Dermatitis; WPAI-AD = Work Productivity and Activity Impairment Questionnaire for Atopic Dermatitis

^a Subjects who permanently discontinue investigational product for any reason during the study are encouraged to complete all remaining study visits and procedures with the exception of investigational product administration and post-dose monitoring procedures through week 24, for the evaluation of the coprimary endpoints, which will correspond to their EOT visit. Subjects who permanently discontinue investigational product and do not complete the remaining study visits through week 24 should complete the EOT visit (see W24/EOT in [Table 1-1](#)) at the next scheduled visit following the last dose of the investigational product. A safety follow-up visit is required [REDACTED] after the last dose of investigational product for all subjects who do not enroll into the long-term maintenance study (Study [REDACTED]).

^b Only certain eligibility criteria will be re-evaluated at the day 1 prerandomization visit. These criteria are required to be met for enrollment/randomization. All baseline assessments at day 1 postrandomization visit must be completed prior to administration of investigational product.

^c For subjects who enroll into the long-term maintenance study (Study [REDACTED]), W24/EOT visit will be considered EOS visit, and a safety follow-up visit will not be required. For subjects who do not enroll into the long-term maintenance study (Study [REDACTED]), a SFU visit will be required for subjects who have not been followed for at least [REDACTED] after the last dose of investigational product.

^d Systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature measured before investigational product administration.

[REDACTED]

Alcohol, recreational drugs, and tobacco use.

[REDACTED]

^h Once the study has ended, the investigator will report to Amgen immediately and no later than 24 hours following the investigator's awareness of the event, any serious adverse event(s) suspected to be related to the investigational product that they become aware of. Refer to Section [8.4.5](#) for additional details.

ⁱ To be collected predose.

^j Hepatitis B DNA testing will be performed for subjects with positive HBsAg and/or HBV core Ab.

^k Additional on-study pregnancy testing may be performed at the investigator's discretion if there is suspicion that a female subject is pregnant or per local laws and regulations.

^l Additional urinalysis can be performed on-study at the investigator's discretion per standard of care.

^m Refer to Section 8.10.1 for additional information on TB assessments.

ⁿ Skin tape sample will be collected from subjects who sign separate optional consent. These samples will only be collected in countries where the skin tape strip materials are approved for use.

^o Only for subjects who achieve vIGA-AD score of 1.

^p This screening assessment will be collected using the site tablet at the initial screening visit and will have a 7-day recall. Throughout the rest of the study, the daily recall NRS will be collected on the subject's handheld device.

[REDACTED]

Daily NRS diary entries to begin the day after the initial screening visit through W24/EOT visit.

^v Subjects must be monitored for 2 hours following at least the first 2 doses of investigational product on day 1 and week [REDACTED]. If no systemic injection-related reactions, including immediate type hypersensitivity reactions, are observed after the first 2 doses, the post-dose monitoring period may be reduced to at least 30 minutes for subsequent doses. If systemic injection-related reactions are observed after the first 2 doses, the 2-hour post-dose monitoring period will remain as needed. Refer to Section 8.4.2 for additional information on post-dose monitoring.

^w Systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature must be measured only at the end of the 2-hour post-dose monitoring period before subject is discharged. (X): as needed.

^x Unscheduled visits may occur at any time point during the treatment period, and only those assessments deemed necessary should be performed at the discretion of the investigator.

^y The screening period, which starts with the initial screening visit and ends with the day 1 prandomization visit, will be a minimum of [REDACTED] days and a maximum of [REDACTED] days. At the day 1 prandomization visit, subjects who meet all eligibility criteria will be randomized.

^z For subjects with positive HBsAg and/or HBV core Ab at initial screening. Any additional testing may be performed per investigator's discretion. For sites and subjects participating in the European Economic Area (EEA), please refer to Section 11.9 (Appendix 9).

^{aa} COAs should be performed prior to any other activity at each visit.

[REDACTED]

^{cc} Complete physical examination will be conducted at screening, and symptom-directed physical examination at subsequent study visits at the discretion of the investigator per standard of care. Refer to Section 8.2.4 for additional information.

[REDACTED]

Investigator must review latest central mental health professional recommendation prior to enrollment and/or dosing.

2. Introduction

2.1 Study Rationale

Atopic dermatitis (AD) is a chronic relapsing and remitting, inflammatory skin disease dominated by reactive T helper type 2 (Th2) cells. The proximate pathophysiologic mechanism for eczematous lesions is now understood to be largely due to inflammation related to dysregulation of Th2 cells (Guttman-Yassky, 2018). OX40 (CD134) is expressed predominantly on T-cells, including effector cells, shortly after their activation (Croft, 2010). OX40 and its ligand, OX40L, are crucial for the generation of Th2 memory cells, and may thus play a central role in the pathogenesis and chronicity of AD (Sitrin et al, 2017). Blocking OX40 signaling has resulted in inhibition of T-cell responses and pathogenic symptoms in animal models of autoimmune diseases (Salek-Ardakani and Croft, 2006; Croft et al, 2009). Rocatinlimab (formerly known as AMG 451 and KHK4083) is a human, non-fucosylated, immunoglobulin G1 (IgG1) monoclonal antibody that binds and inhibits the OX40/OX40L interaction, and thereby, suppresses clonal T-cell expansion. In a Phase 2 study (Study 4083-006) evaluating the efficacy, safety, and tolerability of repeated doses of rocatinlimab in subjects with moderate-to-severe AD, and conducted by Amgen partner Kyowa Kirin Co., Ltd, statistically significant improvements in percent change from baseline to week 16 in Eczema Area and Severity Index (EASI) score was observed in all rocatinlimab-treated cohorts versus placebo. In this study, all doses tested were well tolerated with an acceptable adverse event profile.

The current phase 3 placebo-controlled study will be conducted in adult subjects presenting with moderate-to-severe AD whose disease cannot be adequately controlled with topical medications or for whom topical medications cannot be prescribed medically because of intolerance or safety risks. The study is designed to confirm the efficacy and safety of 2 doses of rocatinlimab monotherapy and to establish the beneficial impact on the related patient reported outcomes including pruritus, skin pain, sleep loss, and impaired quality of life.

Benefit/Risk Assessment

Rocatinlimab has been generally well tolerated and no adverse events with fatal outcome attributed to rocatinlimab have been reported in the completed studies.

Only the SC route of administration is planned, which limits the risk of adverse effects associated with IV infusion. Overall, SC administration is associated with lower incidence of systemic reactions and/or lower severity of acute reactions that tend to be local (Mateos et al 2020, Davies et al 2017, Assouline et al 2016). Eligibility criteria have been implemented to exclude subjects vulnerable to acute allergic reactions and infections and all subjects will be observed after investigational product administration and will be monitored throughout the study with hematology and standard adverse event and serious adverse event reporting.

2.2 Background

2.2.1 Disease

Atopic dermatitis (AD) is one of the most prevalent inflammatory skin diseases. It usually develops in childhood and may persist into adulthood; less frequently, it starts in midlife or late life (Barbarot et al, 2018). The disorder is characterized by recurrent, pruritic, localized eczema, often with seasonal fluctuations. Many patients also have allergic asthma, allergic rhino-conjunctivitis, food allergies, and other immediate hypersensitivity (type 1) allergies (Stander, 2021). The prevalence and incidence of AD have increased over the past several decades. Globally, the prevalence of AD is up to 10% among adults and up to 20% among children, making AD the 15th most common nonfatal disease and the skin disorder with the highest disease burden, in terms of disability-adjusted life-years (Laughter et al, 2021; Stander, 2021).

In clinical practice, AD is classified as mild, moderate, or severe based on a variety of clinical features, including severity of skin lesions and pruritus, and extent of disease (body surface area [BSA] involved). The goals of treatment are to reduce symptoms (pruritus and dermatitis), prevent exacerbations and minimize therapeutic risks (Eichenfield et al, 2014). Current AD therapeutic armamentarium includes

emollients/skin care, topical or systemic corticosteroids, phototherapy, topical calcineurin inhibitors, crisaborole, delgocitinib, systemic immunosuppressants, and biologics (Wollenberg et al, 2018). Patients with moderate-to-severe AD are often given topical treatments before or in conjunction with a systemic treatment or as maintenance therapy after tapering off systemic treatment.


Until recently, the lack of safe and effective systemic treatments meant that most patients with moderate-to-severe AD were not well controlled. Emerging, narrow targeting biologic agents blocking specific cytokine or cytokine receptors have shown significant clinical benefit in these patients. Dupilumab, a monoclonal antibody that binds to the IL-4R α subunit shared by the IL-4 and IL-13 receptor complexes, is the first biologic approved in the United States (US) for patients 6 months and older with moderate-to-severe AD, in the European Union for patients 12 years and older with moderate-to-severe AD and for patients 6 months to 11 years old with severe AD who are candidates for systemic therapy, and in Japan for adults with moderate-to-severe AD. While dupilumab has shown favorable efficacy data in moderate-to-severe AD, nearly half of the patients receiving █ mg every 1 or 2 weeks fail to reach achievement of $\geq 75\%$ reduction from baseline in EASI score (EASI 75) at week 16 (Snast et al, 2018). Additionally, exacerbation or new onset head and neck dermatitis and conjunctivitis have been reported in up to 10% of adults on dupilumab after a median time of 65 days (Jo et al, 2021). Therefore, there is still a large unmet need for novel biologic therapies with different mechanism of action and with improved safety profile for this population.

2.2.2 Amgen Investigational Product Background: Rocatinlimab

Rocatinlimab is an investigational human, non-fucosylated IgG1 mAb specific for inhibiting OX40/OX40L interaction to treat the chronic inflammation in AD and other autoimmune diseases. To date, the efficacy and safety of intravenous (IV) and subcutaneous (SC) rocatinlimab has been evaluated in 5 early phase clinical studies.

A detailed description of the chemistry, pharmacology, efficacy, and safety of rocatinlimab is provided in the investigator's brochure (IB).


2.3 Benefit Risk Assessment





As of the end of the phase 2b study 4083-006, approximately [REDACTED] subjects in the entire development program had received at least 1 dose of rocatinlimab, including healthy subjects, and subjects with plaque psoriasis, ulcerative colitis, and atopic dermatitis, from which [REDACTED] have been treated for at least 6 months and [REDACTED] subjects have been exposed for 1 year.

Rocatinlimab has been generally well tolerated and no adverse events with fatal outcome attributed to rocatinlimab have been reported in the completed studies.



The mechanism of action of rocatinlimab and its immunomodulatory activity may suggest potential effects on host's response to infections. No imbalance in subject incidence of infections has been observed in the completed studies to date.

As further described in this protocol, only the SC route of administration is planned, which limits the risk of adverse effects associated with IV infusion. Overall, SC administration is associated with lower incidence of systemic reactions and/or lower severity of acute reactions that tend to be local (Mateos et al 2020, Davies et al 2017, Assouline et al 2016). In addition, eligibility criteria have been implemented to exclude subjects vulnerable to acute allergic reactions and infections. All subjects will be

observed after investigational product administration and will be monitored throughout the study with hematology and standard adverse event and serious adverse event reporting.

Overall, the above benefit risk assessment supports the conduct of this clinical trial. Reference should be made to the IB for further data on rocatinlimab.

2.3.1 COVID-19

Amgen closely monitors the coronavirus disease 19 (COVID-19) pandemic around the world. As part of this effort, Amgen performs a rigorous assessment, considering the study design, subject safety, public health risk, benefit-risk assessment, as well as the burden on country healthcare systems. Decisions are made on a study-by-study and country-by-country basis to minimize risk to subjects and avoid undue burden on healthcare facilities.

Subjects who display symptoms consistent with COVID-19 infections or who have tested positive for COVID-19 should contact the investigator to ensure appropriate care as well as documentation and management of study activities.

Amgen considers that it is important to continue the proposed development of rocatinlimab in this study in order to advance potential therapy options for patients as rapidly as possible, while balancing this with appropriate measures to monitor and mitigate the potential impact of COVID-19.

Subjects enrolled in this study are permitted to receive vaccinations for COVID-19 as described in Section 6.7.2.

3. Objectives and Endpoints/Estimands

Objectives	Endpoints
Coprimary	
• To evaluate the efficacy of rocatinlimab ■ mg and ■ mg compared with placebo at week 24, assessed using the Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™)	• Achieving a vIGA-AD score of 0 (clear) or 1 (almost clear) with ≥ 2-point reduction from baseline (vIGA-AD 0/1) at week 24
• To evaluate the efficacy of rocatinlimab ■ mg and rocatinlimab ■ mg compared with placebo at week 24, assessed using Eczema Area and Severity Index (EASI)	• Achieving ≥ 75% reduction from baseline in EASI score (EASI 75) at week 24

Key Secondary	
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 16, assessed using EASI	Achieving EASI 75 at week 16
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 16, assessed using vIGA-AD	Achieving vIGA-AD 0/1 at week 16
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 16 and week 24 on the patient-reported outcome (PRO) measure of pruritus	- Achieving [REDACTED] from baseline in weekly average of daily worst pruritus numeric rating scale (NRS) score at week 16 in subjects with baseline weekly average of daily worst pruritus NRS score [REDACTED] - Achieving [REDACTED] from baseline in weekly average of daily worst pruritus NRS score at week 24 in subjects with baseline weekly average of daily worst pruritus NRS score [REDACTED]
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 24, assessed using EASI	Achieving [REDACTED] from baseline in EASI score ([REDACTED]) at week 24
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 24 on the PRO measure of atopic dermatitis (AD) skin pain	Achieving [REDACTED] from baseline in weekly average of daily AD skin pain NRS score at week 24 in subjects with baseline weekly average of AD skin pain NRS score [REDACTED]
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 24, assessed using vIGA-AD with an additional assessment of morphology	Achieving vIGA-AD 1 response with presence of only barely perceptible erythema or vIGA-AD 0 response (revised Investigator's Global Assessment [rIGA™] 0/1) at week 24
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo on [REDACTED]	Achieving a [REDACTED]
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo on [REDACTED]	Achieving a [REDACTED]

Other Secondary	
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 16 and week 24 on the PRO measure of pruritus	- Change from baseline in weekly average of daily worst pruritus NRS score at week 16 - Change from baseline in weekly average of daily worst pruritus NRS score at week 24 - Change from baseline in SCORAD itch VAS score at week 16 - Change from baseline in SCORAD itch VAS score at week 24
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 24 on the PRO measure using the Dermatology Life Quality Index (DLQI)	- Achieving [REDACTED] from baseline in DLQI score at week 24 in subjects with baseline DLQI score [REDACTED] Change from baseline in DLQI score at week 24
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 24 on the PRO measure using the Patient Oriented Eczema Measure (POEM)	- Achieving [REDACTED] from baseline in POEM score at week 24 in subjects with baseline POEM score [REDACTED] - Change from baseline in POEM score at week 24
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 16 and week 24 on the PRO measure of AD skin pain	Achieving [REDACTED] from baseline in weekly average of AD skin pain NRS score at week 16 in subjects with baseline weekly average of AD skin pain NRS score [REDACTED] - Change from baseline in weekly average of daily AD skin pain NRS score at week 24 Change from baseline in weekly average of daily AD skin pain NRS score at week 16 Achieving [REDACTED] from baseline in weekly average of AD skin pain NRS score at week 24 in subjects with baseline weekly average of AD skin pain NRS score [REDACTED] Achieving [REDACTED] from baseline in weekly average of AD skin pain NRS score at week 16 in subjects with baseline weekly average of AD skin pain NRS score [REDACTED]

To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 24 on the PRO measure of sleep disturbance	Change from baseline in weekly average of daily sleep disturbance NRS score at week 24
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 24 on the PRO measure of anxiety and depression using the Hospital Anxiety and Depression Scale (HADS)	- Achieving HADS-anxiety subscale score [REDACTED] at week 24 in subjects with baseline HADS-anxiety subscale score [REDACTED] - Achieving HADS-depression subscale score [REDACTED] at week 24 in subjects with baseline HADS-depression subscale score [REDACTED] - Change from baseline in HADS-anxiety subscale score at week 24 - Change from baseline in HADS-depression subscale score at week 24
To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 24 using the SCORAD	Achieving [REDACTED] from baseline in SCORAD score at week 24 in subjects with baseline SCORAD score [REDACTED]
Safety and Immunogenicity	
To characterize the safety and tolerability of rocatinlimab in the proposed population	Treatment-emergent adverse events (including clinically significant changes in laboratory values and vital signs) and serious adverse events
[REDACTED]	

Primary Estimands


Two intercurrent events will be considered to estimate the treatment effects: initiation of rescue therapy for AD (Table 6-3) and permanent discontinuation of investigational product without rescue therapy for AD. Subjects are encouraged to complete all remaining study visits and procedures with the exception of investigational product administration and post-dose monitoring procedures through week 24 after permanent discontinuation of investigational product for evaluation of endpoints (see Section 1.3).


The primary estimand for a binary endpoint is to measure the effect of rocatinlimab as assessed by the difference in response rates between each of the 2 rocatinlimab treatment groups ([REDACTED] mg and [REDACTED] mg) and placebo among randomized subjects within moderate-to-severe AD population without rescue therapy for AD, regardless of


permanent discontinuation of investigational product. Subjects initiating rescue therapy for AD will be classified as nonresponders at all subsequent time points (composite strategy reflecting lack of response). For subjects who do not use rescue therapy for AD but permanently discontinue investigational product, data retrieved after permanent discontinuation of investigational product will be included as collected (treatment policy strategy).

The primary estimand for a continuous endpoint is to measure the effect of rocatinlimab as assessed by the difference in **means of change or percent** change from baseline value between each of the 2 rocatinlimab treatment groups (■ mg and ■ mg) and placebo among randomized subjects within moderate-to-severe AD population without rescue therapy for AD, regardless of permanent discontinuation of investigational product. Subjects initiating rescue therapy for AD will be included in the analysis, and each subject's worst observation, including baseline value, before initiation of rescue therapy for AD will be carried forward (worst observation carried forward, WOCF) to all subsequent time points (composite strategy reflecting lack of response). For subjects who do not use rescue therapy for AD but permanently discontinue investigational product, data retrieved after permanent discontinuation of investigational product will be included as collected (treatment policy strategy).

Objectives	Endpoints







Exploratory (Pharmacodynamic and Pharmacokinetics)

4. Study Design

4.1 Overall Design

This is a phase 3, 24-week, randomized, placebo-controlled, double-blind study to assess the efficacy, safety, and tolerability of rocatinlimab monotherapy in adult subjects with moderate-to-severe AD with inadequate response to topical medications. Prior advanced therapy, including biologic or targeted-small molecules (eg, Janus kinase [JAK] inhibitors) use is allowed with an adequate washout period.

Subjects will undergo an initial screening visit to confirm eligibility requirements, and those who meet all eligibility criteria that can be confirmed at the initial screening visit will be assigned an electronic diary (eDiary) device where they will be expected to complete the daily questionnaires each day throughout the screening period. The screening period, which starts with the initial screening visit and ends with the day 1 prerandomization visit, will be a minimum of [REDACTED] days and a maximum of [REDACTED] days. At the day 1 prerandomization visit, subjects who meet all eligibility criteria will be randomized. Subjects who do not meet all eligibility requirements at the initial screening and day 1 prerandomization visits will be considered screen failures. Subjects may be allowed to rescreen once.

Treatment Period

Approximately [REDACTED] eligible subjects will be randomized in [REDACTED] ratio to 3 treatment groups for a duration of 24 weeks as follows:

- Rocatinlimab [REDACTED] mg [REDACTED] with a loading dose at week [REDACTED] (N = [REDACTED])
- Rocatinlimab [REDACTED] mg [REDACTED] with a loading dose at week [REDACTED] (N = [REDACTED])
- Placebo [REDACTED] with a loading dose at week [REDACTED] (N = [REDACTED])

Randomization will be stratified by baseline disease severity (moderate validated investigator's global assessment for atopic dermatitis [vIGA-AD™ score = 3] versus

severe [vIGA-AD™ score = 4]) and geographic region (Japan versus non-Japan Asian countries versus Rest of World).

Subjects may be eligible to enroll into a long-term maintenance study (Study [REDACTED]).

Rescue Therapies for AD

Use of topical corticosteroids (TCS) of any potency, topical calcineurin inhibitors (TCI), topical PDE4 inhibitors, topical JAK inhibitors, phototherapy, or systemic therapies for AD during the 24-week treatment period will be considered use of rescue therapy in the analysis. Allowed rescue therapies are those approved for treatment of AD as well as local standard of care. Subjects may continue investigational product if there is concurrent use of topical rescue therapies (excluding topical JAK inhibitors), or phototherapy. Subjects may require temporary interruption of investigational product if systemic corticosteroids are used for ≤ 2 consecutive weeks to avoid concurrent administration with investigational product. Subjects must permanently discontinue investigational product if there is use of specific prohibited therapies, systemic corticosteroids for > 2 consecutive weeks, conventional non-biologic, non-targeted immunosuppressive systemic therapies, biologics, targeted systemic AD rescue therapies, or topical JAK inhibitors (see [Table 6-2](#) and Table 6-3 for additional details).

Discontinuation of Study Treatment and Subject Discontinuation

Subjects who permanently discontinue investigational product for any reason during the study are encouraged to complete all remaining study visits and procedures with the exception of investigational product administration and post-dose monitoring procedures through week 24 for the evaluation of the coprimary endpoints, which will correspond to their EOT visit.

Subjects who permanently discontinue investigational product and do not complete the remaining study visits through week 24 should complete the EOT visit at the next scheduled visit following the last dose of the investigational product.

Safety Follow-up

A safety follow-up (SFU) visit is required [REDACTED] weeks after the last dose of investigational product for all subjects who do not enroll into the long-term maintenance study (Study [REDACTED]).

The maximum study duration for a single subject will be approximately [REDACTED] weeks, including [REDACTED]

The overall study design is described by a study schema in [Section 1.2](#). The endpoints are defined in [Section 3](#).

Participants in this clinical investigation shall be referred to as “subjects”. For the sample size justification, see [Section 9.2](#).

4.2 Patient Input into the Study Design

Patient input was not obtained for this study.

4.3 Justification for Dose

4.3.1 Justification for Investigational Product Dose

This study will be used to investigate rocatinlimab [REDACTED] mg [REDACTED] for 24 weeks with an additional [REDACTED] mg dose on week [REDACTED] and [REDACTED] mg [REDACTED] for 24 weeks with an additional [REDACTED] mg dose on week [REDACTED]

In the phase 2 Study 4083-006, 3 dose levels and 2 dosing frequencies ([REDACTED] mg [REDACTED] [REDACTED] mg [REDACTED] 300 mg Q2W, and [REDACTED] mg Q2W) were tested. All doses were associated with improved Investigator’s Global Assessment (IGA) and EASI 75 responses compared with placebo. The adverse event profile was overall consistent across the different active treatment groups.

4.4 End of Study

The End of Study (EOS) date is defined as the date when the last subject across all sites is assessed or receives an intervention for evaluation in the study (ie, last subject last visit), including any additional parts in the study (eg, long-term follow-up, [REDACTED] [REDACTED] as applicable.

An individual subject is considered to have completed the study if they have completed the last scheduled visit shown in the Schedule of Activities (see Section 1.3). The maximum total study duration for an individual subject is approximately [REDACTED] weeks.

5. Study Population

Investigators will be expected to maintain a screening log of all potential study candidates that includes limited information about the potential candidate (eg, date of screening). This log may be completed and updated via an Interactive Response Technology (IRT).

Eligibility criteria will be evaluated during the screening period through day 1 prerandomization visit.

Before any study-specific activities/procedures, the appropriate written informed consent must be obtained (see [Section 11.3](#)).

Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions will not be provided.

The sponsor will monitor the study population baseline characteristics during enrollment. If necessary, the sponsor may restrict enrollment of certain populations in order to ensure the appropriate distributions of subject characteristics.

5.1 Inclusion Criteria

Subjects are eligible to be included in the study only if all of the following criteria apply:

- 101 Subject has provided informed consent prior to initiation of any study-specific activities/procedures.

- 102 Age $\geq$ 18 years or legal adult age within country, whichever is older at signing of informed consent.
- 113 Subject has a diagnosis of AD (according to American Academy of Dermatology Consensus Criteria [Eichenfield et al, 2014]) that has been present for at least 12 months before signing of informed consent.
- 114 Prior to informed consent, history of inadequate response to TCS of medium to higher potency (refer to [Table 11-4](#)) () or for whom topical treatments are otherwise medically inadvisable (eg, because of important side effects or safety risks).

- 105 EASI score $\geq$ 16 at initial screening.
- 106 EASI score $\geq$ 16 at day 1 prerandomization.
- 107 vIGA-AD score $\geq$ 3 (on the 0 to 4 vIGA-AD scale, in which 3 is moderate and 4 is severe) at initial screening.
- 108 vIGA-AD score $\geq$ 3 (on the 0 to 4 vIGA-AD scale, in which 3 is moderate and 4 is severe) at day 1 prerandomization.
- 109
- 110
- 111 Patient-reported Worst Pruritus NRS $\geq$ 4 based on a single-question item with 7-day recall at initial screening.
- 112 Subjects must have completed at least 4 days of daily diary entries within the 14 days preceding and including day 1 prerandomization.

5.2 Exclusion Criteria

Subjects are excluded from the study if any of the following criteria apply:

Other Medical Conditions

- 201 Active malignancy, multiple myeloma; myeloproliferative or lymphoproliferative disorder; or a history of any of these conditions within 5 years prior to informed consent (except curatively treated in situ cervical carcinoma, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma).
- 202 History of major immunologic reaction (eg, serum sickness, anaphylaxis, or anaphylactic reaction) to any other biologic product or any excipient of rocatinlimab.

- 203 Known sensitivity to any of the products or components to be administered during dosing.
- 204 Diagnosis of a helminth parasitic infection within 6 months prior to day 1 prerandomization that had not been treated with or had failed to respond to standard of care therapy.
- 205 Evidence of human immunodeficiency virus (HIV) infection or positive for HIV antibodies at initial screening or current acquired, common variable or inherited, primary or secondary immunodeficiency.
- 206 Positive for hepatitis C virus (HCV) antibody at initial screening with confirmed positive HCV RNA.
- 207 Active and non-virally suppressed hepatitis B infection at initial screening, defined as detectable hepatitis B DNA polymerase chain reaction (PCR) test in a subject with detectable hepatitis B surface antigen (HBsAg) and/or antibodies to hepatitis B core (anti-HBc). Subjects with detectable HBsAg are required to be virally suppressed with an approved hepatitis B antiviral therapy during the study. For sites and subjects participating in the European Economic Area (EEA), please refer to Section 11.9 (Appendix 9).
- 237 Positive or indeterminate QuantiFERON GOLD from central laboratory at initial screening
- Exception: A positive or indeterminate QuantiFERON test is allowed if ALL of the following are present at day 1 prerandomization per Screening TB Risk Assessment Questionnaire provided by Amgen:
 - No symptoms of tuberculosis (TB)
 - Documented history of a completed course of adequate prophylaxis (completed treatment for latent TB per local standard of care prior to start of investigational product)
 - No known exposure to a case of active TB after most recent prophylaxis
 - No evidence of active TB on chest radiograph obtained within 3 months prior to day 1 prerandomization
- For sites and subjects participating in the EEA, please refer to Section 11.9 (Appendix 9).
- 209 A corrected QT interval (QTc) of > 450 msec in males or > 470 msec in females at initial screening as assessed by the investigator, or history of long QT syndrome.
- 230 Active chronic or acute infection requiring treatment with systemic antibiotics, antiviral, antiparasitic, antiprotozoal, or antifungals which has not completely resolved, or for which therapy has not been completed, within 4 weeks before day 1 prerandomization.
- 211 Superficial skin infections within 2 weeks before day 1 prerandomization.
- 213 Any of the following laboratory abnormalities at initial screening:
- Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m²

- Aspartate aminotransaminase (AST) or alanine aminotransaminase (ALT) ≥ 2.5 times the upper limit of normal (ULN)
 - Neutrophil count $< 1.5 \times 10^3/\mu\text{L}$
- 228 Severe depression, poorly controlled schizophrenia, or subjects who have had an inpatient psychiatric admission within the last year. Subjects who are receiving a psychiatric treatment regimen must be stable on treatment for at least 8 weeks prior to day 1.

- 231 History of New York Heart Association class III/IV heart failure; uncontrolled hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg) at initial screening; or inadequately treated cardiovascular conditions at initial screening including: cardiomyopathy, major congenital heart disease, or second- or third-degree atrioventricular block.
- 232 Recent cardiovascular events including: cerebrovascular accident, myocardial infarction, coronary stenting, or unstable angina within 6 months of day 1 prerandomization.

Prior/Concomitant Therapy

- 214 Treatment with a biological immunosuppressive or immunomodulatory therapy for AD or any other autoimmune, inflammatory, or allergic condition (eg, dupilumab, tralokinumab, lebrikizumab, other interleukin inhibitors, anti-immunoglobulin E [IgE], tumor necrosis factor [TNF] inhibitors) within 12 weeks or 5 half-lives, whichever is longer, prior to day 1 prerandomization.
- 215 Any cell depletion therapy within 12 months from initial screening or until cell count returns to normal before screening, whichever is longer.
- 233 Treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to day 1 prerandomization.
- Systemic corticosteroids (inhaled corticosteroids, intra-articular steroid injection, eye, ear, or nasal drops containing corticosteroids are allowed, suppositories or enemas containing corticosteroids are not allowed)
 - Systemic treatment with methotrexate, mycophenolate, calcineurin inhibitors, or other non-biologic, non-targeted systemic immunosuppressants
 - Phototherapy
 - Oral or topical JAK inhibitors
- 238 Treatment with any of the following agents within 1 week before day 1 prerandomization:
- TCS of any potency
 - TCI
 - Topical phosphodiesterase 4 (PDE4) inhibitors
 - Other topical immunosuppressive agents
 - Combination topical agents including TCS of any potency, TCI, PDE4 inhibitors, or other topical immunosuppressive agents

- 219 Treatment with live virus including live attenuated vaccination 12 weeks prior to day 1 prerandomization. Inactive vaccination (eg, non-live or nonreplicating agent), including COVID-19 vaccination, is allowed.

Prior/Concurrent Clinical Study Experience

- 220 Previous participation in a study including rocatinlimab (formerly AMG 451 and KHK4083) or any therapy selectively targeting OX40/OX40L and receipt of active investigational product.
- 239 Currently receiving treatment in another investigational device or drug study, or less than 30 days (16 weeks for Japan) or 5 half-lives, whichever is longer, since ending treatment on another investigational device or drug study(ies) prior to day 1 prerandomization. Other investigational procedures while participating in this study are excluded.

Other Exclusions

- 222 Female subjects of childbearing potential unwilling to use protocol specified method of contraception see Appendix 5 ([Section 11.5](#)) during treatment and for an additional 16 weeks after the last dose of investigational product.
- 223 Female subjects who are breastfeeding or who plan to breastfeed while on study through 16 weeks after the last dose of investigational product.
- 224 Female subjects planning to become pregnant while on study through 16 weeks after the last dose of investigational product.
- 225 Female subjects of childbearing potential with a positive pregnancy test assessed at initial screening and day 1 prerandomization by a highly sensitive serum or urine pregnancy test respectively.
- 226 Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (eg, Clinical Outcome Assessments) to the best of the subject and investigator's knowledge.
- 227 History or evidence of any other clinically significant disorder (including concomitant dermatologic conditions such as psoriasis), or disease, including non-AD dermatologic conditions (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.

5.3 Lifestyle Considerations

5.3.1 Meals and Dietary Restrictions

The pathogenesis of AD associated with food allergy is complex. The importance of diet as a potential trigger of AD has been a subject of debate for a long time (Lever, 2001). However, there is not enough evidence that can demonstrate improvement in AD through dietary elimination, so this is not recommended routinely. Study subjects should be encouraged to adhere to their usual diet and avoid any foods known to trigger allergic sensitivity of their AD for the duration of the study.

5.3.2 Activity

Emotional stress, defined as general response of the body to external or internal challenges to the AD pathology, can impact disease severity. Factors like lifestyle and leisure activities may change the behavior of immune cells in AD with an impact on the evolution of the disease (Bridgette and Noren, 2017). However, there is not enough evidence that can demonstrate improvement in AD through specific activity elimination, so this is not recommended routinely. Study subjects should be encouraged to adhere to usual activity and avoid any activities known to affect their AD.

5.4 Subject Enrollment

Before subjects begin participation in any study-specific activities/procedures, Amgen requires a copy of the site's written institutional review board/independent ethics committee (IRB/IEC) approval of the protocol, informed consent form, and all other subject information and/or recruitment material, if applicable (see [Section 11.3](#)).

The subject or the subject's legally authorized representative (if allowed, depending on the country concerned) must personally sign and date the IRB/IEC and Amgen-approved informed consent before commencement of study-specific procedures.

Each subject who enters into the screening period for the study (defined as when they sign the informed consent) receives a unique subject identification number before any study-related activities/procedures are performed. The subject identification number will be assigned via IRT. This number will be used to identify the subject throughout the clinical study and must be used on all study documentation related to that subject.

The subject identification number must remain constant throughout the entire clinical study; it must not be changed after initial assignment, including if a subject is rescreened. This number will not necessarily be the same as the randomization number assigned for the study.

Subjects are eligible to be enrolled into the study when the investigator determines that the subject has met all eligibility criteria. Subjects are considered enrolled at the time when a randomization number is assigned via IRT. The investigator is to document enrollment decision and date, in the subject's medical record and in/on the Subject Enrollment Case Report Form (CRF) [via IRT].

Sites that do not enroll subjects within 3 months of site initiation may be closed.

5.5 Screen Failures

Screen failures are defined as subjects who consent to participate in the clinical study but are not subsequently enrolled in the study. A minimal set of screen failure information will be collected that includes demography, screen failure details, eligibility criteria, and any serious adverse events.

Individuals who do not meet the criteria for participation in this study (screen failure), regardless of reason, may be rescreened 1 time. Refer to [Section 8.1.1](#).

6. Study Intervention

Study intervention is defined as any investigational product(s), noninvestigational product(s), placebo, combination product(s), or medical device(s) intended to be administered to a study subject according to the study protocol.

Note that according to local regulations in several countries, investigational product(s) described in [Section 6.1.1](#) are referred to as investigational medicinal product(s) and


A summary of the dosing and administration of each treatment is shown in [Table 6-1](#) below.

6.1 Study Interventions Administered


6.1.1 Investigational Products

Table 6-1. Investigational Products

Study Treatment Name	Amgen Investigational Product: ^a Rocatinlimab	Placebo
Dosage Formulation	████ mg/mL Supplied as a single-use, preservative free solution for injection	Placebo will be presented in identical containers, and stored/packaged the same as rocatinlimab
Unit Dose Strength(s)	████ mg per vial	N/A
Dosage Level(s)	Rocatinlimab █████ mg █████ or rocatinlimab █████ mg █████ with a loading dose given at week █████	Placebo █████ with a loading dose given at week █████
Route of Administration	SC Injection	
Accountability	The quantity of investigational product administered per vial, start date/time, and box number of investigational product are to be recorded on each subject's CRF(s).	

	
Dosage Preparation	Information regarding dose preparation/administration will be provided to the site.

CRF = case report form; N/A = not applicable; SC = subcutaneous; 
Note: Blinding on dose level is maintained through utilization of a multipack configuration^a
Rocatinlimab/placebo will be manufactured and packaged by Amgen and distributed using Amgen clinical study drug distribution procedures.



6.1.3 Medical Devices

Medical devices will not be used in this study.

Other noninvestigational medical devices may be used in the conduct of this study as part of standard care.

Non-Amgen noninvestigational medical devices (eg, syringes, sterile needles), that are commercially available are not usually provided or reimbursed by Amgen (except, for

example, if required by local regulation). The investigator will be responsible for obtaining supplies of these devices.

6.1.4 Other Intervention Procedures

There are no other interventional procedures in this study.

6.1.5 Product Complaints

A product complaint is any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a drug, combination product, or device after it is released for distribution to market or clinic by either (1) Amgen or (2) distributors or partners for whom Amgen manufactures the material. This includes all components distributed with the drug, such as packaging drug containers, delivery systems, labeling, and inserts.

This includes any investigational product provisioned and/or repackaged/modified by Amgen.

Any product complaint(s) associated with an investigational product supplied by Amgen are to be reported.

6.1.6 Excluded Treatments, Medical Devices, and/or Procedures During Study Period

6.1.6.1 Atopic Dermatitis Rescue Therapy

Topical and systemic rescue therapies for AD are discouraged during the study period with the investigational product (see Section [6.7.3](#)).

6.1.6.2 Other Excluded/Discouraged Therapies for Atopic Dermatitis or Related Conditions

The use of the following therapies is discouraged at any time during the study.

However, subjects may continue investigational product if there is the concurrent use of any of these therapies:

- Emollients containing added pharmacological agents with antipruritic, antiseptic, and/or keratolytic properties, such as urea $\geq 20\%$, ammonium lactate $\geq 12\%$, or salicylic acid $\geq 3\%$
- Antihistamines for treatment of pruritus

6.1.6.3 Guidance for Certain Therapeutics for Non-atopic Dermatitis Related Conditions, Including Prohibited Therapies

Guidance for therapeutics for non-AD related conditions is provided in [Table 6-2](#).

Table 6-2. Guidance for Certain Therapeutics for Non-atopic Dermatitis Related Conditions, Including Prohibited Therapies

Therapies if given for non-AD-related conditions	Restrictions	Requires Temporary Interruption or Permanent Discontinuation of Investigational Product
• Live vaccines • Any investigational product in another device or drug study	Always prohibited	Permanent discontinuation
• Systemic corticosteroids (eg, oral, IV, or intramuscular)	Strong recommendation to use alternative non-systemic therapy for non-AD-related indications prior to using systemic therapies	If treatment duration ≤ 2 consecutive weeks • May require temporary Interruption to avoid concurrent administration • No temporary interruption required if systemic corticosteroid and adequate washout period (5 half-lives) have completed by next investigational product dose If treatment duration > 2 consecutive weeks • Permanent discontinuation
Conventional immunosuppressive or immunomodulatory agents (non-biologic, non-targeted), eg, • Cyclosporine • Azathioprine • Methotrexate • Mycophenolate	Strong recommendation to use alternative non-systemic therapy for non-AD-related indications prior to using systemic therapies	Permanent discontinuation

Therapies if given for non-AD-related conditions	Restrictions	Requires Temporary Interruption or Permanent Discontinuation of Investigational Product
- Immunosuppressive or immunomodulatory biologics for the treatment of non-AD autoimmune, inflammatory, or allergic diseases (eg, dupilumab, interleukin inhibitors, anti-IgE, or TNF inhibitors) - Immunotherapy (eg, PD1 inhibitors), cytotoxic, or cell-depleting therapies (eg, cyclophosphamide) - Oral kinase inhibitors (eg, inhibitors of JAK, BTK, or TYK2)	Prohibited until 16 weeks after discontinuation of investigational product	Permanent discontinuation

AD = atopic dermatitis; BTK = Bruton's tyrosine kinase; IgE = immunoglobulin E; IV = intravenous;
JAK = Janus kinase; PD1 = programmed cell death 1 receptor; TNF = tumor necrosis factor
TYK2 = tyrosine kinase 2.

6.2 Dose Modification

6.2.1 Dose-group/Cohort Study Escalation/De-escalation and Stopping Rules

Not applicable.

6.2.2 Dosage Adjustments, Delays, Rules for Withholding or Restarting, Permanent Discontinuation


6.2.2.1 Amgen Investigational Product: Rocatinlimab/Placebo

The following adverse events require permanent discontinuation from investigational product:

- Anaphylactic reaction or other serious hypersensitivity/allergic reaction assessed as related to investigational product by the investigator.
- Malignancy (excluding carcinoma in situ of the cervix, or squamous or basal cell carcinoma of the skin).
- Opportunistic infection, such as active TB and other infections whose nature or course may suggest an immunocompromised status.

For sites and subjects participating the EEA, please refer to Section [11.9](#) (Appendix 9).

- Serious or severe infection requiring systemic treatment with antibiotic, antifungal, antiviral, anti-parasitic, or anti-protozoal agents for longer than 2 weeks.



- Severe depression as assessed by the investigator. The investigator should immediately refer the subject for mental health assessment and treatment, as per local standard of care (see Sections [REDACTED] and 8.2.8).
- Other serious neuropsychiatric event requiring psychiatric hospitalization.
- Any of the following laboratory results:
 - Neutrophil count $\leq 0.5 \times 10^9/L$ confirmed by 2 consecutive tests (confirmatory test by the central laboratory must be performed as soon as possible, and results reviewed prior to next scheduled dose).
 - Hepatotoxicity meeting criteria for permanent discontinuation of investigational product as provided in Table 11-3.

The following adverse events require temporary interruption of investigational product:

- Presence of a serious or severe infection on the day of a scheduled investigational product. Investigational product may resume at the discretion of the principal investigator (PI) or in consultation with the medical monitor.

Use of certain rescue therapies may require permanent discontinuation or temporary interruption of investigational product (see Table 6-2 and Table 6-3).

6.2.3 Hepatotoxicity Stopping and Rechallenge Rules

Refer to Section 11.7 for details regarding drug-induced liver injury guidelines, as specified in the Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation, July 2009.

6.3 Preparation/Handling/Storage/Accountability

Guidance and information on drug accountability for the investigational product will be provided to the site. If permitted by local regulations, the site may ship investigational product to the subject. If the site does not have its own courier, shipment can be organized by a third-party courier engaged by sponsor. The courier's information must be included on the Delegation of Authority Form. The investigator is responsible for directing and supervising the shipment and activities of the courier. Subjects should be informed of their responsibilities for receipt, handling, storage, and accountability if site

to subject shipments will be performed. Additional guidance will be provided to the site. There is no additional risk to subjects with the Site to Patient process. Site to Subject specific training will be provided and support materials for the sites and subjects as necessary. Management of temperature data and status check of investigational product will be completed post-delivery by way of courier review of the temperature logger.

6.4 Measures to Minimize Bias: Randomization and Blinding


6.4.1 Method of Treatment Assignment

The randomization for the treatment period as described in Section 4.1 will be performed by IRT according to the randomization list generated by Amgen Global Randomization and Blinding group, and randomization date will be captured in IRT.

6.4.2 Blinding

This is a double-blinded study. Unblinding information consists of subject treatment assignments, including contents of investigational product boxes (eg, manufacturing lot number), and potentially unblinding data (PUBD) which has the potential to indicate treatment assignment for an individual subject.

The following assessments will also be considered unblinding information:



Unblinding information will be blinded to all subjects, site personnel, and Amgen study personnel or designee as described below (Section 6.4.2.1 and Section 6.4.2.2).

6.4.2.1 Site Personnel Access to Unblinding Information

A subject's treatment assignment is to only be unblinded by the investigator when knowledge of the treatment is essential for the further management of the subject on this study or may potentially impact the safety of the subject. Unblinding at the study site for any other reason will be considered a protocol deviation. It is encouraged that the Amgen Trial Manager be notified before the blind is broken unless the investigator believes that identification of the study treatment is required for a medical emergency. If this is not possible, the Amgen Trial Manager must be notified immediately and no later than 24 hours after breaking the blind. The date and reason that the blind was broken must be recorded in the source documentation.

Except for emergency unblinding of individual subjects, unblinding information will not be accessible by investigative sites or subjects prior to all subjects receiving blinded maintenance treatment in the long-term maintenance study (Study [REDACTED]) having switched to open-label treatment or completed the SFU.

6.4.2.2 Access to Unblinding Information by Amgen or Designees

Pre-identified members of the clinical study team will be unblinded in order to conduct the primary analysis (Section 9.4.1.1). Other members of the clinical study team will not have access to unblinding information prior to all subjects receiving blinded maintenance treatment in the long-term maintenance study (Study [REDACTED]) having switched to open-label treatment or completed the SFU.

6.5 Treatment Compliance


When subjects are dosed at the site, they will receive rocatinlimab or placebo directly from the investigator or designee, under medical supervision. The date and time of each dose administered in the clinic will be recorded in the source documents and recorded in the CRF.


6.6 Treatment of Overdose

Overdose, defined for the purpose of this study as any dose above the highest dose specified in this protocol (see Section 6.1), is anticipated to be low. The investigational product will be administered under medical supervision by qualified personnel and the maximum possible dose to be administered in case of dosing preparation error is [REDACTED] mg. Treatment of overdose of rocatinlimab consists of general supportive measures directed to the observed clinical effects. There is no known specific antidote for overdose of rocatinlimab. In case of suspected overdose, the investigator should:

- Contact the Amgen medical monitor immediately.
- Closely monitor the participant for any adverse event/serious adverse event and laboratory abnormalities for at least 16 weeks after the administration of the suspected overdose.
- Document the quantity of the excess dose as well as the duration of the overdose in the CRF.

6.7 Prior and Concomitant Treatment





6.7.2 Concomitant Treatment

Investigators may prescribe any concomitant medications or treatments deemed necessary to provide adequate supportive care in accordance with the restrictions listed in Section 6.1.7. Subjects will be instructed to consult the investigator or other appropriate study personnel at the site before taking any new medications or supplements during the study.

The following non-exhaustive list of therapies is permitted during the study and will not be considered as rescue therapies:

- For those subjects on stable dosing of prescription sleep medications at entry, downward dose adjustments or discontinuation of treatment may occur during the study.
- Non-sedating antihistamines including, but not limited to, acrivastine, bilastine, cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine, mizolastine, and rupatadine are allowed for treatment of allergic conditions other than AD. Use of antihistamines for treatment of pruritus is discouraged during the study.
- Single intra-articular or soft tissue (bursa, tendons, and ligaments) corticosteroid injection is allowed.
- Intranasal or inhaled steroid use is allowed.

- Topical anesthetics and topical and systemic anti-infective medications are allowed.
- Non-live vaccinations (eg, COVID-19) are allowed.
- Ophthalmic drugs containing antihistamines, corticosteroids or other immunosuppressants are allowed.
- Treatment with concomitant therapies for other medical conditions such as diabetes, hypertension, hyperlipidemia, and psychiatric illnesses is permitted during the study.

Concomitant therapies are to be collected from enrollment through the end of study. All concomitant medications or treatments, whether prescription or over the counter, used during the course of the study, must be recorded on the concomitant medication **electronic Case Report Form (eCRF)**. Any changes must be recorded.

For concomitant therapies being taken, collect therapy name, indication, dose, unit, frequency, route, start date, and stop date.

6.7.3 Rescue Therapies for Atopic Dermatitis or Related Conditions

In the event of worsening and/or unacceptable symptoms of AD, rescue with standard of care therapies may be given if deemed necessary by the investigator. Rescue therapies for AD are defined as therapies concordant with AD treatment and are listed in Table 6-3. It is recommended to use topical rescue therapies before considering using systemic rescue.

Any use of rescue therapy as described in Table 6-3 will result in the subject being considered a nonresponder for all subsequent efficacy assessments in the analysis (Section 9.4.2.2).

Table 6-3. Rescue Therapy for Atopic Dermatitis

Rescue Therapy for AD	If deemed necessary, when permitted for use	Requires Temporary Interruption or Permanent Discontinuation of Investigational Product
Topical rescue therapy and phototherapy: • Topical corticosteroids of any potency^a • Topical calcineurin inhibitors • Topical PDE4 inhibitors • Other topical immunosuppressive agents	Use is discouraged during study, however permitted if deemed necessary.	No

Rescue Therapy for AD	If deemed necessary, when permitted for use	Requires Temporary Interruption or Permanent Discontinuation of Investigational Product
with the exception of topical JAK inhibitors (see below) - Combination agents including TCS of any potency or TCI, PDE4 inhibitors, or other topical immunosuppressive agents - Phototherapy		
Systemic corticosteroids (eg, oral, IV, or intramuscular)	Use is discouraged during study, however permitted if deemed necessary. NOTE: Recommend consideration of topical rescue therapies first	If rescue treatment duration ≤ 2 consecutive weeks - May require temporary interruption to avoid concurrent administration - No temporary interruption required if rescue treatment and an adequate washout period (5 half-lives) have completed by next investigational product dose If rescue treatment duration >2 consecutive weeks - Permanent discontinuation
Conventional immunosuppressive systemic therapies (non-biologic, non-targeted), eg, - Cyclosporine - Azathioprine - Methotrexate - Mycophenolate	Use is discouraged during study, however permitted if deemed necessary. NOTE: Recommend use of topical rescue therapies before escalating to systemic rescue therapy	Permanent discontinuation
Biologic or targeted systemic AD therapies, including: Biologics (eg, dupilumab, tralokinumab)	At least 16 weeks after discontinuation of the investigational product	Permanent discontinuation

Rescue Therapy for AD	If deemed necessary, when permitted for use	Requires Temporary Interruption or Permanent Discontinuation of Investigational Product
• Oral JAK inhibitors (eg, upadacitinib, baricitinib, or abrocitinib) • Topical JAK inhibitors (eg, ruxolitinib cream)	NOTE: Recommend use of topical rescue therapies before escalating to systemic rescue therapy	

AD = atopic dermatitis; IV = intravenous; JAK = janus kinase; PDE4 inhibitor = phosphodiesterase 4 inhibitor; TCI = topical calcineurin inhibitor; TCS = topical corticosteroids;

^a A full list of topical corticosteroids and potency category is provided in Appendix 8 (Section 11.8).

7. Discontinuation of Study Treatment and Subject Discontinuation/Withdrawal

Subjects have the right to withdraw from investigational product, [REDACTED] and/or protocol procedures, or the study as a whole at any time and for any reason without prejudice to their future medical care by the physician or at the institution.

The investigator and/or sponsor can decide to withdraw a subject(s) from investigational product, device, and/or [REDACTED] protocol procedures, or the study as a whole at any time prior to study completion for the reasons listed in Section 7.1.

7.1 Discontinuation of Study Treatment

Subjects (or a legally authorized representative [if allowed, depending on the country concerned]) can decline to continue receiving investigational product and/or [REDACTED] and/or procedures at any time during the study but continue participation in the study. If this occurs, the investigator is to discuss with the subject the appropriate processes for discontinuation from investigational product and/or [REDACTED] and must discuss with the subject the possibilities for continuation of the Schedule of Activities (see Section 1.3) including different options of follow-up (eg, in person, by phone/mail, through family/friends, in correspondence/communication with other treating physicians, from the review of medical records) and collection of data, including endpoints, adverse events, and product complaints (including device-related adverse events, as applicable) and must document this decision in the subject's medical records. Subjects are encouraged to complete all remaining study visits and procedures with the exception of investigational product administration and post-dose monitoring

procedures through week 24 after permanent discontinuation of investigational product. Subjects who have discontinued investigational product and/or **noninvestigational product(s)/auxiliary medicinal product(s)** and/or procedures should not be automatically removed from the study. Whenever safe and feasible, it is imperative that subjects remain on-study to ensure safety surveillance and/or collection of outcome data.

Reasons for early removal from protocol-required investigational product(s) or procedural assessments may include any of the following:

- decision by sponsor
- lost to follow-up
- death
- adverse event
- subject request
- ineligibility determined
- protocol deviation
- non-compliance
- requirement for alternative therapy (see [Table 6-2](#) and [Table 6-3](#))
- pregnancy

7.2 Subject Discontinuation/Withdrawal From the Study

Withdrawal of consent for a study means that the subject does not wish to receive further protocol-required therapies or procedures, and the subject does not wish to or is unable to continue further study participation. Subject data up to withdrawal of consent will be included in the analysis of the study, and where permitted, publicly available data can be included after withdrawal of consent. The investigator is to discuss with the subject appropriate procedures for withdrawal from the study and must document the subject's decision to withdraw in the subject's medical records. Subjects who are withdrawn or removed from treatment or the study will not be replaced.

If a subject withdraws from the study, he/she may request destruction of any samples taken and not tested, and the investigator must notify Amgen accordingly (see [Section 11.6](#) for further details). Refer to the Schedule of Activities ([Section 1.3](#)) for data to be collected at the time of study discontinuation and follow-up and for any further evaluations that need to be completed.

7.2.1 Reasons for Removal From Study

Reasons for removal of a subject from the study are:

- decision by sponsor
- withdrawal of consent from study
- death
- lost to follow-up

7.3 Lost to Follow-up

A subject will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site.

The following actions must be taken if a subject fails to return to the clinic for a required study visit:

- The site must attempt to contact the subject and reschedule the missed visit as soon as possible and counsel the subject on the importance of maintaining the assigned visit schedule and ascertain whether or not the subject wishes to and/or is able to continue in the study.
- In cases in which the subject is deemed lost to follow-up, the investigator or designee must make every effort to regain contact with the subject (where possible, 3 telephone calls and, if necessary, a certified letter to the subject's last known mailing address or local equivalent methods). These contact attempts are to be documented in the subject's medical record.
- If the subject continues to be unreachable, he/she will be considered to have withdrawn from the study with a primary reason of lost to follow-up.
- For subjects who are lost to follow-up, the investigator should search publicly available records where permitted to ascertain survival status. This ensures that the data set(s) produced as an outcome of the study is/are as comprehensive as possible.

8. Study Assessments and Procedures

Study procedures and their time points are summarized in the Schedule of Activities (see Section 1.3).

If an enrolled subject is subsequently determined to be ineligible for the study, this must be discussed with the sponsor immediately upon occurrence or awareness to determine if the subject is to continue or discontinue study treatment.

Adherence to the study design requirements, including those specified in the Schedule of Activities, is essential and required for study conduct.

8.1 General Study Periods

8.1.1 Screening, Enrollment, and/or Randomization

Informed consent must be obtained before completing any screening procedure or discontinuation of standard therapy for any disallowed therapy. After the subject has signed the informed consent form, the site will register the subject in the IRT and screen

the subject in order to assess eligibility for participation. The screening window is a minimum of [REDACTED] days and up to [REDACTED] days.

All screening evaluations must be completed and reviewed to confirm that potential subjects meet all eligibility criteria. The investigator will maintain a screening log to record details of all subjects screened and to confirm eligibility or record reasons for screening failure, (see [Section 5.5](#)) as applicable.

If a subject has not met all eligibility criteria at both initial screening and day 1 prerandomization visits, the subject will be registered as a screen fail. Screen fail subjects may be eligible for rescreening 1 time.

Rescreen subjects must first be registered as screen failures in IRT and subsequently registered as rescreens. Once the subject is registered as rescreened, a new screening window will begin. Subjects will retain the same subject identification number assigned at the original screening. If the rescreening period begins more than 30 days after the original signing of the informed consent form, all screening procedures, including informed consent, must be repeated.

8.1.2 Treatment Period

Visits will occur per the Schedule of Activities ([Section 1.3](#)). On-study visits may be completed within ± 3 days. The date of the first dose of investigational product is defined as day 1. All subsequent doses and study visits will be scheduled based on the day 1 date. Administration of **investigational product(s) and/or** [REDACTED] [REDACTED] is to be administered last during each visit that it is required.

Subjects may be eligible to enroll into a long-term maintenance study (Study [REDACTED]).

8.1.3 End of Treatment

Subjects who permanently discontinue investigational product for any reason before week 24 are encouraged to complete all remaining study visits and procedures with the exception of investigational product administration and post-dose monitoring procedures through week 24 for the evaluation of the coprimary endpoints, which will correspond to their EOT visit.

Subjects who permanently discontinue investigational product and do not complete the remaining study visits through week 24 should complete the EOT visit at the next scheduled visit following the last dose of investigational product (see W24/EOT in [Section 1.3](#)).

8.1.4 Safety Follow-up

An SFU visit is required [REDACTED] after the last dose of investigational product for all subjects who do not continue into the long-term maintenance study (Study [REDACTED]). An additional SFU visit will not be required for subjects who discontinue investigational product and do not enroll into the maintenance study but who complete the remaining study visits for at least [REDACTED] after the last dose of investigational product before or at week 24.

8.1.5 End of Study

Refer to Section 4.4 for the EOS definition.

All end of study procedures should be performed at the final visit for subjects who discontinue study before the defined end of study visit.

8.2 General Assessments

8.2.1 Informed Consent

All subjects or their legally authorized representative (if allowed, depending on the country concerned) must sign and personally date the IRB/IEC approved informed consent before any study-specific procedures are performed (see Section 11.3 [Appendix 3] for further details).

If remote consent is used:

1. The subject should be sent a blank informed consent form/informed consent addendum via mail or email.
2. A member of the study site team (investigator or designee) will call the subject to walk through the document via phone and answer questions. The time and date of the phone conversation should be recorded in the subject's medical record.
3. The subject should sign the informed consent form/informed consent addendum after all questions are answered and return the original or scanned copy via mail or email, respectively. The date and time of the subject's consent should be recorded in the medical record. The subject should take a photograph of the signature page and send it to the person conducting the informed consent discussion.
4. The person who conducted the informed consent discussion should then sign and date the informed consent form/informed consent addendum, when received.

5. A fully signed version of the informed consent form/informed consent addendum should be provided to the subject.

8.2.2 Demographics

Demographic data collection including sex, age, race, and ethnicity will be collected in order to study their possible association with subject safety and treatment effectiveness. Additionally, demographic data will be used to study the impact on [REDACTED] of the **investigational product(s)**.

8.2.3 Medical History

The Investigator or designee will collect a complete medical, dermatological, immunological, and surgical history. Medical history will include information on the subject's concurrent medical conditions. The current severity will be collected for each condition that has not resolved. Record all findings on the medical history CRF. The investigator or designee will also collect any cardiovascular history and cardiovascular risk factors.

In addition to the medical history above, AD history must date back to the original diagnosis.

8.2.4 Physical Examination


A complete physical examination will be conducted at screening and cover general appearance, dermatological, head, ears, eyes, nose, throat, respiratory, cardiovascular, abdominal, neurological, musculoskeletal, and lymphatic body systems. At subsequent study visits, a symptom-directed physical examination may be conducted at the discretion of the investigator per standard of care. Physical examination findings should be recorded on the appropriate eCRF (eg, medical history, events).


8.2.5 Physical Measurements

Height in centimeters should be measured without shoes. Weight in kilograms should be measured without shoes.

8.2.6 Substance Use History


Obtain a detailed history of prior and/or concurrent use of alcohol, recreational drugs, and tobacco.





8.2.8 Mental Health Assessment

As AD is associated with higher rates of depression [REDACTED] compared to the general population, screening and on-study monitoring of mental health will be performed. Central Mental Health professionals contributing to this study will have adequate training to assess psychiatric conditions in the study population.



Screening

Investigators must review relevant subject data reviewed at screening, including but not limited to, medical history, prior and current medications, substance use, [REDACTED]



[REDACTED]

[REDACTED] The investigator should immediately refer the subject for local mental health assessment and treatment as per local standard of care. Subjects ineligible due to depression [REDACTED] or behavior may be rescreened once after 1 year or 6 months, respectively.

On-Study

[REDACTED]

Subjects with severe depression as assessed by the investigator, are to permanently discontinue investigational product and should immediately be referred to mental health assessment and treatment, as per local standard of care.

[REDACTED]

Any psychiatric adverse event is to be followed and reported in the Events CRF as provided in Section 8.4.5. Referral to mental health services must be entered by the investigator in the Other Action Taken field of the corresponding adverse event.

8.3 Efficacy Assessments

Clinical evaluations of AD should be performed by an experienced and qualified dermatologist (board certified or equivalent). An experienced and qualified non-dermatologist physician or experienced medical professional with experience in the conduct of AD clinical trials may be permitted to perform the clinical evaluations of AD when designated by the primary site Investigator. The evaluator must receive and document protocol specific and applicable efficacy assessment scales training prior to performing these evaluations. To assure consistency and reduce variability, the same evaluator must assess all dermatological clinical evaluations for any individual subject throughout the study whenever possible; a back-up experienced and qualified, protocol-trained evaluator will only be allowed and documented in case of emergency or special situations when the designated evaluator is unable to perform the evaluation. At each visit, clinical outcome assessments (COAs) are to be performed prior to any other activity specified in the Schedule of Activities (see Section 1.3).

8.3.1 Assessments Completed by Investigator

Efficacy assessments should be collected on an electronic device and completed at scheduled visits.

8.3.1.1 Validated Investigator Global Assessment for Atopic Dermatitis

The vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 (clear) to 4 (severe) (Simpson et al, 2020) (Copyright ©Eli Lilly and Company – used with the permission of the Eli Lilly and Company under a Creative Commons Attributable-No Derivatives 4.0 International License - <https://creativecommons.org/licenses/by-nd/4.0/>). The vIGA-AD score will be assessed at time points according to the Schedule of Activities (see Section 1.3). To enable the harmonization of clinical efficacy results of this investigational AD drug, the vIGA-AD and associated training module available through the International Eczema Council will be used in this protocol.

The vIGA-AD will be assessed at the time points shown in the Schedule of Activities (see Section 1.3). Whenever possible, the vIGA-AD should be assessed by the same investigator at each visit to reduce the inter-rater variability.


8.3.1.3 Eczema Area and Severity Index

The EASI was designed by modifying the Psoriasis Area and Severity index, which has been widely used in clinical trials and has been established as a well-accepted and standardized instrument for assessing therapeutic response in patients with psoriasis (Schmitt et al, 2007). The EASI evaluates 4 natural anatomical regions for severity and extent of key disease signs and focuses on key acute and chronic signs of inflammation (ie, erythema, induration, papulation, excoriation, and lichenification). The maximum score is 72, with higher values indicating more severe disease.

The EASI will be assessed at the time points shown in the Schedule of Activities (Section 1.3). Whenever possible, the EASI should be assessed by the same investigator at each visit to reduce the inter-rater variability.

8.3.1.4 Severity Scoring of Atopic Dermatitis

The severity scoring of atopic dermatitis (SCORAD) is a measurement tool for assessing the severity (ie, extent, intensity) of AD using both physician and patient-reported data. The tool evaluates the extent and intensity of the AD lesions, along with subjective symptoms (Kunz et al, 1997). The SCORAD will be assessed at the time points shown in the Schedule of Activities (Section 1.3). The SCORAD should be assessed by the same investigator at each visit, whenever possible, to reduce inter-rater variability. The patient reported items of the SCORAD will be assessed at the study center at the time points indicated in the Schedule of Activities (Section 1.3).



8.3.2 Assessments Completed by Subject

8.3.2.1 Worst Pruritus NRS

In the electronic daily diary assessment, subjects report the severity of pruritus over the past 24 hours. The Worst Pruritus is an NRS comprised of 1 item and represents the numbers 0 to 10. Subjects are asked to rate the intensity of their worst itch using this scale with 10 being the highest amount of itch. It features high reliability and concurrent validity and is an appropriate choice for all subjects due to its simple format. At initial screening, subjects are asked to rate the intensity of their worst pruritus using this NRS with a 7-day recall.

8.3.2.2 Atopic Dermatitis Skin Pain NRS

In the electronic daily diary assessment, subjects report the severity of AD skin pain over the past 24 hours. The AD Skin Pain is an NRS comprised of 1 item and represents the numbers 0 to 10. Subjects are asked to rate the intensity of their AD skin pain using this scale with 10 being the highest amount of AD skin pain.

8.3.2.3 Sleep Disturbance NRS

In the electronic daily diary assessment, subjects report the quality of their sleep over the past 24 hours. The Sleep Disturbance is an NRS comprised of 1 item and represents the numbers 0 to 10, with 10 being the highest amount of sleep disturbance. Subjects are asked to rate the intensity of their sleep disturbance using this scale. Content validity is established, and it is an appropriate choice for all subjects due to its simple format.

8.3.2.4 Dermatology Life Quality Index

The Dermatology Life Quality Index (DLQI) is a 10-item, self-administered questionnaire, and is designed to measure the health-related quality of life of adult patients suffering from skin disease. The DLQI measures patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week.

The DLQI is the most frequently used patient reported outcome measure in randomized controlled trials in dermatology. The DLQI will be assessed at the study center at the time points indicated in the Schedule of Activities (Section 1.3).

8.3.2.5 Patient Oriented Eczema Measure

The Patient Oriented Eczema Measure (POEM) is a 7-item validated questionnaire used to assess disease symptoms in children and adults (Charman, 2004). It evaluates time spent in the past week with AD signs and symptoms: individual items of bleeding, oozing, cracked, flaking and dry/rough skin, and their impact on sleep. The POEM will be assessed at the study center at the time points indicated in the Schedule of Activities (Section 1.3).

8.3.2.6 Hospital Anxiety and Depression Scale (HADS)

The Hospital Anxiety and Depression Scale (HADS) is a self-assessment questionnaire that has been found to be a reliable instrument for detecting states of anxiety and depression in the setting of hospital outpatient clinic. The HADS questionnaire has 7 items each for depression and anxiety subscales. The HADS will be assessed at the study center at the time points indicated in the Schedule of Activities (Section 1.3).

Table 8-1 includes HADS Anxiety and Depression categorization scores categorization. These categorizations are listed to support the investigator's screening of a subject's level of anxiety and depression, however diagnosis of depression and assessment of the severity of depression should be made by a qualified clinician.

Table 8-1. Hospital Anxiety and Depression Score Categorization

HADS-depression or HADS anxiety Score	Categorization
0 to 7	Normal
8 to 10	Mild
11 to 14	Moderate
15 to 21	Severe

8.3.2.7 EuroQol-5 Dimension-5 Level (EQ-5D-5L)

The EQ-5D-5L questionnaire is a 2-page, standardized instrument for use as a measure of health outcome developed by the EuroQol group (Rabin and de Charro, 2001). It is comprised of a 5-dimension health status measure and a visual analog scale (VAS). The 5-dimension health status measure evaluates: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression based on a 5-level scale: no problems, slight problems, moderate problems, severe problems, an extreme problem. The visual analogue scale records the subject's self-rated health on a vertical, visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'. The EQ-5D-5L takes about 3 minutes to complete. The EQ-5D-5L will be assessed at the study center at the time points indicated in the Schedule of Activities (Section 1.3).

8.3.2.8 Work Productivity and Activity Impairment (WPAI) for AD

The Work Productivity and Activity Impairment (WPAI): Atopic Dermatitis questionnaire is an instrument to measure impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as the impairments in unpaid activity because of health problem during the past 7 days. The WPAI will be assessed at the study center at the time points indicated in the Schedule of Activities (Section 1.3).

8.3.2.9 Patient Global Impression of Severity (PGI-S)

The Patient Global Impression of Severity (PGI-S) is a single item designed to capture the subject's perception of symptom severity at the time of completion on a categorical response scale. There will be 2 PGI-S items, 1 each for AD skin pain and sleep

disturbance. The PGI-S will be completed by the subject at the study center according to the Schedule of Activities (Section 1.3).

8.3.2.10 Patient Global Impression of Change (PGI-C)

The Patient Global Impression of Change (PGI-C) is a single item designed to capture the subject's perception of response to treatment at the time of completion. The assessment uses a 7-point rating scale, very much better to very much worse. There will be 2 PGI-C items, one each for AD skin pain and sleep disturbance. The PGI-C will be completed by the subject at the study center according to the Schedule of Activities (Section 1.3).

8.4 Safety Assessments

Planned time points for all safety assessments are listed in the Schedule of Activities see (Section 1.3).

8.4.1 Vital Signs

The following measurements must be performed before administration of investigational product as specified in the Schedule of Activities (Section 1.3): systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature. Subject must be in a rested and calm state for at least 5 minutes before blood pressure assessment is conducted. The position selected for a subject should be the same that is used throughout the study and documented on the vital signs CRF. The temperature location selected for a subject should be the same that is used throughout the study and documented on the vital signs CRF. Record all measurements on the vital signs CRF.

8.4.2 Post-dose Monitoring and Vital Signs

Subjects will be observed for 2 hours following at least the first 2 doses of investigational product on day 1 and week 1. Any subject experiencing an acute reaction must receive immediate medical assessment and indicated supportive management according to the institutional standard of care and investigator judgement until the signs/symptoms of the reaction have resolved. If no systemic injection-related reactions, including immediate type hypersensitivity reactions, are observed after the first 2 doses, the post-dose monitoring period may be reduced to at least 30 minutes for subsequent doses. If systemic injection-related reactions are observed after the first 2 doses, the 2-hour post-dose monitoring period will remain as needed.

Systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature must be measured only at the end of the 2-hour post-dose monitoring period before the subject is

discharged at specific time points described in the Schedule of Activities (Section 1.3) and Section 8.4.1. Record all measurements on the vital signs CRF.

Clinically significant changes in vital signs as assessed by the investigator and any adverse events are to be reported as per Section 8.4.5.

8.4.3 Electrocardiograms (ECGs)

Subject must be in supine position in a rested and calm state for at least 5 minutes before ECG assessment is conducted. If the subject is unable to be in the supine position, the subject should be in most recumbent position as possible. The ECG must include the following measurements: Heart Rate, QRS, QT, QTc, and PR intervals. The PI, or designated site physician, will review all ECGs. Once signed, the original ECG tracing will be retained with the subject's source documents. At the request of the sponsor, a copy of the original ECG will be made available to Amgen. Findings should be recorded on the ECG eCRF and any adverse event is to be recorded as per Section 8.4.5.

8.4.4 Clinical Laboratory Assessments

Refer to Section 11.2 for the list of clinical laboratory tests to be performed and to the Schedule of Activities (Section 1.3) for the timing and frequency.

The investigator is responsible for reviewing laboratory test results and recording any clinically relevant changes occurring during the study in the Events CRF. The investigator must determine whether an abnormal value in an individual study subject represents a clinically significant change from the subject's baseline values. In general, abnormal laboratory findings without clinical significance (based on the investigator's judgment) are not to be recorded as adverse events. However, laboratory value changes that require treatment or adjustment in current therapy are considered adverse events. Where applicable, clinical sequelae (not the laboratory abnormality) are to be recorded as the adverse event.

All protocol-required laboratory assessments, as defined in Section 11.2, must be conducted in accordance with the laboratory manual and the Schedule of Activities (Section 1.3).

Laboratory results that could potentially unblind the individual treatment assignment (see potentially unblinding laboratory analytes in Appendix 2, Section 11.2) will not be reported to investigative sites or accessible by blinded personnel prior to all subjects

receiving blinded maintenance treatment in the long-term maintenance study (Study [REDACTED]) having switched to open-label treatment or completed the SFU.

8.4.5 Adverse Events and Serious Adverse Events

The method of recording, evaluating, and assessing causality of adverse events, and serious adverse events and the procedures for completing and transmitting serious adverse event reports are provided in [Section 11.4](#).

8.4.5.1 Time Period and Frequency for Collecting and Reporting Safety Event Information

8.4.5.1.1 Adverse Events

The adverse event grading scale to be used for this study will be the Severity Intensity Scale for Adverse Events and is described in [Section 11.4](#).

The investigator is responsible for ensuring that all adverse events observed by the investigator or reported by the subject that occur after first dose of investigational product through W24/EOT for those subjects who are enrolled in the long-term maintenance study (Study [REDACTED]); or through the SFU visit for those subjects who do not enroll into the long-term maintenance study, are reported using the Events CRF.

Adverse events of special interest (AESIs) including but not exclusive to infections, injection-related reactions, hypersensitivity reactions, major adverse cardiovascular events (MACE), malignancy, neuropsychiatric adverse events, aphthous ulcer, and gastrointestinal ulceration/perforation will be monitored.

8.4.5.1.2 Serious Adverse Events

The investigator is responsible for ensuring that all serious adverse events observed by the investigator or reported by the subject that occur after signing of the informed consent through W24/EOT for those subjects who are enrolled in the long-term maintenance study (Study [REDACTED]); or through the SFU visit for those subjects who do not enroll into the long-term maintenance study, are reported using the Events CRF.

All serious adverse events will be collected, recorded, and reported to the sponsor or designee immediately and no later than 24 hours of the investigator's awareness of the event, as indicated in [Section 11.4](#). The investigator will submit any updated serious adverse event data to the sponsor immediately and no later than 24 hours of it being available.

8.4.5.1.3 Adverse Event Adjudication

Potential Cardiovascular Events

In order to evaluate cardiovascular events during the study, all deaths, and serious adverse events that are deemed to be of potential cardiovascular origin or etiology, will be submitted to an independent committee for adjudication. Serious adverse events with terms mapping to a pre-defined preferred term list potentially indicative of cardiovascular etiology will also be adjudicated. All serious adverse events will be collected, recorded, and reported to the sponsor or designee immediately and no later than 24 hours of the investigator's awareness of the event, as indicated in Section 11.4.

8.4.5.1.4 Serious Adverse Events After the Protocol Required Reporting Period

There is no requirement to actively monitor study subjects after the study has ended with regards to study subjects treated by the investigator. However, if the investigator becomes aware of serious adverse events suspected to be related to the investigational product, then these serious adverse events will be reported to Amgen immediately and no later than 24 hours following the investigator's awareness of the event.

Serious adverse events reported outside of the protocol-required reporting period will be captured within the safety database as clinical trial cases and handled accordingly based on relationship to investigational product.

If further safety related data is needed to fulfill any regulatory reporting requirements for a reportable event, then additional information may need to be collected from the subject's records after the subject ends the study.

8.4.5.2 Method of Detecting Adverse Events and Serious Adverse Events

Care will be taken not to introduce bias when detecting adverse events and/or serious adverse events. Open-ended and non-leading verbal questioning of the subject is the preferred method to inquire about adverse event occurrence.

If a subject reports or the investigator observes an adverse event of reaction at the site of study drug administration, the investigator is to capture as part of the primary event verbatim in the Events CRF the location of the reaction together with the type of reaction that better describes the event(s) (eg, injection site pain, injection site erythema, injection site induration, injection site swelling, injection site itching) with clear start and stop dates, rather than only using a general term of "injection site reaction." If there are multiple signs or symptoms at an injection site, each symptom of the event should be reported individually.

8.4.5.3 Follow-up of Adverse Events and Serious Adverse Events

After the initial adverse event/serious adverse event report, the investigator is required to proactively follow each subject at subsequent visits/contacts. All adverse events and serious adverse events will be followed until resolution, stabilization, until the event is otherwise explained, or the subject is lost to follow-up (as defined in [Section 7.3](#)).

Further information on follow-up procedures is given in [Section 11.4](#).

All new information for previously reported serious adverse events must be sent to Amgen immediately and no later than 24 hours following awareness of the new information. If specifically requested, the investigator may need to provide additional follow-up information, such as discharge summaries, medical records, or extracts from the medical records. Information provided about the serious adverse event must be consistent with that recorded on the Events CRF.

8.4.5.4 Regulatory Reporting Requirements for Safety Information

If subject is permanently withdrawn from **investigational product(s), and/or**

[REDACTED] because of a serious adverse event, this information must be submitted to Amgen.

Prompt notification by the investigator to the sponsor of serious adverse events is essential so that legal obligations and ethical responsibilities towards the safety of subjects and the safety of a study treatment under clinical investigation are met.

The sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study treatment under clinical investigation. The sponsor will comply with country-specific regulatory requirements relating to safety reporting to the regulatory authority, IRBs/IECs, and investigators.

Individual safety reports must be prepared for suspected unexpected serious adverse reactions according to local regulatory requirements and sponsor policy and forwarded to investigators as necessary.

An investigator who receives an individual safety report describing a serious adverse event or other specific safety information (eg, summary or listing of serious adverse events) from the sponsor will file it along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.

Amgen will prepare a single Development Safety Update Report (DSUR) (also referred to as Annual Safety Report [ASR] in the European Union) for the Amgen Investigational Product. In order to ensure that consolidated safety information for the trial is provided,

this single DSUR will also include appropriate information on any other investigational products used in the clinical trial, if applicable.

For studies in which the treatment assignment is blinded, to comply with worldwide reporting regulations for serious adverse events, the treatment assignment of subjects who develop serious, unexpected, and related adverse events may be unblinded by Amgen before submission to regulatory authorities. Aggregate analyses may also be unblinded by the Safety Assessment Team, as appropriate. Investigators will receive notification of related serious adverse events reports sent to regulatory authorities in accordance with local requirements.

8.4.5.5 Safety Monitoring Plan

Subject safety will be routinely monitored as defined in Amgen's safety surveillance and signal management processes.

8.4.5.6 Pregnancy and Lactation

Details of all pregnancies and/or lactation in female subjects will be collected after the start of study treatment and until 16 weeks after the last dose of investigational product.

If a pregnancy is reported, the investigator is to inform Amgen immediately and no later than 24 hours of learning of the pregnancy and/or lactation and is to follow the procedures outlined in [Section 11.5](#). Amgen Global Patient Safety will follow-up with the investigator regarding additional information that may be requested.

Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital anomalies, and ectopic pregnancy) are considered serious adverse events.

Further details regarding pregnancy and lactation are provided in [Section 11.5](#).


Pregnancy Testing


A highly sensitive serum pregnancy test should be completed at initial screening, and a confirmatory urine pregnancy test should be completed on day 1 prerandomization for female subjects of childbearing potential, as described in the Schedule of Activities.


Note: Females who have undergone a bilateral tubal ligation/occlusion should have pregnancy testing per protocol requirements. (If a female subject, or the partner of a male subject, becomes pregnant it must be reported on the Pregnancy Notification Form, see [Figure 11-2](#)). Refer to [Section 11.5](#) for contraceptive requirements.


Additional pregnancy testing should be performed [REDACTED] during treatment with **investigational product(s)** and at the SFU visit when applicable, or 16 weeks after the last dose of investigational product for subjects who discontinue treatment prematurely.

Additional on-treatment pregnancy testing may be performed at the investigator's discretion or as required per local laws and regulations.









8.10 Other Assessments

8.10.1 Tuberculosis Testing and Tuberculosis Risk Assessment Questionnaire

Screening

All subjects must receive QuantiFERON GOLD test from central laboratory at initial screening and Screening TB Risk Assessment Questionnaire must be completed for all subjects as defined in the Schedule of Activities (Section 1.3). Subjects with a positive or indeterminate QuantiFERON GOLD test are ineligible unless specific additional requirements are met (see Section 5.2). For subjects with a positive or indeterminate QuantiFERON GOLD test, the radiograph report should be read by a radiologist or per local requirement and the report must be reviewed by the investigator before enrollment.

For sites and subjects participating in the EEA, please refer to Section 11.9 (Appendix 9).

On-Study

A TB Risk Assessment Questionnaire will be administered by the investigator or delegated site staff as per the Schedule of Activities to evaluate subjects for risk and symptoms of TB. If a subject is experiencing signs or symptoms suspicious of TB or has reported changes in medical history to warrant additional on-study TB testing:

- The investigator is to follow local guidelines for the diagnosis and treatment (including prophylaxis) of active or latent TB, as applicable.
- On-study TB testing and chest X-ray may be performed and repeated at the discretion of the investigator.
- Any diagnosis of TB should be reported as a Serious Adverse Event in the Events CRF whether as active or latent TB, as applicable, based on final diagnosis.
- Subjects with confirmed active TB require permanent discontinuation of the investigational product as indicated in Section 6.2.2.1.
- In case of diagnosis of latent TB during investigational product treatment, prophylaxis treatment should be initiated immediately based on the local guideline. The investigational product should not be withheld but may be interrupted per PI discretion. The subject should be re-evaluated for signs and symptoms of TB and for prophylactic toxicity within 4 weeks of initiation of prophylactic treatment. For sites and subjects participating in the EEA, please refer to Section 11.9 (Appendix 9).

If at any time point the QuantiFERON GOLD test is positive or indeterminate, the test may be repeated. If the repeated result is negative, the investigator may consider the subject to be negative based on the absence of symptoms and clinical judgement; if the repeat testing result is positive or indeterminate, then the subject is considered to be positive and additional assessments (eg, chest X-ray) may be performed as per local standard of care to confirm whether latent or active TB is present, and any confirmed diagnosis is to be entered as Serious Adverse Event in the Events CRF.

9. Statistical Considerations

9.1 Statistical Hypotheses

The primary hypothesis is that either rocatinlimab ■■■ mg or ■■■ mg is superior to placebo as treatment in subjects with moderate-to-severe AD, as assessed by the coprimary endpoints, and both coprimary endpoints need to achieve statistical significance to declare success for each rocatinlimab dose.

9.2 Sample Size Determination

A total of [REDACTED] subjects will be randomized in [REDACTED] ratio to 3 treatment groups for a duration of 24 weeks as follows:

- Rocatinlimab [REDACTED] mg [REDACTED] with a loading dose at week [REDACTED] (N = [REDACTED])
- Rocatinlimab [REDACTED] mg [REDACTED] with a loading dose at week [REDACTED] (N = [REDACTED])
- Placebo [REDACTED] with a loading dose at week [REDACTED] (N = [REDACTED])

9.3 Populations for Analysis

The following populations are defined:

Population	Description
Full Analysis Set	All randomized subjects. Subjects will be analyzed according to the randomized treatment.
Safety Analysis Set	All subjects who receive at least 1 dose of investigational product. Subjects will be analyzed according to the actual treatment received.

9.3.1 Covariates

All analyses of efficacy endpoints will be adjusted for the effect of the stratification factors, including baseline disease severity (vIGA-AD score of 3 [moderate] versus 4 [severe] and geographic region (Japan versus non-Japan Asian countries versus Rest of World), as well as baseline value of the efficacy endpoint of interest, when applicable.

9.3.2 Subgroups

The coprimary and selected **key** secondary endpoints will be analyzed by but not limited to the following subgroups:

- age group (18 to < 40 years, 40 to < 65 years, ≥ 65 years)
- sex (male, female)

- geographic region (Japan, non-Japan Asian countries, rest of world)
- baseline weight group (< 70 kg, ≥ 70 kg)
- baseline body mass index (< 25 kg/m², ≥ 25 kg/m²)
- baseline disease severity (moderate [vIGA-AD = 3], severe [vIGA-AD = 4])
- prior use of systemic therapy for the treatment of AD (yes, no)
- prior failure to systemic therapy for AD due to inadequate response or adverse reaction (yes, no)

9.4 Statistical Analyses

The SAP will be developed and finalized before database lock for the first unblinding analysis. Below is a summary of the timing and methods for the planned statistical analyses.

9.4.1 Planned Analyses

9.4.1.1 Primary Analysis

The primary analysis will be conducted when all subjects have completed the week-24/EOT visit, and the data have been entered, cleaned, and locked. The objective of the primary analysis is to assess complete efficacy and safety data through week 24 and additional safety data available during SFU as of the data cutoff date.

9.4.1.2 Final Analysis

The final analysis will be conducted at the end of the study when all subjects have completed the EOS visit, and the data have been entered, cleaned, and locked.

The objective of the final analysis is to assess complete safety data through EOS on all subjects over the entire study period.

9.4.2 Methods of Analyses

9.4.2.1 General Considerations

Subject disposition, demographics, and baseline disease characteristics will be summarized descriptively by the randomized treatment. For categorical endpoints, the descriptive statistics will contain frequency and percentage, and corresponding 95% confidence interval (CI) where appropriate. For continuous endpoints, the descriptive statistics will include the number of observations, mean, standard deviation, median, first quartile, third quartile, minimum, and maximum.



9.4.2.2 Efficacy Analyses

Endpoint	Statistical Analysis Methods
Binary	The primary estimand for a binary endpoint is to measure the effect of rocatinlimab as assessed by the difference in response rates between each of the 2 rocatinlimab treatment groups (■ mg and ■ mg) and placebo among randomized subjects within moderate-to-severe AD population without rescue therapy for AD, regardless of permanent discontinuation of investigational product. Subjects initiating rescue therapy for AD will be classified as nonresponders at all subsequent time points (composite strategy reflecting lack of response). For subjects who do not use rescue therapy for AD but permanently discontinue investigational product, data retrieved after permanent discontinuation of investigational product will be included as collected (treatment policy strategy). The primary method for handling remaining missing responses will be ■. Additional sensitivity analyses using ■. ■. Details about missing data imputation will be specified in the SAP. The analysis of the binary endpoints will include ■.
Continuous	The primary estimand for a continuous endpoint is to measure the effect of rocatinlimab as assessed by the difference in means of change or percent change from baseline value between each of the 2 rocatinlimab treatment groups (■ mg and ■ mg) and placebo in randomized subjects within moderate-to-severe AD population without rescue medication for AD, regardless of permanent discontinuation of investigational product. Subjects initiating rescue therapy for AD will be included in the analysis, and each subject's worst observation, including baseline value, before initiation of rescue therapy for AD will

	be carried forward (WOCF) to all subsequent time points (composite strategy reflecting lack of response). For subjects who do not use rescue therapy for AD but permanently discontinue investigational product, data retrieved after permanent discontinuation of investigational product will be included as collected (treatment policy strategy). The remaining missing continuous data will be imputed using [REDACTED]. Treatment comparisons will be performed using [REDACTED] and relevant baseline value as covariates. Treatment differences in least square means between each rocatinlimab treatment group and placebo, [REDACTED] will be provided.
--	---

9.4.2.3 Safety Analyses

9.4.2.3.1 Adverse Events

Subject incidence of all treatment-emergent adverse events will be tabulated by system organ class, preferred term, and worst grade of severity. Tables of fatal adverse events, serious adverse events, adverse events leading to discontinuation from investigational product, treatment-related adverse events, and events of interest will also be provided. Subject incidence of device-related adverse events, if applicable, may also be provided by system organ class and preferred term.

9.4.2.3.2 Laboratory Test Results

The analyses of safety laboratory results will include summary statistics over time/at selected time points by treatment group. Shifts in grades of safety laboratory values between baseline and the worst on-study value will be tabulated by treatment group, as applicable.

9.4.2.3.3 Vital Signs

The analyses of vital signs will include summary statistics over time by treatment group. Shifts in vital sign values between baseline and the worst on-study value will be tabulated by treatment group.

9.4.2.3.4 Electrocardiogram

The ECG measurements in this clinical study are to be performed as per standard of care for routine safety monitoring, rather than for purposes of assessment of potential QTc effect. Since these evaluations may not necessarily be performed under the rigorous conditions expected to lead to meaningful evaluation of QTc data, summaries and statistical analyses of ECG measurements are not planned, and these data would

not be expected to be useful for meta-analysis with data from other trials. The subject incidence of abnormal ECG diagnosis will be summarized by treatment group.

9.4.2.3.5 Antibody Formation

The incidence and percentage of subjects who develop [REDACTED] at any time will be tabulated by treatment group.

A listing of antibody results for all time points tested for each subject will be reported.

9.4.2.3.6 Exposure to Investigational Product

Exposure to investigational product will be summarized by treatment group. The summary of study drug exposure will include descriptive statistics for the number of study drug doses administered, and total amount of study drug exposure.

9.4.2.3.7 Exposure to Concomitant Medication

Number and percentage of subjects receiving rescue therapies will be summarized by category for each treatment group.

9.4.2.4 Other Analyses

Not applicable.

10. References

Anna FS. The Hospital Anxiety and Depression Scale. *Occupational Medicine*. 2014;64(5):393–394.

Assouline S, Bucchini V, Delmer A, et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. *Lancet Haematol* 2016; 3:e128.

Barbarot S, Auziere S, Gadkari A et al. Epidemiology of atopic dermatitis in adults: results from an international survey. *Allergy* 2018; 73:1284–93.

Bridgett C and Norén P. Stress and Atopic Dermatitis. *Stress and Skin Disorders*, 2019. 199-125.

Bodey G, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. *Ann Intern Med*. 1966;64:328-340.

Carlier TDB, Badloe FMS, Ring J, Gutermuth J, et al. Autoreactive T-cells and their role in atopic dermatitis. *J Autoimmun*. 2021;120:102364.

Cavanagh MM, Hussell T. Is it wise to target the late costimulatory molecule OX40 as a therapeutic target? *Arch Immunol Ther Exp (Warsz)*. 2008 Sep-Oct;56 (5):291-7.

Charman, 2004. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. *Arch Dermatol*. 2004;140(12):1513-1519.

Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. *Immunol Rev*. 2009;229 (1):173-191.

Croft, M. Control of Immunity by the TNFR-Related Molecule OX40 (CD134). *Annu. Rev. Immunol*. 2010, 28, 57–78.

Davies A, Merli F, Mihaljević B, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. *Lancet Haematol* 2017; 4:e272.

Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. *J Am Acad Dermatol*. 2014 Feb;70 (2):338-51

Guttman-Yassky E. Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. *Exp Dermatol*. 2018 Apr;27 (4):409-417

International Committee of Medical Journal Editors, Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication. 2019. <http://www.icmje.org/>

Jo CE. Facial and neck erythema associated with dupilumab treatment: A systemic review. *J Am Acad Dermatol* 2021; 84(5): 1339

Kunz B, Oranje AP, Labreze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. *Dermatology*. 1997;195(1):10-19.

Langan SM, Irvine AD, Weidinger S. *Atopic dermatitis*. *Lancet* 2020; 396: 345-60.

Laughter MR, Maymone MBC, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017. *Br J Dermatol*. 2021;184:304-309.

Lever R. The role of food in atopic eczema. *J Am Acad Dermatol*. 2001;45(1 suppl):S57-S60.

Mateos M-V, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomized, phase 3 trial. *Lancet Haematol*. 2020;7(5):e370-e380.

Matsumura Y. Expression of CD134 and CD134 ligand in lesional and nonlesional psoriatic skin. *Arch Dermatol Res*. 2003 Mar;294(12):563-6.

Nakagawa H. Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis. *J Dermatol Sci*. 2020 Aug;99 (2):82-89

Rabin R, de Charro F. EQ 5D: a measure of health status from the EuroQol Group. *Ann Med*. 2001;33(5):337-343.

Posner K, Brown GK, Stanely B, et al. The Columbia-Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies with Adolescents and Adults. *Am J Psychiatry*. 2011;168(12):1266-1277.

Rocatinlimab Investigator's Brochure. Thousand Oaks, CA. Amgen Inc.

Rogers PR. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T-cells. *Immunity*. 2001 Sep;15 (3):445-55.

Salek-Ardakani S, Croft M. Regulation of CD4 T-cell memory by OX40 (CD134). *Vaccine*. 2006 Feb 13;24 (7):872-83. doi: 10.1016/j.vaccine.2005.07.108

Schmitt J, Langan S, Williams HW, et al. What are the best outcome measurements for atopic eczema? A systematic review. *J Allergy Clin Immunol*. 2007;120(6):1389-1398.

Sitrin J, Suto E, Wuster A, Eastham-Anderson J, et al. The OX40/OX40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice. *J Immunol*. 2017;199 (4):1238-1249.

Simpson E, Bissonnette R, Eichenfield LF, et al. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. *J Am Acad Dermatol*. 2020;83(3):839-846.

Snast, I., Reiter, O., Hodak, E. et al. Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis. *Am J Clin Dermatol*. 2018;19, 145–165

Song A. OX40 and Bcl-xL Promote the Persistence of CD8 T-cells to Recall Tumor-Associated Antigen. *J Immunol*. 2005;175 (6) 3534-3541

Stander S. Atopic Dermatitis. *N Engl J Med*. 2021;384 (12):1136-1143.

Tadicherla S, Ross K, Shenefelt PD, Fenske NA. Topical corticosteroids in dermatology. *J Drugs Dermatol*. 2009;8(12):1093-1105.

World Health Organization [WHO]. Model Prescribing Information: Drugs used in skin diseases. 1997; Geneva.

Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. *J Eur Acad Dermatol Venereol*. 2018;32 (6):850-878.

11. Appendices

11.1 Appendix 1. List of Abbreviations

Abbreviation	Explanation
AD	atopic dermatitis
ALP	alkaline phosphatase
ALT	alanine aminotransferase
ANCOVA	analysis of covariance
ASR	Annual Safety Report
AST	aspartate aminotransferase
AUC	area under the concentration time curve
BIL	bilirubin
BSA	body surface area
CFR	U.S. Code of Federal Regulations
C _{max}	maximum plasma concentration
COVID-19	coronavirus disease-19
CRF	Case Report Form
CRO	contract research organization
DILI	drug induced liver injury
DLQI	Dermatology Life Quality Index
DMC	data monitoring committee
DSUR	Development Safety Update Report
EASI	Eczema Area and Severity Index
EASI 75	achievement of $\geq 75\%$ reduction from baseline in EASI score
ECG	electrocardiogram
eCRF	electronic Case Report Form
EDC	electronic data capture
EEA	European Economic Area
eGFR	estimated glomerular filtration rate
EOS	end of study
EOT	end of treatment
EQ-5D-5L	EuroQol 5 Dimension-5 Level

FDA	United States Food and Drug Administration
FSH	follicle stimulating hormone
GCP	Good Clinical Practice
HADS	Hospital Anxiety and Depression Scale
HBsAg	hepatitis B surface antigen
HCV	hepatitis C virus
HIPAA	Health Insurance Portability and Accountability Act
HIV	human immunodeficiency virus
HRQL	health-related quality of life
IB	investigator's brochure
IBG	Independent Biostatistics Group
ICF	informed consent form
ICH	International Council for Harmonisation
IEC	Independent Ethics Committee
IGA	Investigator's Global Assessment
IgE	immunoglobulin E
IgG	immunoglobulin G
INR	international normalized ratio
IRB	Institutional Review Board
IRT	interactive response technology
IV	intravenous
JAK	janus kinase
NCT	National Clinical Trials
NRS	numeric rating scale
OX40	CD134
OX40L	OX40 Ligand
PCR	polymerase chain reaction
PDE4	phosphodiesterase 4 inhibitor
PGI-C	Patient Global Impression of Change
PGI-S	Patient Global Impression of Severity
PI	principal investigator
POEM	Patient Oriented Eczema Measure

PUBD	potentially unblinding data
■	■
QTc	corrected QT interval
QTcF	corrected QT interval by Fredericia
Q8W	every 8 weeks
rIGA	revised Investigator's Global Assessment
rIGA 0/1	achieving vIGA-AD 1 response with presence of only barely perceptible erythema or vIGA-AD 0 response
SAP	statistical analysis plan
SC	subcutaneous
SCORAD	scoring atopic dermatitis
SFU	safety follow-up
STS	skin tape strips
TARC	thymus and activation-regulated chemokine
TB	tuberculosis
TBL	total bilirubin
TCI	topical calcineurin inhibitor
TCS	topical corticosteroids
TEWL	transepidermal water loss
Th	t helper cell
Th2	t helper type 2 cell
TNF	tumor necrosis factor
ULN	upper limit of normal
US	United States
VAS	visual analog scale
vIGA-AD™	Validated Investigator's Global Assessment for Atopic Dermatitis
vIGA-AD 0/1	Achieving a vIGA-AD score of 0 (clear) or 1 (almost clear) with $\geq$ 2-point reduction from baseline
vIGA-AD 0	Achieving a vIGA-AD score of 0 (clear) with $\geq$ 2-point reduction from baseline
vIGA-AD 1	Achieving a vIGA-AD score of 1 (almost clear) with $\geq$ 2-point reduction from baseline
WOCF	Worst O bservation C arried F orward
WPAI-AD	Work Productivity and Activity Impairment for Atopic Dermatitis

11.2 Appendix 2. Clinical Laboratory Tests

The tests detailed in [Table 11-1](#) will be performed by the central laboratory and/or by the local laboratory. Additional analyte test results may be reported by the local or central laboratory, in accordance with standard laboratory procedures (eg, components of a hematology panel).

Protocol-specific requirements for inclusion or exclusion of subjects are detailed in [Sections 5.1](#) to [5.2](#) of the protocol.

Additional tests may be performed at any time during the study as determined necessary by the investigator or required by local regulations.

Table 11-1. Analyte Listing

Central Laboratory: Chemistry	Central Laboratory: Coagulation	Central Laboratory: Urinalysis	Central Laboratory: Hematology	Other Lab Analytes
Sodium	PT/INR	Specific gravity	RBC	<u>Central Laboratory:</u>
Potassium	PTT/APTT	pH	Nucleated RBC	Drug concentration ^a
Chloride		Blood	Hemoglobin	Antidrug antibodies ^a
Bicarbonate		Protein	Hematocrit	Hep B surface antigen
Total protein		Glucose	MCV	Anti-Hep B core antibody
Albumin		Bilirubin	MCH	Hep C antibody
Calcium		WBC	MCHC	HIV antibody
Magnesium		RBC	RDW	HCV RNA
Phosphorus		Epithelial cells	Reticulocytes	HBV DNA
Glucose		Bacteria	Platelets	QuantiFERON GOLD
BUN (Urea)		Casts	WBC	Serum pregnancy test
Creatinine		Crystals	Differential	
Creatine Kinase			• Bands/stabs	
Uric acid			• Segmented Neutrophils	
Total bilirubin			• Total Neutrophils	
Direct bilirubin			• Eosinophils	
ALP			• Basophils	
LDH			• Lymphocytes	
AST (SGOT)			• Monocytes	
ALT (SGPT)				<u>Local Laboratory:</u>
Lipids (Cholesterol, HDL, LDL, Triglycerides)				Urine
eGFR				Pregnancy

ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; DNA = deoxyribonucleic acid; eGFR = estimated glomerular filtration rate as determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation using creatinine; HDL = high density lipoprotein; Hep = hepatitis; HIV = human immunodeficiency virus; HBV = hepatitis B virus; HCV = hepatitis C virus; HLA = human leukocyte antigen; INR = international normalized ratio; LDH = lactate dehydrogenase; LDL = low density lipoprotein; MCH = mean corpuscular hemoglobin; MCHC = mean corpuscular hemoglobin concentration; MCV = mean corpuscular volume; PCR = polymerase chain reaction; PT = prothrombin time; PTT = partial thromboplastin time; RBC = red blood cell count; RDW = Red cell distribution width; RNA = ribonucleic acid; SGOT = serum glutamic-oxaloacetic transaminase; SGPT = serum glutamic-pyruvic transaminase; WBC = white blood cell count

^a Potentially unblinding laboratory analyte

If the subject is being followed for possible drug induced liver injury (DILI), the following analytes may be tested at the local laboratory depending on the clinical situation (see Appendix 7 [Section 11.7]).

Table 11-2. Potential DILI Analyte Listing

Chemistry	Total bilirubin, direct bilirubin, ALP, LDH, AST (SGOT), ALT (SGPT), creatine kinase, ferritin, gamma-glutamyl transferase, haptoglobin
Hematology	Hemoglobin, Platelets, RBC Morphology, RBC Count, WBC Count, WBC Differential
Coagulation	PT, INR, APTT
Immunology	5 Prime Nucleotidase, Alpha-1 Antitrypsin, Antinuclear Antibodies, Anti-Smooth Muscle Antibody, Anti-Soluble Liver Ag/Liver-Pancreas Ag, Cytomegalovirus IgG Antibody, Cytomegalovirus IgM Antibody, Endomysial IgA Antibody, Epstein-Barr Virus EDA IgG Antibody, Epstein-Barr Virus NA IgG Antibody, Epstein-Barr Virus VCA IgG Antibody, Epstein-Barr Virus VCA IgM Antibody, Hepatitis A Virus IgG Antibody, Hepatitis A Virus IgM Antibody, Hepatitis B Core Antibodies, Hepatitis B Core IgM Antibody, Hepatitis B Surface Antigen, Hepatitis B Virus DNA Genotyping, Hepatitis B Virus Surface Antibody, Hepatitis C Antibodies, Hepatitis C Virus RNA Genotyping, Hepatitis D Virus Antibody, Hepatitis D RNA, Hepatitis E RNA, Hepatitis E IgG Antibody, Hepatitis E IgM Antibody, Herpes Simplex Virus Type 1_2 IgG AB, Herpes Simplex Virus Type 1_2 IgM AB, Human Herpes Virus 6 DNA, Human Herpes Virus 7 DNA, Human Herpes Virus 8 DNA, Immunoglobulin G, Liver Kidney AB 1, Parvovirus IgM/IgG Antibody, Serum Caeruloplasmin, Tissue Transglutaminase IgA Antibody, Toxoplasma IgM/IgG, Varicella Zoster Virus Antibody
Toxicology	Acetaminophen

ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase;

DILI = drug-induced liver injury; EDA = early antigen; Ig = immunoglobulin; INR = international normalized

ratio; LDH = lactate dehydrogenase; NA = nuclear antigen; PT = prothrombin time; RBC = red blood cell;

RNA = ribonucleic acid; SGOT = serum glutamic-oxaloacetic transaminase; SGPT = serum glutamic pyruvic

transaminase; VCA = viral capsid antigen; WBC = white blood cell

11.3 Appendix 3. Study Governance Considerations

Data Monitoring Committee(s)

The data monitoring committee (DMC) will review all available safety data periodically and consider efficacy data in order to assess the risk/benefit profile of rocatinlimab. An Independent Biostatistics Group (IBG) will perform the analysis to the DMC. The IBG and DMC will have access to subjects' individual treatment assignments. To minimize the potential introduction of bias to the conduct of the study, members of the DMC and IBG will not have any direct contact with study site personnel or subjects. The DMC will communicate major safety concerns and recommendations regarding study modification or termination based on the safety and efficacy parameters to Amgen in accordance with the DMC charter.

Records of all meetings will be maintained by the DMC for the duration of the study. Records of all meetings will be transferred and stored in the trial master file at the conclusion of the study. Further details are provided in the DMC charter.

Regulatory and Ethical Considerations

This study will be conducted in accordance with the protocol and with:

- Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines
- Applicable International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines
- Applicable ICH laws and regulations

The protocol, protocol amendments, informed consent form, investigator's brochure (IB), and other relevant documents (eg, subject recruitment advertisements) must be submitted to an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) by the investigator and reviewed and approved by the IRB/IEC. A copy of the written approval of the protocol and informed consent form must be received by Amgen before recruitment of subjects into the study and shipment of Amgen investigational product.

Amgen may amend the protocol at any time. The investigator must submit and, where necessary, obtain approval from the IRB/IEC for all protocol amendments and changes to the informed consent document that Amgen distributes to the site. The investigator must send a copy of the approval letter from the IRB/IEC and amended protocol Investigator's Signature page to Amgen prior to implementation of the protocol amendment at their site.

During the course of the study, if new information becomes available that alters the benefit-risk of the study or the study drug, Amgen will follow applicable regulations to notify investigators, the IRB/IEC, and regulatory authorities, as appropriate.

The investigator will be responsible for the following:

- Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC
- Obtaining annual IRB/IEC approval/renewal throughout the duration of the study. Copies of the investigator's reports and the IRB/IEC continuance of approval must be sent to Amgen
- Notifying the IRB/IEC of serious adverse events occurring at the site, deviations from the protocol or other adverse event reports received from Amgen, in accordance with local procedures
- Overall conduct of the study at the site and adherence to requirements of Title 21 of the U.S. Code of Federal Regulations (CFR), ICH guidelines, the IRB/IEC, and all other applicable local regulations

Informed Consent Process

An initial sample informed consent form is provided for the investigator to prepare the informed consent document to be used at his or her site. Updates to the sample informed consent form are to be communicated formally in writing from the Amgen Trial Manager to the investigator. The written informed consent form is to be prepared in the language(s) of the potential patient population.

The investigator or his/her delegated representative will explain to the subject, or his/her legally authorized representative (if allowed, depending on the country concerned), the aims, methods, anticipated benefits, and potential hazards of the study before any protocol-specific screening procedures or any investigational product(s) is/are administered, and answer all questions regarding the study.

Subjects must be informed that their participation is voluntary. Subjects or their legally authorized representative (if allowed, depending on the country concerned) defined as an individual or other body authorized under applicable law to consent, on behalf of a prospective subject, to the subject's participation in the clinical study will then be required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portability and Accountability Act requirements, where applicable, and the IRB/IEC or study site.

The medical record must include a statement that written informed consent was obtained before the subject was enrolled in the study and the date the written consent was

obtained. The authorized person obtaining the informed consent must also sign the informed consent form.

The investigator is also responsible for asking the subject if the subject has a primary care physician and if the subject agrees to have his/her primary care physician informed of the subject's participation in the clinical study unless it is a local requirement. The investigator shall then inform the primary care physician. If the subject agrees to such notification, the investigator is to inform the subject's primary care physician of the subject's participation in the clinical study. If the subject does not have a primary care physician and the investigator will be acting in that capacity, the investigator is to document such in the subject's medical record.

The acquisition of informed consent and the subject's agreement or refusal of his/her notification of the primary care physician is to be documented in the subject's medical records, and the informed consent form is to be signed and personally dated by the subject or a legally authorized representative (if allowed, depending on the country concerned) and by the person who conducted the informed consent discussion. Subject withdrawal of consent or discontinuation from study treatment and/or procedures must also be documented in the subject's medical records; refer to [Section 7](#).

If important new information becomes available that may be relevant to the subject's consent form(s) during their participation in the study, subjects will be reconsented.

The original signed informed consent form is to be retained in accordance with institutional policy, and a copy of the informed consent form(s) must be provided to the subject or the subject's legally authorized representative (if allowed, depending on the country concerned).

A subject who is rescreened is not required to sign another informed consent form if the rescreening occurs within 30 days from the previous informed consent form signature date.

The informed consent form (ICF) will contain a separate section that addresses the use of remaining mandatory samples for optional future research. The investigator or authorized designee will explain to each subject the objectives of the future research. Subjects will be told that they are free to refuse to participate and may withdraw their specimens at any time and for any reason during the storage period. A separate signature will be required to document a subject's agreement to allow any remaining

specimens to be used for future research. Subjects who decline to participate will not provide this separate signature.

Data Protection/Subject Confidentiality

The investigator must ensure that the subject's confidentiality is maintained for documents submitted to Amgen.

The subject will be assigned a unique identifier by the sponsor. Any subject records or datasets that are transferred to the sponsor will contain the identifier only; subject names or any information which would make the subject identifiable will not be transferred.

On the Case Report Form (CRF) demographics page, in addition to the unique subject identification number, include the age at time of enrollment.

For serious adverse events reported to Amgen, subjects are to be identified by their unique subject identification number, initials (for faxed reports, in accordance with local laws and regulations), and age (in accordance with local laws and regulations).

Documents that are not submitted to Amgen (eg, signed informed consent forms) are to be kept in confidence by the investigator, except as described below.

Subject data should be kept in a secure location. Access to subject data will be limited to authorized individuals, as described below.

In compliance with governmental regulations/ICH GCP Guidelines, it is required that the investigator and institution permit authorized representatives of the company, of the regulatory agency(s), and the IRB/IEC direct access to review the subject's original medical records for verification of study-related procedures and data. Direct access includes examining, analyzing, verifying, and reproducing any records and reports that are important to the evaluation of the study.

The investigator is obligated to inform and obtain the consent of the subject to permit such individuals to have access to his/her study-related records, including personal information.

Amgen complies with all relevant and applicable laws and regulations that protect personal information in order to ensure subject confidentiality and privacy. Subjects are designated by a unique subject identification number in the Sponsor's systems. The Sponsor uses access-controlled systems to house, review and analyze subject data. These systems are backed-up regularly to minimize the risk of loss of subject data; procedures are also defined for data recovery in the event of data loss. The Sponsor

has standard operating procedures in place that restrict access to subject data to those who require access to this data based on their role and have also completed the required training. These procedures also outline the process for revoking access to such data when it is no longer needed. In the event of a security breach, the Sponsor has procedures in place for notification of privacy incidents and to address these incidents, via its Business Conduct Hotline.

Publication Policy

To coordinate dissemination of data from this study, Amgen may facilitate the formation of a publication committee consisting of several investigators and appropriate Amgen staff, the governance, and responsibilities of which are set forth in a Publication Charter. The committee is expected to solicit input and assistance from other investigators and to collaborate with authors and Amgen staff, as appropriate, as defined in the Publication Charter. Membership on the committee (both for investigators and Amgen staff) does not guarantee authorship. The criteria described below are to be met for every publication.

All publications (eg, manuscripts, abstracts, oral/slide presentations, book chapters) based on this study must be prepared in accordance with Amgen's publications policy and submitted to Amgen for review. Authorship of any publications resulting from this study will be determined on the basis of the Uniform Requirement for Manuscripts Submitted to Biomedical Journals International Committee of Medical Journal Editors Recommendations for the Conduct of Reporting, Editing, and Publications of Scholarly Work in Medical Journals, which states: Authorship credit is to be based on: (1) substantial contributions to conception and design, or the acquisition, analysis, or interpretation of data for the work; (2) drafting the work or revising it critically for important intellectual content; (3) final approval of the version to be published; and (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Authors need to meet conditions 1, 2, 3, and 4.

When a large, multicenter group has conducted the work, the group is to identify the individuals who accept direct responsibility for the manuscript. These individuals must fully meet the criteria for authorship defined above. Acquisition of funding, collection of data, or general supervision of the research group, alone, does not justify authorship. All persons designated as authors must qualify for authorship, and all those who qualify are to be listed. Each author must have participated sufficiently in the work to take public

responsibility for appropriate portions of the content. All publications (eg, manuscripts, abstracts, oral/slide presentations, book chapters) based on this study must be submitted to Amgen for review. The Clinical Trial Agreement among the institution, investigator, and Amgen will detail the procedures for, and timing of, Amgen's review of publications.

Investigator Signatory Obligations

Each clinical study report is to be signed by the investigator or, in the case of multicenter studies, the coordinating investigator.

The coordinating investigator, identified by Amgen, will be any or all of the following:

- A recognized expert in the therapeutic area
- An Investigator who provided significant contributions to either the design or interpretation of the study
- An Investigator contributing a high number of eligible subjects

Data Quality Assurance

All subject data relating to the study will be recorded on printed or electronic CRF unless transmitted to the sponsor or designee electronically (eg, laboratory data, centrally or adjudicated data). The investigator is responsible for verifying that data entries are accurate and correct by physically or electronically signing the CRF.

The investigator must maintain accurate documentation (source data) that supports the information entered in the CRF.

The investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory agency inspections and provide direct access to source data documents.

The sponsor or designee is responsible for the data management of this study including quality checking of the data.

The sponsor or designee will perform ongoing source data verification to confirm that data entered into the CRF by authorized site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of subjects are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements per the sponsor's monitoring plan.

The investigator agrees to cooperate with the clinical monitor to ensure that any problems detected in the course of these monitoring visits, including delays in completing CRFs, are resolved.

The Amgen representative(s) and regulatory authority inspectors are responsible for contacting and visiting the investigator for the purpose of inspecting the facilities and, upon request, inspecting the various records of the clinical study (eg, CRFs and other pertinent data) provided that subject confidentiality is respected.

In accordance with ICH GCP and the sponsor's audit plans, this study may be selected for audit by representatives from Amgen's Global Research and Development Compliance and Audit function (or designees). Inspection of site facilities (eg, pharmacy, **investigational product(s), and/or** [REDACTED] [REDACTED] storage areas, laboratories) and review of study-related records will occur to evaluate the study conduct and compliance with the protocol, ICH GCP, and applicable regulatory requirements.

Retention of study documents will be governed by the Clinical Trial Agreement.

Case Report Forms (CRF) must be completed in English. TRADENAMES® (if used) for concomitant medications may be entered in the local language. Consult the country-specific language requirements.

All written information and other material to be used by subjects and investigative staff must use vocabulary and language that are clearly understood.

Source Documents

The investigator is to maintain a list of appropriately qualified persons to whom he/she has delegated study duties. All persons authorized to make entries and/or corrections on CRFs will be included on the Amgen Delegation of Authority Form.

Source documents provide evidence for the existence of the subject and substantiate the integrity of the data collected. Source documents are filed at the investigator's site.

Source documents are original documents, data, and records from which the subject's CRF data are obtained. These include but are not limited to hospital records, clinical and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, and correspondence. Source documents may also include data captured in the IRT system (if used, such as subject ID and randomization number) and CRF entries if the CRF is the site of the original recording (ie, there is no other written or electronic record

of data, such as paper questionnaires for a clinical outcome assessment or certain demographic information, such as gender, race, and ethnicity).

Data reported on the CRF or entered in the electronic CRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.

The Investigator and study staff are responsible for maintaining a comprehensive and centralized filing system of all study-related (essential) documentation, suitable for inspection at any time by representatives from Amgen and/or applicable regulatory authorities.

Elements to include:

- Subject files containing completed CRFs, informed consent forms, and subject identification list
- Study files containing the protocol with all amendments, IB, copies of prestudy documentation, and all correspondence to and from the IRB/IEC and Amgen
- Investigational product-related correspondence including [Proof of Receipts, Investigational Product Accountability Record(s), Return of Investigational Product for Destruction Form(s), Final Investigational Product Reconciliation Statement, as applicable
- [REDACTED] and/or medical device(s) or combination product(s) documentation, as applicable

Retention of study documents will be governed by the Clinical Trial Agreement.

Remote Source Data Review and Verification

If permitted by national and/or local regulations, remote Source Data Review and Verification (rSDR/V) can be implemented. The clinical monitor should be provided with a secure, read-only access to the Electronic Medical Record (EMR) system, including all modules relevant for review. This access should be restricted to the records of only those subjects who participate in the study and who did not object to remote access to their medical records. A list of the monitors to whom remote access has been granted should be maintained. In order to prevent unauthorized access, access rights should be revoked once rSDR/V tasks have been completed for the study. The EMR system should have an audit trail and be able to log information on who accessed data and when. Remote access to the EMR should only be possible using a 2-factor authentication.

Study and Site Closure

Amgen or its designee may stop the study or study site participation in the study for medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, regulations, and GCP.

Both Amgen and the Investigator reserve the right to terminate the Investigator's participation in the study according to the Clinical Trial Agreement. The investigator is to notify the IRB/IEC in writing of the study's completion or early termination and send a copy of the notification to Amgen.

Subjects may be eligible for continued treatment with Amgen investigational product(s) by a separate protocol or as provided for by the local country's regulatory mechanism. However, Amgen reserves the unilateral right, at its sole discretion, to determine whether to supply Amgen investigational product(s) and by what mechanism, after termination of the study and before the product(s) is/are available commercially.

Compensation

Any arrangements for compensation to subjects for injury or illness that arises in the study are described in the Compensation for Injury section of the Informed Consent that is available as a separate document.

11.4 Appendix 4. Safety Events: Definitions and Procedures for Recording, Evaluating, Follow-up and Reporting

Definition of Adverse Event

Adverse Event Definition
• An adverse event is any untoward medical occurrence in a clinical study subject irrespective of a causal relationship with the study treatment. • Note: An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a treatment, combination product, medical device or procedure. • Note: Treatment-emergent adverse events will be defined in the Statistical Analysis Plan (SAP).
Events Meeting the Adverse Event Definition
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (eg, ECG, radiological scans, vital signs measurements), including those that worsen from baseline, that are considered clinically significant in the medical and scientific judgment of the investigator (ie, not related to progression of underlying disease). • Exacerbation of a chronic or intermittent preexisting condition including either an increase in frequency and/or intensity of the condition. • New conditions detected or diagnosed after study treatment administration even though it may have been present before the start of the study. • Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. • Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a concomitant medication. Overdose per se will not be reported as an adverse event/serious adverse event unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses are to be reported regardless of sequelae. • “Lack of efficacy” or “failure of expected pharmacological action” per se will not be reported as an adverse event or serious adverse event. Such instances will be captured in the efficacy assessments. However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as adverse event or serious adverse event if they fulfill the definition of an adverse event or serious adverse event.
Events NOT Meeting the Adverse Event Definition
• Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the procedure is the adverse event. • Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital). • Anticipated day-to-day fluctuations of preexisting disease(s) or condition(s) present or detected at the start of the study that do not worsen.

Definition of Serious Adverse Event

A Serious Adverse Event is defined as any untoward medical occurrence that, meets at least 1 of the following serious criteria:
Results in death (fatal)
Immediately life-threatening The term “life-threatening” in the definition of “serious” refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.
Requires in-patient hospitalization or prolongation of existing hospitalization In general, hospitalization signifies that the subject has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician’s office or outpatient setting. Complications that occur during hospitalization are an adverse event. If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as to whether “hospitalization” occurred or was necessary, the adverse event is to be considered serious. Hospitalization for elective treatment of a preexisting condition that did not worsen from baseline is not considered an adverse event.
Results in persistent or significant disability/incapacity The term disability means a substantial disruption of a person’s ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.
Is a congenital anomaly/birth defect
Other medically important serious event Medical or scientific judgment is to be exercised in deciding whether serious adverse event reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require medical or surgical intervention to prevent 1 of

the other outcomes listed in the above definition. These events are typically to be considered serious.

Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.

Recording Adverse Events and Serious Adverse Events

Adverse Event and Serious Adverse Event Recording

- When an adverse event or serious adverse event occurs, it is the responsibility of the investigator to review all documentation (eg, hospital progress notes, laboratory, and diagnostics reports) related to the event.
- The investigator will then record all relevant adverse event/serious adverse event information in the Event Case Report Form (CRF).
- The investigator must assign the following mandatory adverse event attributes:
 - Adverse event diagnosis or syndrome(s), if known (if not known, signs or symptoms);
 - Dates of onset and resolution (if resolved);
 - Did the event start prior to first dose of investigational product
 - Assessment of seriousness;
 - Severity (or toxicity defined below);
 - Assessment of relatedness to investigational product
 - Assessment of relatedness to study-required activity is only required for Serious Adverse Events.
 - Action taken; and
 - Outcome of event.
- If the severity of an adverse event changes from the date of onset to the date of resolution, record as a single event with the worst severity on the Event CRF
- It is not acceptable for the investigator to send photocopies of the subject's medical records to sponsor/responsible contract research organization (CRO) in lieu of completion of the Events CRF page.
- If specifically requested, the investigator may need to provide additional follow-up information, such as discharge summaries, medical records, or extracts from the medical records. In this case, all subject identifiers, with the exception of the subject number, will be blinded on the copies of the medical records before submission to Amgen or delegated party (if applicable).
- The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. In such cases, the diagnosis (not the individual signs/symptoms) will be documented as the adverse event/serious adverse event.

Evaluating Adverse Events and Serious Adverse Events

Assessment of Severity	
The investigator will make an assessment of severity for each adverse event and serious adverse event reported during the study. The assessment of severity will be based on: The Severity Intensity Scale for Adverse Events as shown below:	
Grade	Definition
MILD	Aware of sign or symptom, but easily tolerated
MODERATE	Discomfort enough to cause interference with usual activity
SEVERE ^a	Incapacitating with inability to work or do usual activity
^a An event is defined as 'serious' when it meets at least 1 of the predefined outcomes as described in the definition of a serious adverse event, NOT when it is rated as severe.	
Assessment of Causality	
- The investigator is obligated to assess the relationship between investigational product and each occurrence of each adverse event. The investigator is obligated to assess the relationship between investigational product, [REDACTED] device, study-required activity and/or procedure(s) and each occurrence of each serious adverse event. - Relatedness means that there are facts or reasons to support a relationship between investigational product and the event. - The investigator will use clinical judgment to determine the relationship. - Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study treatment administration will be considered and investigated. - The investigator will also consult the IB and/or Product Information, for marketed products, in his/her assessment. - For each adverse event/serious adverse event, the investigator must document in the medical notes that he/she has reviewed the adverse event/serious adverse event and has provided an assessment of causality. For sites reporting serious adverse events via electronic data capture (EDC), the investigator or sub investigator must confirm causality in EDC within 72 hours of the serious adverse event being entered on the Events CRF. - There may be situations in which a serious adverse event has occurred and the investigator has minimal information to include in the initial report. However, it is very important that the investigator always make an assessment of causality for every event before the initial transmission of the serious adverse event data. - The investigator may change his/her opinion of causality in light of follow-up information and send a serious adverse event follow-up report with the updated causality assessment. In this case, for sites reporting serious adverse events via	

EDC, the investigator or sub-investigator must reconfirm causality in the EDC system within 72 hours of the serious adverse event being entered on the Events CRF.

- The causality assessment is 1 of the criteria used when determining regulatory reporting requirements.

Follow-up of Adverse Event and Serious Adverse Event

- The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by Amgen to elucidate the nature and/or causality of the adverse event or serious adverse event as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals.
- If a subject is permanently withdrawn from **investigational product(s) and/or noninvestigational product(s)/auxiliary medicinal product(s)** because of a serious adverse event, this information must be submitted to Amgen.
- If a subject dies during participation in the study or during a recognized follow-up period, the investigator will provide Amgen with a copy of any postmortem findings including histopathology.
- New or updated information will be recorded in the originally completed Events CRF.
- The investigator will submit any updated serious adverse event data to Amgen immediately and no later than 24 hours of receipt of the information.

Reporting of Serious Adverse Event

Serious Adverse Event Reporting via Electronic Data Collection Tool

- The primary mechanism for reporting serious adverse event will be the electronic data capture (EDC) system.
- If the EDC system is unavailable, then the site will report the information to Amgen using a paper-based Serious Adverse Event Contingency Report Form (also referred to as the electronic Serious Adverse Event (eSAE) Contingency Report Form) (see [Figure 11-1](#)) immediately and no later than 24 hours of the investigator's awareness of the event.
- The site will enter the serious adverse event data into the electronic system as soon as it becomes available.
- After the study is completed at a given site, the EDC system will be taken off-line to prevent the entry of new data or changes to existing data.
- If a site receives a report of a new serious adverse event from a study subject or receives updated data on a previously reported serious adverse event after the EDC system has been taken off-line, then the site can report this information on the paper-based Serious Adverse Event Contingency Report Form (see [Figure 11-1](#)).
- Once the study has ended, serious adverse event(s) suspected to be related to investigational product will be reported to Amgen immediately and no later than 24 hours following the investigator's awareness of a serious adverse event. The

investigator should use the paper-based Serious Adverse Event Contingency Report Form to report the event.

Figure 11-1. Sample Electronic Serious Adverse Event Contingency Report Form (paper-based form)

Completion Instructions - Electronic Adverse Event Contingency Report Form
(For use for clinical trial studies using Electronic Data Capture [EDC])

NOTE: This form is to be used under restricted conditions outlined on page 1 below. If you must fax an event report to Amgen, you must also enter that event into the EDC system (eg, Rave) when it becomes available.

General Instructions

The protocol will provide instruction on what types of events to report for the study. This form is to be used ONLY to report events that must be captured in the Amgen safety database. *Indicates a mandatory field.

Types of Events to be reported on this form

- Serious Adverse Events (regardless of causal relationship to IP)

1. Site Information

Site Number* – Enter your assigned site number for this study

Investigator*, Country*, Reporter*, Phone No., and Fax No. – Enter information requested

2. Subject Information

Subject ID Number* – Enter the entire number assigned to the subject

Age at event onset, Sex, and Race – Enter the subject's demographic information

End of Study date – If the subject has already completed the study or terminated the study early, enter the End of Study date

If you are submitting follow-up information to a previous report, provide the serious adverse event term for the previous report as well as the start date for the initial event.

3. Serious Adverse Event

Provide the date the Investigator became aware of this Information

Serious Adverse Event Diagnosis or Syndrome* –

- If the diagnosis is known, it should be entered. Do not list all signs/symptoms if they are included in the diagnosis.
- If a diagnosis is not known, the relevant signs/symptoms should be entered.
- If the event is fatal, the cause of death should be entered and autopsy results should be submitted, when available.

Date Started* – Enter date the adverse event first started (not the date on which the event met serious criteria) rather than the date of diagnosis or hospitalization. **This is a mandatory field.**

Date Ended – Enter date the adverse event ended and not the date when the event no longer met serious criteria. If the event has not ended at the time of the initial report, a follow-up report should be completed when the end date is known. If the event is fatal, enter the date of death as the end date.

If event occurred before the first dose of Investigational Product (IP)/drug under study, add a check mark in the corresponding box.

Is event serious?* – Indicate Yes or No. **This is a mandatory field.**

Serious Criteria Code* – **This is a mandatory field for serious events.** Enter all reasons why the reported event has met serious criteria:

- Immediately life-threatening – Use only if the subject was at immediate risk of death from the event as it occurred. Emergency treatment is often required to sustain life in this situation.
- If the investigator decides an event should be reported in an expedited manner, but it does not meet other serious criteria, "Other Medically Important Serious Event" may be the appropriate serious criterion.

Relationship to IP – The Investigator must determine and enter the relationship of the event to the IP at the time the event is initially reported. **This is a mandatory field.**

Relationship to Amgen device* – The Investigator must determine and enter the relationship of the event to the Amgen device (e.g. prefilled syringe, auto-injector) at the time the event is initially reported. **If the study involves an Amgen device, this is a mandatory field. This question does not apply to non-Amgen devices used in the study (e.g. heating pads, infusion pumps)**

Outcome of Event* – Enter the code for the outcome of the event at the time the form is completed. **This is a mandatory field.**

- Resolved – End date is known
- Not resolved / Unknown – End date is unknown
- Fatal – Event led to death

If event is related to a study procedure, such as a biopsy, radiotherapy or withdrawal of a current drug treatment during a wash-out period, add a check mark to the corresponding box. This does not include relationship to IP or concomitant medication – only diagnostic tests or activities mandated by the protocol.

4. Hospitalization

If the subject was hospitalized, enter admission and discharge dates. Hospitalization is any in-patient hospital admission for medical reasons, including an overnight stay in a healthcare facility, regardless of duration. A pre-existing condition that did

not worsen while on study which involved a hospitalization for an elective treatment, is not considered an adverse event. Protocol specified hospitalizations are exempt.

Completion Instructions - Electronic Adverse Event Contingency Report Form
(for use for Studies using Electronic Data Capture [EDC])

Note, this form is to be used under restricted conditions outlined on page 1 of the form. If you must fax an event report to Amgen, you must also enter that event into the EDC system (eg, Rave) when it becomes available.

At the top of Page 2, provide your Site Number and the Subject ID Number in the designated section.

5. IP Administration including Lot # and Serial # when known / available.
Blinded or open-label – If applicable, indicate whether the investigational product is blinded or open-label
Initial Start Date – Enter date the product was first administered, regardless of dose.
Date of Dose Prior to or at the time of the Event – Enter date the product was last administered prior to, or at the time of, the onset of the event.
Dose, Route, and Frequency at or prior to the event – Enter the appropriate information for the dose, route and frequency at, or prior to, the onset of the event.
Action Taken with Product – Enter the status of the product administration.
6. Concomitant Medications
Indicate if there are any medications.
Medication Name, Start Date, Stop Date, Dose, Route, and Frequency – Enter information for any other medications the subject is taking. Include any study drugs not included in section 5 (Product Administration) such as chemotherapy, which may be considered co-suspect.
Co-suspect – Indicate if the medication is co-suspect in the event
Continuing – Indicate if the subject is still taking the medication
Event Treatment – Indicate if the medication was used to treat the event
7. Relevant Medical History
Enter medical history that is relevant to the reported event, not the event description. This may include pre-existing conditions that contributed to the event allergies and any relevant prior therapy, such as radiation. Include dates if available.
8. Relevant Laboratory Tests
Indicate if there are any relevant laboratory values.
For each test type, enter the test name, units, date the test was run and the results.
9. Other Relevant Tests
Indicate if there are any tests, including any diagnostics or procedures.
For each test type, enter the date, name, results and units (if applicable).

At the top of Page 3, provide your Site Number and the Subject ID Number in the designated section.

10. Case Description

Describe Event – Enter summary of the event. Provide narrative details of the events listed in section 3. Include any therapy administered, such as radiotherapy; (excluding medications, which will be captured in section 6). If necessary, provide additional pages to Amgen.

Complete the signature section at the bottom of page 3 and fax the form to Amgen. If the reporter is not the investigator, designee must be identified on the Delegation of Authority form.

A Study # 20210142 Rocatinlimab (AMG 451)		Electronic Serious Adverse Event Contingency Report Form For Restricted Use																																																																																					
Reason for reporting this event via fax The Clinical Trial Database (eg, Rave): ☐ Is not available due to internet outage at my site ☐ Is not yet available for this study ☐ Has been closed for this study																																																																																							
<<For completion by COM prior to providing to sites: SELECT OR TYPE IN A FAX#>>																																																																																							
1. SITE INFORMATION																																																																																							
Site Number		Investigator				Country																																																																																	
Reporter		Phone Number ()				Fax Number ()																																																																																	
2. SUBJECT INFORMATION																																																																																							
Subject ID Number		Age at event onset				Sex ☐ F ☐ M		Race		If applicable, provide End of Study date																																																																													
If this is a follow-up to an event reported in the EDC system (eg, Rave), provide the adverse event term: _____ and start date: Day _____ Month _____ Year _____																																																																																							
3. SERIOUS ADVERSE EVENT																																																																																							
Provide the date the Investigator became aware of this information: Day _____ Month _____ Year _____																																																																																							
<table border="1"><thead><tr><th rowspan="2">Serious Adverse Event diagnosis or syndrome If diagnosis is unknown, enter signs / symptoms and provide diagnosis, when known, in a follow- up report <i>List one event per line. If event is fatal, enter the cause of death. Entry of "death" is not acceptable, as this is an outcome.</i></th><th rowspan="2">Date Started Day Month Year</th><th rowspan="2">Date Ended Day Month Year</th><th rowspan="2">Check only if event occurred before first dose of IP</th><th rowspan="2">Is event serious? ☐ Yes ☐ No</th><th rowspan="2">Is serious, enter Serious Criteria code (see codes below)</th><th colspan="4">Relationship Is there a reasonable possibility that the Event may have been caused by IP or an Amgen device used to administer the IP?</th><th rowspan="2">Outcome of Event Resolved Not resolved Fatal Unknown eg, biopsy</th><th rowspan="2">Check only if event is related to study procedure</th></tr><tr><th colspan="4">Rocatinlimab (AMG 451)</th></tr><tr><th></th><th></th><th></th><th></th><th></th><th></th><th>No</th><th>Yes</th><th>No</th><th>Yes</th><th></th><th></th></tr></thead><tbody><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table>												Serious Adverse Event diagnosis or syndrome If diagnosis is unknown, enter signs / symptoms and provide diagnosis, when known, in a follow- up report <i>List one event per line. If event is fatal, enter the cause of death. Entry of "death" is not acceptable, as this is an outcome.</i>	Date Started Day Month Year	Date Ended Day Month Year	Check only if event occurred before first dose of IP	Is event serious? ☐ Yes ☐ No	Is serious, enter Serious Criteria code (see codes below)	Relationship Is there a reasonable possibility that the Event may have been caused by IP or an Amgen device used to administer the IP?				Outcome of Event Resolved Not resolved Fatal Unknown eg, biopsy	Check only if event is related to study procedure	Rocatinlimab (AMG 451)										No	Yes	No	Yes																																																		
Serious Adverse Event diagnosis or syndrome If diagnosis is unknown, enter signs / symptoms and provide diagnosis, when known, in a follow- up report <i>List one event per line. If event is fatal, enter the cause of death. Entry of "death" is not acceptable, as this is an outcome.</i>	Date Started Day Month Year	Date Ended Day Month Year	Check only if event occurred before first dose of IP	Is event serious? ☐ Yes ☐ No	Is serious, enter Serious Criteria code (see codes below)	Relationship Is there a reasonable possibility that the Event may have been caused by IP or an Amgen device used to administer the IP?				Outcome of Event Resolved Not resolved Fatal Unknown eg, biopsy	Check only if event is related to study procedure																																																																												
						Rocatinlimab (AMG 451)																																																																																	
						No	Yes	No	Yes																																																																														
Serious Criteria: 01 Fatal 03 Required/prolonged hospitalization 05 Congenital anomaly / birth defect 02 Immediately life-threatening 04 Persistent or significant disability /incapacity 06 Other medically important serious event																																																																																							
4. Was subject hospitalized or was a hospitalization prolonged due to this event? ☐ No ☐ Yes If yes, please complete all of Section 4																																																																																							
Date Admitted Day Month Year						Date Discharged Day Month Year																																																																																	
5. Was IP/drug under study administered/taken prior to this event? ☐ No ☐ Yes If yes, please complete all of Section 5																																																																																							
IP/Amgen Device:		Date of Initial Dose Day Month Year		Date of Dose Day Month Year		Dose		Route		Frequency																																																																													
Rocatinlimab (AMG 451)										Action Taken with Product 01 Still being Administered 02 Permanently discontinued 03 Withheld																																																																													
										Lot # and Serial # Lot # _____ ☐ Unknown Serial # _____ ☐ Unavailable /																																																																													

FORM-056006

Page 1 of 3

Version 7.0 Effective Date: 1 February 2016

FORM-056006

	Site Number	Subject ID Number																
10. CASE DESCRIPTION (<i>Provide narrative details of events listed in section 3</i>) Provide additional pages if necessary. For each event in section 3, where relationship=Yes, please provide rationale.																		
Signature of Investigator or Designee - _____ I confirm by signing this report that the information on this form, including seriousness and causality assessments, is being provided to Amgen by the investigator for this study, or by a Qualified Medical Person authorized by the investigator for this study.														Title			Date	

11.5 Appendix 5. Contraceptive Guidance and Collection of Pregnancy and Lactation Information

Study-specific contraception requirements for females of childbearing potential are outlined in [Section 5.2](#). Contraceptive use and methods should be consistent with local regulations for subjects participating in clinical studies.

Female subjects should be advised of the pregnancy prevention requirements and the potential risk to the fetus if they become pregnant during treatment and for 16 weeks after the last dose of **investigational product(s) and/or noninvestigational product(s)/auxiliary medicinal product(s)**.

Definition of Females of Childbearing Potential

A female is considered fertile following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilization methods include documented hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. Females with documented permanent infertility due to an alternate medical cause (eg, Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), can be considered not of childbearing potential.

Note: Bilateral tubal ligation/occlusion is not considered a permanent sterilization method.

Note: Documentation from the following sources is acceptable to provide confirmation of each sterilization method: 1) review of subject's medical records; 2) subject's medical examination; or 3) subject's medical history interview.

A postmenopausal female is defined as:

- A woman of ≥ 55 years with no menses for 12 months without an alternative medical cause OR
- A woman age < 55 years with no menses for at least 12 months and with a follicle-stimulating hormone (FSH) level within the definition of "postmenopausal range" for the laboratory involved. In the absence of 12 months of amenorrhea, confirmation with more than 1 FSH measurement is required.

Contraception Methods for Female Subjects

Highly Effective Contraceptive Methods

- Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal)
- Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
- Intrauterine device
- Intrauterine hormonal-releasing system
- Bilateral tubal ligation/occlusion
- Vasectomized partner (provided that partner is the sole sexual partner of the female subject of childbearing potential and that the vasectomized partner has received medical assessment of the surgical success)
- Sexual abstinence (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments; the reliability of sexual abstinence must be evaluated in relation to the duration of the trial and the preferred and usual lifestyle of the subject)

Collection of Pregnancy Information

Female Subjects Who Become Pregnant

- Investigator will collect pregnancy information on any female subject who becomes pregnant while taking **investigational product(s) and/or noninvestigational product(s)/auxiliary medicinal product(s)** through 16 weeks after the last dose of investigational product.
- Information will be recorded on the Pregnancy Notification Form (see [Figure 11-2](#)). The form must be submitted to Amgen Global Patient Safety immediately and no later than 24 hours of the site's awareness of a subject's pregnancy. (Note: Sites are not required to provide any information on the Pregnancy Notification Form that violates the country or regions local privacy laws).
- After obtaining the female subject's signed consent for release of pregnancy and infant health information, the investigator will collect pregnancy and infant health information and complete the pregnancy questionnaire for any female subject who becomes pregnant while taking **investigational product(s) and/or noninvestigational product(s)/auxiliary medicinal product(s)** through 16 weeks after the last dose of investigational product. This information will be forwarded to Amgen Global Patient Safety. Generally, infant follow-up will be conducted up to 12 months after the birth of the child (if applicable).
- Any termination of pregnancy will be reported to Amgen Global Patient Safety, regardless of fetal status (presence or absence of anomalies) or indication for procedure.
- While pregnancy itself is not considered to be an adverse event or serious adverse event, any pregnancy complication or elective termination of a pregnancy for medical reasons will be reported as an adverse event or serious adverse event. Abnormal pregnancy outcomes (eg, spontaneous abortions, stillbirth, fetal death, congenital anomalies) will be reported as an adverse event or serious adverse event. Note that an elective termination with no information on a fetal congenital malformation or

maternal complication is generally not considered an adverse event, but still must be reported to Amgen as a pregnancy exposure case.

- Any serious adverse event occurring as a result of a poststudy pregnancy which is considered reasonably related to the study treatment by the investigator, will be reported to Amgen Global Patient Safety as described in [Section 11.4](#). While the investigator is not obligated to actively seek this information in former study subjects, he or she may learn of a serious adverse event through spontaneous reporting.
- Any female subject who becomes pregnant while participating will discontinue study treatment while pregnant (see [Section 7.1](#) for details).

Male Subjects With Partners Who Become Pregnant or Were Pregnant at the Time of Enrollment

- Male participants are not required to use forms of contraception during treatment with rocatinlimab. However, male participants should let their female partner know they are in this study.
- In the event a male subject fathers a child during treatment, and for an additional 16 weeks after the last dose of **investigational product(s) and/or noninvestigational product(s)/auxiliary medicinal product(s)**, the information will be recorded on the Pregnancy Notification Form. The form (see [Figure 11-2](#)) must be submitted to Amgen Global Patient Safety immediately and no later than 24 hours of the site's awareness of the pregnancy. (Note: Sites are not required to provide any information on the Pregnancy Notification Form that violates the country or regions local privacy laws).
- The investigator will attempt to obtain a signed consent for release of pregnancy and infant health information directly from the pregnant female partner to obtain additional pregnancy information.
- After obtaining the female partner's signed consent for release of pregnancy and infant health information, the investigator will collect pregnancy outcome and infant health information on the pregnant partner and her baby and complete the pregnancy questionnaires. This information will be forwarded to Amgen Global Patient Safety.
- Generally, infant follow-up will be conducted up to 12 months after the birth of the child (if applicable).
- Any termination of the pregnancy will be reported to Amgen Global Patient Safety regardless of fetal status (presence or absence of anomalies) or indication for procedure.

Collection of Lactation Information

- Investigator will collect lactation information on any female subject who breastfeeds while taking **investigational product(s) and/or noninvestigational product(s)/auxiliary medicinal product(s)** through 16 weeks after last dose of investigational product.
- Information will be recorded on the Lactation Notification Form (see below) and submitted to Amgen Global Patient Safety immediately and no later than 24 hours of the investigator's awareness of the event.
- Study treatment will be discontinued if female subject breastfeeds during the study as described in exclusion criterion 223.
- With the female subjects signed consent for release of mother and infant health information, the investigator will collect mother and infant health information and complete the lactation questionnaire on any female subject who breastfeeds while taking **investigational product(s) and/or noninvestigational product(s)/auxiliary medicinal product(s)** through 16 weeks after discontinuing **investigational product(s) and/or noninvestigational product(s)/auxiliary medicinal product(s)**.

Figure 11-2. Pregnancy and Lactation Notification Forms

Amgen Proprietary - Confidential

AMGEN® Pregnancy Notification Form

Report to Amgen at: USTO fax: +1-888-814-8653, Non-US fax: +44 (0)207-136-1046 or email (worldwide): svc-ags-in-us@amgen.com

1. Case Administrative Information

Protocol/Study Number: 20210142

Study Design: ☐ Interventional ☐ Observational (If Observational: ☐ Prospective ☐ Retrospective)

2. Contact Information

Investigator Name _____ Site # _____
Phone (____) _____ Fax (____) _____ Email _____
Institution _____
Address _____

3. Subject Information

Subject ID # _____ Subject Gender: ☐ Female ☐ Male Subject age (at onset): _____ (in years)

4. Amgen Product Exposure

Amgen Product	Dose at time of conception	Frequency	Route	Start Date
				mm ____/dd ____/yyyy ____

Was the Amgen product (or study drug) discontinued? ☐ Yes ☐ No

If yes, provide product (or study drug) stop date: mm ____/dd ____/yyyy ____

Did the subject withdraw from the study? ☐ Yes ☐ No

5. Pregnancy Information

Pregnant female's last menstrual period (LMP) mm ____/dd ____/yyyy ____ ☐ Unknown ☐ N/A

Estimated date of delivery mm ____/dd ____/yyyy ____

If N/A, date of termination (actual or planned) mm ____/dd ____/yyyy ____

Has the pregnant female already delivered? ☐ Yes ☐ No ☐ Unknown ☐ N/A

If yes, provide date of delivery: mm ____/dd ____/yyyy ____

Was the infant healthy? ☐ Yes ☐ No ☐ Unknown ☐ N/A

If any Adverse Event was experienced by the infant, provide brief details: _____

Form Completed by:

Print Name: _____ Title: _____

Signature: _____ Date: _____

FORM-115199

Version 1.0

Effective Date: 24-Sept-2018

Amgen Proprietary - Confidential

AMGEN Lactation Notification Form

Report to Amgen at: USTO fax: +1-888-814-8653, Non-US fax: +44 (0)207-136-1046 or email (worldwide): svc-ags-in-us@amgen.com

1. Case Administrative Information

Protocol/Study Number: 20210142

Study Design: ☐ Interventional ☐ Observational (If Observational: ☐ Prospective ☐ Retrospective)

2. Contact Information

Investigator Name _____ Site # _____

Phone (____) _____ Fax (____) _____ Email _____

Institution _____

Address _____

3. Subject Information

Subject ID # _____ Subject age (at onset): _____ (in years)

4. Amgen Product Exposure

Amgen Product	Dose at time of breast feeding	Frequency	Route	Start Date
				mm ____/dd ____/yyyy ____

Was the Amgen product (or study drug) discontinued? ☐ Yes ☐ No

If yes, provide product (or study drug) stop date: mm ____/dd ____/yyyy ____

Did the subject withdraw from the study? ☐ Yes ☐ No

5. Breast Feeding Information

Did the mother breastfeed or provide the infant with pumped breast milk while actively taking an Amgen product? ☐ Yes ☐ No

If No, provide stop date: mm ____/dd ____/yyyy ____

Infant date of birth: mm ____/dd ____/yyyy ____

Infant gender: ☐ Female ☐ Male

Is the infant healthy? ☐ Yes ☐ No ☐ Unknown ☐ N/A

If any Adverse Event was experienced by the mother or the infant, provide brief details: _____

Form Completed by:

Print Name: _____ Title: _____

Signature: _____ Date: _____

FORM-115201

Version 1.0

Effective Date: 24-Sept-2018

11.6 Appendix 6. Sample Storage and Destruction

When permitted by local regulations, any blood, [REDACTED] sample collected according to the Schedule of Activities (Section 1.3) can be analyzed for any of the tests outlined in the protocol and for any tests necessary to minimize risks to study subjects. This includes testing to ensure analytical methods produce reliable and valid data throughout the course of the study. This can also include, but is not limited to, investigation of unexpected results, incurred sample reanalysis, and analyses for method transfer and comparability.

All samples and associated results will be coded prior to being shipped from the site for analysis or storage. Samples will be tracked using a unique identifier that is assigned to the samples for the study. Results are stored in a secure database to ensure confidentiality.

When permitted by local regulations and if informed consent is provided by the subject, Amgen can do additional testing on remaining samples (ie, residual and back-up) to investigate and better understand the inflammatory conditions, the dose response and/or prediction of response to rocatinlimab, characterize antibody response, and characterize aspects of the molecule (eg, mechanism of action/target, metabolites). Results from this analysis are to be documented and maintained, but are not necessarily reported as part of this study. Samples can be retained for up to 20 years.

Since the evaluations are not expected to benefit the subject directly or to alter the treatment course, the results of [REDACTED] or other exploratory studies are not placed in the subject's medical record and are not to be made available to the subject, members of the family, the personal physician, or other third parties, except as specified in the informed consent.

The subject retains the right to request that the sample material be destroyed by contacting the investigator. Following the request from the subject, the investigator is to provide the sponsor with the required study and subject number so that any remaining, blood samples and any other components from the cells can be located and destroyed. Samples will be destroyed once all protocol-defined procedures are completed. However, information collected from samples prior to the request for destruction, will be retained by Amgen.

The sponsor is the exclusive owner of any data, discoveries, or derivative materials from the sample materials and is responsible for the destruction of the sample(s) at the

request of the subject through the investigator, at the end of the storage period, or as appropriate (eg, the scientific rationale for experimentation with a certain sample type no longer justifies keeping the sample). If a commercial product is developed from this research project, the sponsor owns the commercial product. The subject has no commercial rights to such product and has no commercial rights to the data, information, discoveries, or derivative materials gained or produced from the sample.

See [Section 11.3](#) for subject confidentiality.

11.7 Appendix 7. Hepatotoxicity Stopping Rules: Suggested Actions and Follow-up Assessments and Study Treatment Rechallenge Guidelines

Subjects with abnormal hepatic laboratory values (ie, alkaline phosphatase [ALP], aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin [TBL]) and/or international normalized ratio (INR) and/or signs/symptoms of hepatitis (as described below) may meet the criteria for withholding or permanent discontinuation of Amgen investigational product or [REDACTED]

[REDACTED] as specified in the *Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation*, July 2009.

Criteria for Withholding and/or Permanent Discontinuation of Amgen Investigational Product and [REDACTED] Due to Potential Hepatotoxicity

The following stopping and/or withholding rules apply to subjects for whom another cause of their changes in liver biomarkers (TBL, INR and transaminases) has not been identified.

Important alternative causes for elevated AST/ALT and/or TBL values include, but are not limited to:

- Hepatobiliary tract disease
- Viral hepatitis (eg, hepatitis A/B/C/D/E, Epstein-Barr Virus, cytomegalovirus, herpes simplex virus, varicella, toxoplasmosis, and parvovirus)
- Right sided heart failure, hypotension, or any cause of hypoxia to the liver causing ischemia
- Exposure to hepatotoxic agents/drugs or hepatotoxins, including herbal and dietary supplements, plants, and mushrooms
- Heritable disorders causing impaired glucuronidation (eg, Gilbert's syndrome, Crigler-Najjar syndrome) and drugs that inhibit bilirubin glucuronidation (eg, indinavir, atazanavir)
- Alpha-1 antitrypsin deficiency
- Alcoholic hepatitis
- Autoimmune hepatitis
- Wilson's disease and hemochromatosis
- Nonalcoholic fatty liver disease including steatohepatitis
- Non-hepatic causes (eg, rhabdomyolysis, hemolysis)

If investigational product(s) is/are withheld, the subject is to be followed for possible drug induced liver injury (DILI) according to recommendations in the last section of this appendix.

Rechallenge may be considered if an alternative cause for impaired liver tests (ALT, AST, ALP) and/or elevated TBL, is discovered and the laboratory abnormalities resolve to normal or baseline (see next section in this appendix).

Table 11-3. Conditions for Withholding and/or Permanent Discontinuation of Amgen Investigational Product and [REDACTED] Due to Potential Hepatotoxicity

Analyte	Temporary Withholding	Permanent Discontinuation
TBL	> 3x ULN at any time	> 2x ULN
INR	--	OR > 1.5x ULN (for subjects not on anticoagulation therapy)
AST/ALT	OR > 8x ULN at any time > 5x ULN but < 8x ULN for ≥ 2 weeks > 5x ULN but < 8x ULN and unable to adhere to enhanced monitoring schedule > 3x ULN with clinical signs or symptoms that are consistent with hepatitis (such as right upper quadrant pain/tenderness, fever, nausea, vomiting, and jaundice)	AND > 3x ULN (when baseline was < ULN), in the presence of no important alternative causes for elevated AST/ALT and/or TBL values
ALP	OR > 8x ULN at any time	--

ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase;
INR = international normalized ratio; TBL = total bilirubin; ULN = upper limit of normal

**Criteria for Rechallenge of Amgen Investigational Product and [REDACTED]
[REDACTED] After Potential Hepatotoxicity**

The decision to rechallenge the subject is to be discussed and agreed upon unanimously by the subject, investigator, and Amgen.

If signs or symptoms recur with rechallenge, then investigational product is to be permanently discontinued. Subjects who clearly meet the criteria for permanent discontinuation (as described in [Table 11-3](#)) are never to be rechallenged.

Drug-induced Liver Injury Reporting and Additional Assessments

Reporting

To facilitate appropriate monitoring for signals of DILI, cases of concurrent AST or ALT and TBL and/or INR elevation, according to the criteria specified in the above, require the following:

- The event is to be reported to Amgen as a serious adverse event immediately and no later than 24 hours of discovery or notification of the event (ie, before additional etiologic investigations have been concluded)
- The appropriate case report form (CRF) (eg, Events CRF) that captures information necessary to facilitate the evaluation of treatment-emergent liver abnormalities is to be completed and sent to Amgen

Other events of hepatotoxicity and potential DILI are to be reported as serious adverse events if they meet the criteria for a serious adverse event defined in [Section 11.4](#).

Additional Clinical Assessments and Observation

All subjects in whom investigational product(s) **and/or** [REDACTED] is/are withheld (either permanently or conditionally) due to potential DILI as specified in [Table 11-3](#) or who experience AST or ALT elevations > 3 x upper limit of normal (ULN) or 2-fold increases above baseline values for subjects with elevated values before drug are to undergo a period of “close observation” until abnormalities return to normal or to the subject’s baseline levels.

Assessments that are to be performed during this period include:

- Repeat AST, ALT, ALP, bilirubin (BIL) (total and direct), and INR within 24 hours
- In cases of TBL > 2x ULN or INR > 1.5, retesting of liver tests, BIL (total and direct), and INR is to be performed every 24 hours until laboratory abnormalities improve

Testing frequency of the above laboratory tests may decrease if the abnormalities stabilize or the investigational product(s) **and/or** [REDACTED]

[REDACTED] has/have been discontinued AND the subject is asymptomatic.

Initiate investigation of alternative causes for elevated AST or ALT and/or elevated TBL.

The following are to be considered depending on the clinical situation:

- Complete blood count with differential to assess for eosinophilia
- Serum total immunoglobulin (Ig)G, anti-nuclear antibody anti-smooth muscle antibody, and liver kidney microsomal antibody-1 to assess for autoimmune hepatitis
- Serum acetaminophen (paracetamol) levels


- A more detailed history of:
 - Prior and/or concurrent diseases or illness
 - Exposure to environmental and/or industrial chemical agents
 - Symptoms (if applicable) including right upper quadrant pain, hypersensitivity-type reactions, fatigue, nausea, vomiting and fever
 - Prior and/or concurrent use of alcohol, recreational drugs, and special diets
 - Concomitant use of medications (including non-prescription medicines and herbal and dietary supplements), plants, and mushrooms
- Viral serologies
- Creatine phosphokinase, haptoglobin, lactate dehydrogenase, and peripheral blood smear
- Appropriate liver imaging if clinically indicated
- Appropriate blood sampling for [REDACTED] if this has not already been collected
- Hepatology consult (liver biopsy may be considered in consultation with a hepatologist)

Follow the subject and the laboratory tests (ALT, AST, TBL, INR) until all laboratory abnormalities return to baseline or normal or considered stable by the investigator. The “close observation period” is to continue for a minimum of 4 weeks after discontinuation of all investigational product(s) and/or [REDACTED]
[REDACTED]

The potential DILI event and additional information such as medical history, concomitant medications, and laboratory results must be captured in the corresponding CRFs.

11.8 Appendix 8. Topical Corticosteroids Potency Category

Table 11-4. Topical Corticosteroids Potency Category





11.9 Appendix 9. Country Specific Requirements

This appendix provides language for country-specific regulatory requirements and other procedures to follow in the execution of the global study in these countries.


The summary of changes outlined below specify requirements for sites and subjects participating in the European Economic Area (EEA).


Table 11-5. European Economic Area Summary of Changes


Protocol Section	Text in Protocol	Text For the EEA
Section 1.3, Schedule of Activities (SoA), Table 1-1. Schedule of Activities, Footnote aa	Replaced the following text: ^{aa} For subjects with positive HBsAg and/or HBV core Ab at initial screening. Any additional testing may be performed per investigator's discretion.	With the following text: ^{aa} For subjects with positive HB core Ab without detectable HBV DNA or HBsAg at initial screening. Any additional testing may be performed per investigator's discretion.
Section 5.2, Exclusion Criteria, Criterion no. 235	Replaced the following text: 207 Active and non-virally suppressed hepatitis B infection at initial screening, defined as detectable hepatitis B DNA polymerase chain reaction (PCR) test in a subject with detectable hepatitis B Surface Antigen (HBsAg) and/or antibodies to hepatitis B core (anti-HBc). Subjects with detectable HBsAg are required to be virally suppressed with an approved hepatitis B antiviral therapy during the study.	With the following text: 235 Chronic hepatitis B infection at initial screening, defined as detectable hepatitis B Surface Antigen (HBsAg) or HBV DNA. Subjects with detectable antibodies to hepatitis B core (anti-HBc) and negative HBsAg/HBV DNA are required to do on-study HBV DNA monitoring .


Protocol Section	Text in Protocol	Text For the EEA
Section 5.2, Exclusion Criteria, Criterion no. 236	Replaced the following text: 237 Positive or indeterminate QuantiFERON GOLD from central laboratory at initial screening - Exception: A positive or indeterminate QuantiFERON test is allowed if ALL of the following are present at day 1 prerandomization per Screening TB Risk Assessment Questionnaire provided by Amgen: - No symptoms of tuberculosis (TB) as per the worksheet provided by Amgen - Documented history of a completed course of adequate prophylaxis (completed treatment for latent TB per local standard of care prior to start of investigational product) - No known exposure to a case of active TB after most recent prophylaxis - No evidence of active TB on chest radiograph obtained within 3 months prior to day 1 prerandomization	With the following text: 236 Latent tuberculosis infection as evident by positive or indeterminate QuantiFERON GOLD from central laboratory at screening and assessed at day 1 prerandomization per Screening TB Risk Assessment Questionnaire provided by Amgen.
Section 6.2.2.1, Amgen Investigational Product: Rocatinlimab/Placebo, Paragraph 1, Bullet no. 3	Replaced the following text Opportunistic infection, such as active TB and other infections whose nature or course may suggest an immunocompromised status	With the following text: Opportunistic infection, such as active TB, latent TB, or other infections whose nature or course may suggest an immunocompromised status


Protocol Section	Text in Protocol	Text For the EEA
Section 8.10.1, Tuberculosis Testing and Tuberculosis Risk Assessment Questionnaire, Screening	Replaced the following text: All subjects must receive QuantiFERON GOLD test from central laboratory at initial screening and Screening TB Risk Assessment Questionnaire must be completed for all subjects as defined in the Schedule of Activities (Section 1.3). Subjects with a positive or indeterminate QuantiFERON GOLD test are ineligible unless specific additional requirements are met (Section 5.2). For subjects with a positive or indeterminate QuantiFERON GOLD test, the radiograph report should be read by a radiologist or per local requirement and the report must be reviewed by the investigator before enrollment.	With the following text: All subjects must receive QuantiFERON GOLD test from central laboratory at initial screening and Screening TB Risk Assessment Questionnaire must be completed for all subjects as defined in the Schedule of Activities (Section 1.3). Subjects with a positive or indeterminate QuantiFERON GOLD test are not eligible to enroll (Section 5.2).
Section 8.10.1, Tuberculosis Testing and Tuberculosis Risk Assessment Questionnaire, On-Study, Paragraph 1, Bullet no. 5	Replaced the following text: In case of diagnosis of latent TB during investigational product treatment, prophylaxis treatment should be initiated immediately based on the local guideline. The investigational product should not be withheld but may be interrupted per PI discretion. The subject should be re-evaluated for signs and symptoms of TB and for prophylactic toxicity within 4 weeks of initiation of prophylactic treatment.	With the following text: In case of diagnosis of latent TB during investigational product treatment, prophylaxis treatment should be initiated immediately based on the local guideline. The investigational product should be discontinued permanently.
Section 11.10,	Added the following text: 	











Amendment 6

Protocol Title: A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite)

Amgen Protocol Number Rocatinlimab (AMG 451) 20210142

NCT Number: NCT05398445

EU CT Number: 2022-501540-15

Amendment Date: 26 February 2024

Rationale:

This protocol has been amended primarily to update the secondary and exploratory endpoints as specified below. Changes to the efficacy analyses and the graphical multiple testing scheme were made to correspond to the changes in the endpoints. Additionally, the projected number of subjects have been increased by 10% from [REDACTED] to approximately [REDACTED] to enroll additional subjects to meet country-specific requirements. Other changes in the protocol are specified below:

- Updated 'key secondary' endpoints section by moving the endpoint that measures the Dermatology Life Quality Index (DLQI) score from baseline to week 24 to 'other secondary' endpoints section, as this continuous endpoint will not be assessed under multiplicity control.
- Updated the key secondary endpoint assessing the change from baseline in weekly average of daily atopic dermatitis (AD) skin pain numeric rating score (NRS) at week 24 to an endpoint evaluating the proportion of subjects who achieve at least a [REDACTED] [REDACTED] from baseline. A [REDACTED] is considered meaningful with-subject change of AD skin pain. This threshold is selected based on published analysis assessing meaningful within-patient change of a similar AD-related skin pain NRS scored between 0-10, using data from a randomized placebo-controlled, double-blind study of upadacitinib in AD (Silverberg, J.I., Leshem, Y.A., Calimlim, B.M., McDonald, J.

Amendment 5

Protocol Title: A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite)

Amgen Protocol Number: 20210142

Amendment Date: 16 January 2024

Rationale:

This protocol is being amended to address feedback received from the regulatory agencies, and to clarify/correct other items in the protocol.

Changes include:

- Updated Section 1.1 (Synopsis) and Section 9 (Statistical Considerations) to clarify graphical testing schemes.
- Updated Section 1.3 (Schedule of Activities, footnotes) and Section 11.9 to clarify the Subject Interview Substudy is not applicable for the EEA region.
- Updated Section 11.4 (Appendix 4) to clarify adverse event and serious adverse event recording requirements.
- Added Section 11.11 (Appendix 11) Graphical Multiple Testing Scheme.
- Administration, typographical and formatting changes were made throughout the protocol.

and Litcher-Kelly, L., 2023. Psychometric evaluation of the NRS, Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS). *Current Medical Research and Opinion*, (just-accepted), pp.1-19. The analysis indicated that score changes ranging between -2.80 and -3.50 for adults and -2.01 and -2.79 for adolescents were associated with minimal clinically meaningful within-patient change, depending on the anchor used. Therefore, the application of a [REDACTED] threshold to capture meaningful change above this minimal improvement is supported by available evidence. Furthermore, the threshold of [REDACTED] in weekly average scores was used to support clinical trial endpoints for AD skin pain in 3 clinical trials of upadacitinib.

- Added an additional 'other secondary' endpoint to evaluate the proportion of subjects who achieve at least a 3-point reduction from baseline AD skin pain NRS score at week 24 and week 16 with baseline weekly average of AD skin pain NRS score ≥ 3 , in line with definition of minimal clinically meaningful within-patient change identified in the analysis.
- Updated 'key secondary' endpoints section by moving the genital AD severity score (GASS) assessment from key secondary to exploratory objective and endpoint due to the small proportion of subjects with genital AD presence at baseline.
- Updated subject interview substudy to clarify that subjects who do not roll-over into the [REDACTED] study will be interviewed at the specific timepoint within the treatment period on which they end the parent study (end of study/safety follow-up).

[REDACTED]

- Updated the Subgroups section for Populations for Analysis to specify the thresholds for defining baseline weight subgroup and baseline body mass index subgroup.

- General editorial changes, including administrative, abbreviations, typographical, and formatting corrections have been made throughout the document.

Amendment 4

Protocol Title: A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite)

Amgen Protocol Number (Rocatinlimab [AMG 451]) 20210142

EU CT Number: 2022-501540-15

NCT Number: NCT05398445

Amendment Date: 24 May 2023

Rationale:

Protocol amendment 4 is being updated to address feedback received from the regulatory agencies. The following changes have been implemented to:

- Update the Schedule of Activities (SoA) table to:
 - Add Screening TB risk assessment questionnaire at day 1 pre-randomization and on-study TB risk assessment questionnaire at unscheduled visit.
 - Add laboratory assessments (coagulation, human immunodeficiency virus (HIV), Hepatitis B and C, QuantiFERON GOLD, and anti-rocatinlimab-antibody at unscheduled visits), pharmacokinetic assessments (rocatinlimab PK sample) clinical outcome assessments, hepatitis B DNA, serum pregnancy, urinalysis, and electrocardiogram (ECG) at unscheduled visits.
 - Remove the “Per Investigator Discretion” from Urinalysis.
 - Add a new row for ‘Mental health randomization review’.
 - Update visits for concomitant therapies review.
 - Add a new optional substudy (patient interview substudy).
 - Add a new study treatment procedure (mental health recommendation review).

- Add that a complete physical examination will be conducted at screening, and symptom-directed physical examination at subsequent study visits at the discretion of the investigator per standard of care.
 - Clarify that the unscheduled visits may occur at any time point during the treatment period, and only those laboratory assessments and/or efficacy/clinical outcome assessments deemed necessary should be performed at the discretion of the investigator.
- Update the Benefit/Risk Assessment
- Update inclusion criteria to specify that subjects with previous systemic treatment for atopic dermatitis (AD) are also considered as inadequate responders to topical treatments and are potentially eligible to be included in the study after appropriate washout.
- Update exclusion criteria to:
 - Clarify that a positive or indeterminate QuantiFERON test is allowed if certain exceptions are present at day 1 prerandomization per Screening tuberculosis (TB) Risk Assessment Questionnaire provided by Amgen.
 - Remove the exclusion criterion 'anti-pruritic agents (eg, crotamiton) or antihistamines used for treatment of pruritus'.
 - Clarify to indicate the following: currently receiving treatment in another investigational device or drug study, or less than 30 days (16 weeks for Japan) or 5 half-lives, whichever is longer, since ending treatment on another investigational device or drug study(ies) prior to day 1 prerandomization. Other investigational procedures while participating in this study are excluded.
- Clarify one of the endpoints to evaluate the efficacy of rocatinlimab is by achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) 1 response with presence of only barely perceptible erythema or vIGA AD 0 response, at week 24 and at assessment time points.

- Clarify that the subjects may require temporary interruption of investigational product if systemic corticosteroids are used for ≤ 2 consecutive weeks to avoid concurrent administration with investigational product.
- Clarify that subjects who permanently discontinue investigational product for any reason during the study are encouraged to complete all remaining study visits and procedures with the exception of investigational product administration and post-dose monitoring procedures through week 24 for the evaluation of the coprimary endpoints, which will correspond to their End of Treatment (EOT) visit.
- Remove the sentence stating subjects who permanently discontinue investigational product will be ineligible for the long-term maintenance study (Study [REDACTED]).
- Clarify that subjects are eligible to be enrolled in the study when the investigator determines that the subject has met all eligibility criteria.
- Clarify that an individual subject is considered to have completed the study if they have completed the last scheduled visit shown in the SoA table and that the maximum total study duration for an individual subject is approximately 40 weeks.
- Update the guidance for certain therapeutics for non-AD related conditions, including prohibited therapies (Table 6-2).
- Update the guidance for rescue therapy for AD (Table 6-3).
- Correct the mis-matched words on-study reported 'suicidal behavior or ideation' identified through positive responses to questions 4 or 5 of the Since Last Visit [REDACTED]
- Update the general assessment 'Columbia Suicide Severity Rating Scale'.
- Update the general assessment 'Mental Health Assessment'.
- Update the general assessment 'Hospital Anxiety and Depression Scale (HADS)' to include HADS Anxiety and Depression categorization scores (Table 8-1).
- Update the safety assessment 'Clinical Laboratory Assessments' for alignment with other studies.
- Specify that the adverse events of special interest will be monitored.

- Inform that the use of prohibited rescue therapies may require permanent discontinuation or temporary interruption of investigational product.
- Update that the reason for discontinuation of prior systemic treatment may include adverse events or inadequate response.
- Clarify that subjects may be eligible to enroll into a long-term maintenance study (Study [REDACTED]).
- Add an additional subgroup to evaluate coprimary and selected secondary endpoints.
- Clarify that a prespecified graphical multiple testing approach will be used to assess the coprimary and all key secondary endpoints for each of the 2 rocatinlimab treatment groups ([REDACTED] mg and [REDACTED] mg) in a parallel manner controlling for the overall type 1 error rate at the 2-sided 5% significance level.
- Add an additional subgroup to evaluate coprimary and selected secondary endpoints.
- Add a new appendix for optional substudy – Patient Interview Substudy.
- Update contraceptive guidance for male subjects whose partner was pregnant at the time of beginning of the study or if the female partner becomes pregnant at any time while the male participant is on-study.
- Remove the details of illiterate and visually impaired subjects are not eligible for study as they cannot complete the eCOAs.
- Update that all subjects must receive QuantiFERON GOLD test from central laboratory at initial screening and Screening TB Risk Assessment Questionnaire must be completed for all subjects.
- Update permanent discontinuation language for neutropenia following an adverse event.
- Minor updates in the list of references.
- Make administrative and editorial changes throughout the protocol for clarification and consistency.

Superseding Amendment 3

Protocol Title: A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET Ignite)

Amgen Protocol Number (Rocatinlimab [AMG 451]) 20210142

EU CT Number: 2022-501540-15

NCT Number: NCT05398445

Amendment Date: 28 February 2023

Superseding Amendment Date: 15 March 2023

Superseding Amendment Date: 23 March 2023

Rationale:

On 23 March 2023, protocol amendment 3 was superseded to add Appendix 9 (Country Specific Requirements) to provide language for country-specific regulatory requirements and other procedures to follow in the execution of the global study in the European Economic Area (EEA):

- To add the sentence “For sites and subjects participating in the European Economic Area (EEA), please refer to Section 11.9 (Appendix 9)”, where applicable, throughout the protocol.
- To update the schedule of activities (SoA) table to clarify footnote ‘cc’.
- To update the exclusion criteria to include chronic hepatitis B virus (HBV) infection and remove a positive or indeterminate QuantiFERON test as an exception.
- To include latent tuberculosis (TB) into discontinuation criteria.

On 15 March 2023, protocol amendment 3 was superseded to correct an autonumbering error in exclusion criteria numbering. All other changes incorporated during authoring of protocol amendment 3 are included below.

Protocol amendment 3 is being updated to address feedback received from the regulatory agencies and is being done:

- To update the rescue therapies for atopic dermatitis (AD) to clarify that subjects may continue investigational product if there is concurrent use of topical rescue therapies (excluding topical Janus kinase [JAK] inhibitors), phototherapy, systemic corticosteroids, or cyclosporine, but investigational product must be permanently discontinued if there is use of specific prohibited therapies, or other conventional non-biologic, non-targeted immunosuppressive systemic therapies, biologics, or targeted systemic AD rescue therapies.
- To update the Schedule of Activities (SoA) table:
 - To add an additional visit at week █ for electrocardiogram (ECG) procedure.
 - To add an additional hepatitis B deoxyribonucleic acid (DNA) procedure (for reactivation monitoring only) with a corresponding footnote 'cc' that this test is for subjects with positive hepatitis B surface antigen (HBsAg) and/or hepatitis B virus (HBV) core antibody (Ab) at initial screening and that any additional testing may be performed per investigator's discretion.
 - To add an additional visit at week █ for 2-hour post-dose monitoring vital signs and add additional as needed visits from week █ to week █
 - To update footnote 'j' that hepatitis B DNA testing will be performed for subjects with positive HBsAg and/or HBV core Ab.
 - To update footnote 'v' that subjects must be monitored for 2 hours following at least the first 2 doses of investigational product on day 1 and week █ and that if no systemic injection-related reactions, including immediate type hypersensitivity reactions, are observed after the first 2 doses, the post-dose monitoring period may be reduced to at least 30 minutes for subsequent doses. If systemic injection-related reactions are observed after the first 2 doses, the 2-hour post-dose monitoring period will remain as needed.
 - To update footnote 'w' that vital signs must be measured only at the end of the 2-hour post-dose monitoring period before subject is discharged.
- To update the inclusion criteria:
 - To specify that the subject should have a diagnosis of AD, according to American Academy of Dermatology Consensus Criteria, that has been present for at least 12 months before signing of informed consent.
- To update the exclusion criteria:
 - To clarify that subjects should not have evidence of human immunodeficiency virus (HIV) infection or positive for HIV antibodies at initial screening or current acquired, common variable or inherited, primary or secondary immunodeficiency.
 - To specify that subjects should not have active chronic or acute infection requiring treatment with systemic antibiotics, antiviral, antiparasitic, antiprotozoal, or antifungals

- which has not completely resolved, or for which therapy has not been completed, within 4 weeks before day 1 prerandomization.
- To add that subjects should not have a history of New York Heart Association class III/IV heart failure; uncontrolled hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg) at initial screening; or inadequately treated cardiovascular conditions at initial screening including: cardiomyopathy, major congenital heart disease, or second- or third-degree atrioventricular block.
 - To add that subjects should not have cardiovascular events including: cerebrovascular accident, myocardial infarction, coronary stenting, or unstable angina within 6 months of day 1 prerandomization.
 - To specify that subjects should not be treated with systemic treatment with methotrexate, mycophenolate/mycophenolate mofetil, calcineurin inhibitors, or other non-biologic, non-targeted systemic immunosuppressants within 4 weeks or 5 half-lives, whichever is longer, prior to day 1 prerandomization.
 - To specify that subjects should not currently be receiving treatment in another investigational device or drug study, or less than 30 days (16 weeks for Japan) or 5 half-lives, whichever is longer, since ending treatment on another investigational device or drug study(ies).
- To clarify that inclusion of the subject's legally authorized representative is optional (depending on the country concerned).
 - To update that daily emollient application (twice daily), excluding those emollients containing added pharmacological agents with antipruritic, antiseptic, and/or keratolytic properties, such as urea $\geq 20\%$, ammonium lactate $\geq 12\%$, or salicylic acid $\geq 3\%$, is required throughout the study.
 - To clarify that topical and systemic rescue therapies for AD are discouraged during the study, subjects may continue investigational product if there is the concurrent use of any of these therapies.
 - To update the guidance for certain therapeutics for non-AD related conditions, including prohibited therapies (Table 6-2).
 - To update that presence of a serious or severe infection on the day of a scheduled investigational product requires temporary interruption of the investigational product and that the investigational product may resume at the discretion of the principal investigator or in consultation with the medical monitor.
 - To update that randomization for the treatment period will be performed by Interactive Response Technology (IRT) according to the randomization list generated by the Amgen Global Randomization and Blinding group, and the randomization date will be captured in IRT.
 - To clarify that in the event of worsening and/or unacceptable symptoms of AD, rescue with standard of care therapies may be given if deemed necessary by the investigator.
 - To update the guidance for rescue therapy for AD (Table 6-3).

- To clarify that the monitoring of mental health is necessary during screening and on-study.
- To clarify that the ECG must include heart rate, QRS, QT, QTc, and PR interval measurements.
- To recommend the immediate prophylactic treatment in case of diagnosis of latent tuberculosis (TB) during investigational product treatment and clarify that the investigational product should not be withheld but may be interrupted per principal investigator discretion and that the subject should be re-evaluated for signs and symptoms of TB and prophylactic toxicity within 4 weeks of initiation of prophylactic treatment.
- To update contraceptive guidance:
 - To update contraception methods for female subjects to highly effective contraceptive methods.
 - To clarify progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) as a highly effective contraceptive method.
 - To remove 3 items (male or female condom with or without spermicide; cap, diaphragm, or sponge with spermicide; and double barrier method) considered as acceptable contraceptive methods from the list of 'highly effective contraceptive methods'.
 - To update that male participants are not required to use contraception during treatment with the investigational product, but they should let their female partner know that they are in this study.
- To update the name and email address of the key sponsor contact.
- To remove the European Union Drug Regulating Authorities Clinical Trial Number: 2022-000711-31.
- To correct the European Union Clinical Trial Number to remove "00".
- To make editorial changes, including administrative, typographical, grammatical, formatting, and abbreviations, throughout the document.

Superseding Amendment 3

Protocol Title: A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET Ignite)

Amgen Protocol Number (Rocatinlimab [AMG 451]) 20210142

EU CT Number: 2022-501540-15

NCT Number: NCT05398445

Amendment Date: 28 February 2023

Superseding Amendment Date: 15 March 2023

Rationale:

On 15 March 2023, protocol amendment 3 was superseded to correct an autonumbering error in exclusion criteria numbering. All other changes incorporated during authoring of protocol amendment 3 are included below.

Protocol amendment 3 is being updated to address feedback received from the regulatory agencies and is being done:

- To update the rescue therapies for atopic dermatitis (AD) to clarify that subjects may continue investigational product if there is concurrent use of topical rescue therapies (excluding topical Janus kinase [JAK] inhibitors), phototherapy, systemic corticosteroids, or cyclosporine, but investigational product must be permanently discontinued if there is use of specific prohibited therapies, or other conventional non-biologic, non-targeted immunosuppressive systemic therapies, biologics, or targeted systemic AD rescue therapies.
- To update the Schedule of Activities (SoA) table:
 - To add an additional visit at week ■ for electrocardiogram (ECG) procedure.
 - To add an additional hepatitis B deoxyribonucleic acid (DNA) procedure (for reactivation monitoring only) with a corresponding footnote 'cc' that this test is for subjects with positive hepatitis B surface antigen (HBsAg) and/or hepatitis B virus (HBV) core antibody (Ab) at initial screening and that any additional testing may be performed per investigator's discretion.

- To add an additional visit at week [] for 2-hour post-dose monitoring vital signs and add additional as needed visits from week [] to week []
- To update footnote 'j' that hepatitis B DNA testing will be performed for subjects with positive HBsAg and/or HBV core Ab.
- To update footnote 'v' that subjects must be monitored for 2 hours following at least the first 2 doses of investigational product on day 1 and week [] and that if no systemic injection-related reactions, including immediate type hypersensitivity reactions, are observed after the first 2 doses, the post-dose monitoring period may be reduced to at least 30 minutes for subsequent doses. If systemic injection-related reactions are observed after the first 2 doses, the 2-hour post-dose monitoring period will remain as needed.
- To update footnote 'w' that vital signs must be measured only at the end of the 2-hour post-dose monitoring period before subject is discharged.
- To update the inclusion criteria:
 - To specify that the subject should have a diagnosis of AD, according to American Academy of Dermatology Consensus Criteria, that has been present for at least 12 months before signing of informed consent.
- To update the exclusion criteria:
 - To clarify that subjects should not have evidence of human immunodeficiency virus (HIV) infection or positive for HIV antibodies at initial screening or current acquired, common variable or inherited, primary or secondary immunodeficiency.
 - To specify that subjects should not have active chronic or acute infection requiring treatment with systemic antibiotics, antiviral, antiparasitic, antiprotozoal, or antifungals which has not completely resolved, or for which therapy has not been completed, within 4 weeks before day 1 prerandomization.
 - To add that subjects should not have a history of New York Heart Association class III/IV heart failure; uncontrolled hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg) at initial screening; or inadequately treated cardiovascular conditions at initial screening including: cardiomyopathy, major congenital heart disease, or second- or third-degree atrioventricular block.
 - To add that subjects should not have cardiovascular events including: cerebrovascular accident, myocardial infarction, coronary stenting, or unstable angina within 6 months of day 1 prerandomization.
 - To specify that subjects should not be treated with systemic treatment with methotrexate, mycophenolate/mycophenolate mofetil, calcineurin inhibitors, or other non-biologic, non-targeted systemic immunosuppressants within 4 weeks or 5 half-lives, whichever is longer, prior to day 1 prerandomization.
 - To specify that subjects should not currently be receiving treatment in another investigational device or drug study, or less than 30 days (16 weeks for Japan) or

5 half-lives, whichever is longer, since ending treatment on another investigational device or drug study(ies).

- To clarify that inclusion of the subject's legally authorized representative is optional (depending on the country concerned).
- To update that daily emollient application (twice daily), excluding those emollients containing added pharmacological agents with antipruritic, antiseptic, and/or keratolytic properties, such as urea $\geq 20\%$, ammonium lactate $\geq 12\%$, or salicylic acid $\geq 3\%$, is required throughout the study.
- To clarify that topical and systemic rescue therapies for AD are discouraged during the study, subjects may continue investigational product if there is the concurrent use of any of these therapies.
- To update the guidance for certain therapeutics for non-AD related conditions, including prohibited therapies (Table 6-2).
- To update that presence of a serious or severe infection on the day of a scheduled investigational product requires temporary interruption of the investigational product and that the investigational product may resume at the discretion of the principal investigator or in consultation with the medical monitor.
- To update that randomization for the treatment period will be performed by Interactive Response Technology (IRT) according to the randomization list generated by the Amgen Global Randomization and Blinding group, and the randomization date will be captured in IRT.
- To clarify that in the event of worsening and/or unacceptable symptoms of AD, rescue with standard of care therapies may be given if deemed necessary by the investigator.
- To update the guidance for rescue therapy for AD (Table 6-3).
- To clarify that the monitoring of mental health is necessary during screening and on-study.
- To clarify that the ECG must include heart rate, QRS, QT, QTc, and PR interval measurements.
- To recommend the immediate prophylactic treatment in case of diagnosis of latent tuberculosis (TB) during investigational product treatment and clarify that the investigational product should not be withheld but may be interrupted per principal investigator discretion and that the subject should be re-evaluated for signs and symptoms of TB and prophylactic toxicity within 4 weeks of initiation of prophylactic treatment.
- To update contraceptive guidance:
 - To update contraception methods for female subjects to highly effective contraceptive methods.
 - To clarify progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) as a highly effective contraceptive method.

- To remove 3 items (male or female condom with or without spermicide; cap, diaphragm, or sponge with spermicide; and double barrier method) considered as acceptable contraceptive methods from the list of 'highly effective contraceptive methods'.
- To update that male participants are not required to use contraception during treatment with the investigational product, but they should let their female partner know that they are in this study.
- To update the name and email address of the key sponsor contact.
- To remove the European Union Drug Regulating Authorities Clinical Trial Number: 2022-000711-31.
- To correct the European Union Clinical Trial Number to remove “00”.
- To make editorial changes, including administrative, typographical, grammatical, formatting, and abbreviations, throughout the document.

Amendment 3

Protocol Title: A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET Ignite)

Amgen Protocol Number (Rocatinlimab [AMG 451]) 20210142

EU CT Number: 2022-501540-15

NCT Number: NCT05398445

Amendment Date: 28 February 2023

Rationale:

Protocol amendment 3 is being updated to address feedback received from the regulatory agencies and is being done:

- To update the rescue therapies for atopic dermatitis (AD) to clarify that subjects may continue investigational product if there is concurrent use of topical rescue therapies (excluding topical Janus kinase [JAK] inhibitors), phototherapy, systemic corticosteroids, or cyclosporine, but investigational product must be permanently discontinued if there is use of specific prohibited therapies, or other conventional non-biologic, non-targeted immunosuppressive systemic therapies, biologics, or targeted systemic AD rescue therapies.
- To update the Schedule of Activities (SoA) table:
 - To add an additional visit at week [REDACTED] for electrocardiogram (ECG) procedure.
 - To add an additional hepatitis B deoxyribonucleic acid (DNA) procedure (for reactivation monitoring only) with a corresponding footnote 'cc' that this test is for subjects with positive hepatitis B surface antigen (HBsAg) and/or hepatitis B virus (HBV) core antibody (Ab) at initial screening and that any additional testing may be performed per investigator's discretion.
 - To add an additional visit at week [REDACTED] for 2-hour post-dose monitoring vital signs and add additional as needed visits from week [REDACTED] to week [REDACTED]
 - To update footnote 'j' that hepatitis B DNA testing will be performed for subjects with positive HBsAg and/or HBV core Ab.
 - To update footnote 'v' that subjects must be monitored for 2 hours following at least the first 2 doses of investigational product on day 1 and week [REDACTED] and that if no systemic

injection-related reactions, including immediate type hypersensitivity reactions, are observed after the first 2 doses, the post-dose monitoring period may be reduced to at least 30 minutes for subsequent doses. If systemic injection-related reactions are observed after the first 2 doses, the 2-hour post-dose monitoring period will remain as needed.

- To update footnote 'w' that vital signs must be measured only at the end of the 2-hour post-dose monitoring period before subject is discharged.
- To update the inclusion criteria:
 - To specify that the subject should have a diagnosis of AD, according to American Academy of Dermatology Consensus Criteria, that has been present for at least 12 months before signing of informed consent.
- To update the exclusion criteria:
 - To clarify that subjects should not have evidence of human immunodeficiency virus (HIV) infection or positive for HIV antibodies at initial screening or current acquired, common variable or inherited, primary or secondary immunodeficiency.
 - To specify that subjects should not have active chronic or acute infection requiring treatment with systemic antibiotics, antiviral, antiparasitic, antiprotozoal, or antifungals which has not completely resolved, or for which therapy has not been completed, within 4 weeks before day 1 prerandomization.
 - To add that subjects should not have a history of New York Heart Association class III/IV heart failure; uncontrolled hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg) at initial screening; or inadequately treated cardiovascular conditions at initial screening including: cardiomyopathy, major congenital heart disease, or second- or third-degree atrioventricular block.
 - To add that subjects should not have cardiovascular events including: cerebrovascular accident, myocardial infarction, coronary stenting, or unstable angina within 6 months of day 1 prerandomization.
 - To specify that subjects should not be treated with systemic treatment with methotrexate, mycophenolate/mycophenolate mofetil, calcineurin inhibitors, or other non-biologic, non-targeted systemic immunosuppressants within 4 weeks or 5 half-lives, whichever is longer, prior to day 1 prerandomization.
 - To specify that subjects should not currently be receiving treatment in another investigational device or drug study, or less than 30 days (16 weeks for Japan) or 5 half-lives, whichever is longer, since ending treatment on another investigational device or drug study(ies).
- To clarify that inclusion of the subject's legally authorized representative is optional (depending on the country concerned).
- To update that daily emollient application (twice daily), excluding those emollients containing added pharmacological agents with antipruritic, antiseptic, and/or keratolytic properties,

such as urea $\geq 20\%$, ammonium lactate $\geq 12\%$, or salicylic acid $\geq 3\%$, is required throughout the study.

- To clarify that topical and systemic rescue therapies for AD are discouraged during the study, subjects may continue investigational product if there is the concurrent use of any of these therapies.
- To update the guidance for certain therapeutics for non-AD related conditions, including prohibited therapies (Table 6-2).
- To update that presence of a serious or severe infection on the day of a scheduled investigational product requires temporary interruption of the investigational product and that the investigational product may resume at the discretion of the principal investigator or in consultation with the medical monitor.
- To update that randomization for the treatment period will be performed by Interactive Response Technology (IRT) according to the randomization list generated by the Amgen Global Randomization and Blinding group, and the randomization date will be captured in IRT.
- To clarify that in the event of worsening and/or unacceptable symptoms of AD, rescue with standard of care therapies may be given if deemed necessary by the investigator.
- To update the guidance for rescue therapy for AD (Table 6-3).
- To clarify that the monitoring of mental health is necessary during screening and on-study.
- To clarify that the ECG must include heart rate, QRS, QT, QTc, and PR interval measurements.
- To recommend the immediate prophylactic treatment in case of diagnosis of latent tuberculosis (TB) during investigational product treatment and clarify that the investigational product should not be withheld but may be interrupted per principal investigator discretion.
- To update contraceptive guidance:
 - To update contraception methods for female subjects to highly effective contraceptive methods.
 - To clarify progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) as a highly effective contraceptive method.
 - To remove 3 items (male or female condom with or without spermicide; cap, diaphragm, or sponge with spermicide; and double barrier method) considered as acceptable contraceptive methods from the list of 'highly effective contraceptive methods'.
 - To update that male participants are not required to use contraception during treatment with the investigational product, but they should let their female partner know that they are in this study.
- To update the name and email address of the key sponsor contact.
- To remove the European Union Drug Regulating Authorities Clinical Trial Number: 2022-000711-31.

- To correct the European Union Clinical Trial Number to remove “00”.
- To make editorial changes, including administrative, typographical, grammatical, formatting, and abbreviations, throughout the document.

Amendment 2

Protocol Title: A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET Ignite)

Amgen Protocol Number (Rocatinlimab) 20210142

EudraCT Number/EU CT Number: 2022-000711-31/2022-501540-15-00

NCT Number: NCT05398445


Amendment Date: 15 September 2022


Rationale:

This protocol is being amended to include administrative changes and important clarifications in various sections of the protocol. These updates include:

- Updates made in response to regulatory agency advice and to simplify design.
- Update study design so that study ends at week 24.
- Add new other secondary objectives and endpoints:
 - To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo on [REDACTED]
 - To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo on [REDACTED]
 - To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo on [REDACTED]
 - To evaluate the efficacy of rocatinlimab [REDACTED] mg and [REDACTED] mg compared with placebo at week 16 and week 24 on the patient-reported outcome (PRO) measure of pruritus
- Clarify that subjects are encouraged to continue all remaining study visits and procedures through week 24 after permanent discontinuation of investigational product.
- Indicate the different scales to be completed by the subjects in the electronic device each day throughout the screening period.

- Include a statement that subjects who do not permanently discontinue investigational product through week 24 will be eligible to enroll into a long-term maintenance study (Study [REDACTED]).
- Include the meaning of allowed rescue therapies.
- Clarify that a safety follow-up visit is required for all subjects who do not enroll into the long-term maintenance study (Study [REDACTED]).

- 
- Changes in inclusion criteria include:
 - Add 7-day recall at initial screening for patient-reported Worst Pruritus NRS ≥ 4 based on a single question item
 - Inform that subjects must have completed at least 4 days of daily diary entries within the 14 days preceding and including day 1 prerandomization
 - Changes in exclusion criteria include:
 - Update Other Medical Conditions to clarify type of disorders and conditions within 5 years prior to informed consent
 - Update Other Medical Conditions to add indeterminate QuantiFERON GOLD from central laboratory at initial screening
 - Update Other Medical Conditions to add that subjects who have had an inpatient psychiatric admission within the last year will be excluded and that subjects who are receiving a psychiatric treatment regimen must be stable on treatment for at least 8 weeks prior to study day 1

- 
- Update Prior/Concomitant Therapy to clarify the treatments that applied within 1 week before day 1 prerandomization will be an exclusion criterion

- Update the dosage level of the investigational product and placebo and included the anatomical sites for its administration (Section 6.1.1).
- Describe all of the events that require permanent discontinuation from investigational product (Section 6.2.2.1).
- Included new detailed information about mental health assessment during the study (Section 8.2.8).
- Update the methods of detecting adverse events and serious adverse events to include that if a subject reports or the investigator observes an adverse event of reaction at the site of study drug administration, the investigator is to capture in the Events case report form (CRF) the location of the reaction together with the type of reaction that better describes the event with clear start and stop dates (Section 8.4.5.2).
- Update Tuberculosis Testing and Tuberculosis Risk Assessment Questionnaire (Section 8.10.1).
- Include the statement that both coprimary endpoints need to achieve statistical significance to declare study success (Section 9.1).
- Update study title with the new duration of the study, the new name of the investigational product, and the new name of the study.
- Update the name of the investigational product to rocatinlimab (formerly known as KHK4083 and AMG 451) in the whole document.
- Add the European Union Clinical Trial (EU CT) number.
- Align the protocol with the latest clinical protocol template version 29.0, effective date 30 May 2022.
- Administrative, abbreviation, typographical, and formatting changes were made throughout the protocol.

Amendment 1

Protocol Title: A Phase 3, 52-week, Treat-through, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 451 Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD)

Amgen Protocol Number 20210142

Amendment Date: 27 April 2022

Rationale:

This protocol is being amended to make program wide study alignment changes.

Changes include, but are not limited to, the following:

- Update electrocardiogram language to remove “central reader.”
- Updates to the study schema and schedule of assessment tables to align with the other protocols in the AMG 451 program.
- Update language for the electrocardiogram assessments, [REDACTED] and tuberculosis testing to align the other protocols in the AMG 451 program.
- Update adverse event adjudication language to no specify that events would be deemed of potential cardiovascular origin or etiology by the investigator.
- Standardize wording around rescue therapy for consistency between the AMG 451 study protocols in the AMG 451 program.
- Remove reference to long-term extension study with regard to discontinuation of investigational product, end of treatment visit, and end of study (EOS) visit.
- Separate Eczema Area and Severity Index (EASI) and [REDACTED] assessments in the Schedule of Assessments (SOA) to align with other AMG 451 protocols.
- Update inclusion criterion 102 to allow inclusion of subjects ≥ 18 years of age, or legal adult age within the subject’s country, whichever is older.
- Update exclusion criterion 208, exceptions, sub-bullet 4 to, “No evidence of active tuberculosis on chest radiograph obtained within 3 months prior to day 1 prerandomization.”
- Update exclusion criterion 213, bullet 1 to, “eGFR < 30 mL/min/1.73 m².”
- Update exclusion criterion 214 to align with other AMG 451 protocols.
- Remove exclusion criterion 218 related to Janus kinase (JAK) inhibitors to align with other AMG 451 protocols.

- Updated exclusion criterion 225 to clarify timing of pregnancy test by replacing “initial screening” with “during screening.”
- Updates to Section 6.1.4 Medical Devices to align with other AMG 451 protocols and clarify the use of non-investigational medical devices as standard of care.
- Update the EOS definition to align with Amgen standard language and with other AMG 451 protocols.
- Update to provide clarification and program-wide alignment with regard to objectives and endpoints.
- Make typographical, formatting, and editorial changes throughout the protocol.

Section: Global

Change: Editorial changes (including abbreviation, typographical, grammatical, and formatting) have been made throughout the document.

Section: Global

Change: The document date was changed from 01 April 2022 to **27 April 2022**

Section: 1.1, Synopsis, Study Rationale, Paragraph 1

Replace:

Atopic dermatitis (AD) is a chronic relapsing and remitting, inflammatory skin disease dominated by reactive T helper type 2 (Th2) cells. The proximate pathophysiologic mechanism for eczematous lesions is now understood to be largely due to inflammation related to dysregulation of Th2 cells (Guttman-Yassky, 2018). OX40 (CD134), a costimulatory molecule of the TNF receptor/TNF superfamily, is expressed predominantly on T-cells, including effector cells, shortly after their activation (Croft, 2010). OX40 and its ligand, OX40L, are crucial for the generation of Th2 memory cells, and may thus play a central role in the pathogenesis and chronicity of AD (Sitrin, 2017). Blocking OX40 signaling has resulted in inhibition of T-cell responses and pathogenic symptoms in animal models of autoimmune diseases (Salek-Ardakani, 2006; Croft, 2009). AMG 451 (formerly known as KHK4083) is a human, non-fucosylated, immunoglobulin G1 (IgG1) monoclonal antibody that binds and inhibits the OX40/OX40L interaction, and thereby, suppresses clonal T-cell expansion. In a Phase 2 study (Study 4083-006) conducted by Amgen partner Kyowa Kirin Co., Ltd, the safety and tolerability of repeated doses of AMG 451 in subjects with moderate-to-severe AD, statistically significant improvements in percent change from baseline to week 16 in Eczema Area and Severity Index (EASI) score was observed in all AMG 451-treated cohorts versus placebo. In this study, all doses tested were well tolerated with an acceptable adverse event profile.